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Abstract 
This study reports on the effect of seminar education by studying changes in knowledge, 
attitude and behaviour to haloperidol prescribing patterns of psychiatrists who attended 
evidence-based schizophrenia seminars presented by the Lundbeck Institute in 
Denmark.  The objectives of the study were two-fold.  Firstly, it set out to determine 
whether changes actually occurred in the post-seminar haloperidol prescribing behaviour 
of participants.  This was done by analysing changes in choice of optimal haloperidol 
dose (both in acute treatment i.e. most effective dose and maintenance treatment i.e. 
minimum effective dose), selected duration of treatment (for first- and multi-episode 
schizophrenia patients) and drug-class used (conventional versus new generation 
antipsychotic).  The study then investigated whether these changes (if they occurred) 
could be ascribed wholly or in part to the effect of schizophrenia seminar attendance, or 
whether other factors e.g. scientific progress over time in understanding schizophrenia 
and its treatment (“background” knowledge) and differences between participant 
datasets studied (only paired pre- and post-seminar data were used in this study) also 
played a role.  Secondly, it attempted to identify factors predictive of seminar 
participants changing their haloperidol prescribing behaviour post-seminar i.e. what were 
the factors that predisposed some attendees to change their prescribing behaviour?  This 
was done by analysing the effect that pre-seminar prescribing behaviour, participant 
nationality, patient caseload, work experience and workplace environment had on post-
seminar behaviour. 
 
Results show that changes did occur in post-seminar haloperidol prescribing behaviour, 
but that they were not always due to an effect of seminar attendance.  Only the changes 
in the minimum effective haloperidol dose and duration of treatment for first- and multi-
episode schizophrenia patients could validly be ascribed to the effects of schizophrenia 
seminar attendance.  Furthermore, multivariate analysis of the factors relating to these 
changes found that a participant was most likely to change their selected minimum 
effective haloperidol dose to be more in line with internationally accepted standards if 
they i) selected above the target dose pre-seminar, ii) had a relatively low caseload 
comprised mainly of schizophrenia patients and iii) came from either Greece, Germany, 
Britain, Spain, Italy or some other Eastern European country. The single most important 
factor related to changes in duration of treatment was found to be pre-seminar 
behaviour: respondents below the recommended duration of treatment increased their 
duration of treatment significantly. 
 
 
In summary, this study demonstrated a direct relationship between seminar attendance 
and changes to selected minimum effective haloperidol dose and duration of treatment.  
However, seminar attendance did not appear to be a significant factor in changes to 
antipsychotic class used for treatment and changes in optimal effective haloperidol dose: 
rather a change in the level of “background” knowledge of participants was most likely 
responsible.  This study also found individual participant characteristic differences in 
those who did change treatment duration and minimum effective dose.  
 
In conclusion, this study showed that the successful integration of international 
treatment recommendations into daily psychiatric practise could be facilitated by the use 
of appropriate educational seminars.  Not all attendees benefit i.e. “learn”, but those 
needing to “learn” most do - i.e. those who need to change their prescribing habits most 
to meet internationally accepted guidelines.  The peer exposure provided allows a format 
for informed discussion and the practise of evidence-based medicine.  The judicious use 
of such seminars should result in better treatment options and outcomes for patients. 
 
 
Abstrak 
Hierdie studie beskryf die effek van seminaargerigte-onderwys deur die meting van 
veranderings in die kennis, gesindheid en gedrag ten opsigte van haloperidol voorskrifte 
van psigiaters, na bywoning van ‘n bewysgebaseerde skisofrenie seminaar, aangebied 
deur die Lundbeck Instituut in Denemarke.  Die doelwitte van hierdie studie was 
tweevoudig.  Eerstens, om te bepaal of verandering in die haloperidol voorskrifte van 
deelnemers werklik plaasgevind het nadat hul die seminaar bygewoon het.  Dit is bereik 
deur die analise van veranderings in die keuse van die optimale haloperidol dosering 
(beide in akute behandeling: mees effektiewe dosering, sowel as langtermyn 
behandeling: minimum effektiewe dosering), keuse van behandelings tydperk (in eerste- 
sowel as multi-episode skisofrenie pasiënte) en die klas van medikasie gebruik 
(konvensionele teenoor die nuwe-generasie antipsigotika).  Hierna het die studie 
ondersoek of die veranderings (indien daar wel veranderings voorgekom het) in die 
geheel of slegs in ‘n mate toegeskryf kon word aan die effek van die seminaar-bywoning, 
of dat ander faktore bv. wetenskaplike vooruitgang in skisofrenie kennis en behandeling 
(“agtergrond” kennis) en die veskille tussen deelnemer datastelle (slegs gepaarde voor- 
en na-seminaardata is in hierdie studie gebruik) ook moontlik ‘n rol gespeel het.  
Tweedens, het die studie gepoog om faktore te identifiseer wat die veranderings in na-
seminaar haloperidol-voorskrifgedrag kon voorspel: watter faktore het bygedra tot die 
verandering in voorskrite van sekere deelnemers?  Dit is bereik deur die analise van hoe 
voor-seminaar voorskrifgewoontes, die deelnemer se nasionaliteit, pasiëntlading, 
praktykservaring en werksomgewing die na-seminaar gedrag beïnvloed het. 
 
Uitslae toon dat veranderings wel plaasgevind het t.o.v na-seminaar haloperidol 
voorskrifgedrag, maar dat nie alle veranderings toegeskryf kon word aan seminaar 
bywoning nie.  Slegs die verandering in die minimum effektiewe dosering van haloperidol 
en behandelings termyne vir eerste- en multi-episode skisofrenie pasiënte statisties aan 
die bywoning van die skisofrenie seminare toegeskryf kon word.  Daar is verder bepaal, 
deur multi-variasie analise van bydraende faktore, dat deelnemers meer geneig was tot 
die aanpassing van hul voorgeskrewe haloperidol dosering tot nader aan internasionale 
standaarde indien hulle i) ’n te hoë dosering gebruik het voor die seminar bywoning, ii) 
’n relatiewe lae pasiëntlading, bestaande uit meestal skisofrenie pasiënte, het en iii) 
herkoms van óf Griekeland, Duitsland, Britanje, Spanië, Italië óf ’n ander Oos-Europese 
land gehad het.  Die belangrikste faktor wat behandelingstermyn verandering bepaal het 
was die voor-seminaar gedrag: respondente onder die aanbevole termyn van 
behandeling het díe behandelingstermyn betekenisvol verleng.  
 
 
 Ter opsomming, het hierdie studie bewys dat daar ‘n direkte verhouding bestaan tussen 
seminaarbywoning en die verandering in die keuse van die minimum effektiewe dosering 
van haloperidol, asook in die duur van behandeling.  Die seminaar bywoning het egter 
nie geblyk om die bepalende faktor te wees in die verandering van antipsigotika klas of 
die optimale effektiewe dosering van haloperidol nie.  Díe veranderings kon eerder 
toegeskryf word aan die veranderings in “agtergrond” kennis van psigiaters.  Die studie 
het wel individuele deelnemer-kenmerke identifiseer wat tot veranderings in behandeling 
gelei het. 
 
Ter afsluiting, het hierdie studie bewys dat die suksesvolle integrasie van internasionale 
behandelingsriglyne in daaglikse psigiatriepraktyk bereik kan word deur voortgesette 
onderwys, deur middel van seminare.  Nie alle deelnemers “leer” in sulke seminare nie, 
maar díe wat die meeste behoort te leer doen dit – deelnemers wie se praktykgedrag ver 
verwyder is van die internasionalbehandelingsriglyne.  Die blootstelling aan eweknie-
psigiatriese portuurgroepe skep ’n formaat vir ingeligte besprekings en die toepassing 
van bewysgebaseerde psigiatrie.  Goed-deurdenkte toepassing van sulke seminare 
behoort beter behandelings opsies en uitkomste van behandeling aan pasiënte te bied.
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Chapter 1 Introduction 
 
“Schizophrenia is arguably the worst disease 
affecting mankind, even AIDS not excepted” 
          (Nature, 1988) 
1.1   Schizophrenia – the illness 
Schizophrenia, one of the major unsolved conditions of our time, contributes significantly 
to disability worldwide, ranking fourth highest as a cause of disability (Murray and Lopez, 
1996; Singh, 2005).  In addition to the personal tragedy it causes, the schizophrenia 
disease syndrome requires clinical care and living support across years of the sufferers’ 
lives and so places a heavy social and economic burden on both sufferers and society 
(Davies and Drummond, 1994; De Hert et al., 1998a). 
 
The schizophrenia syndrome is characterized by disturbing and unusual internal 
experiences – delusions and hallucinations, socially inappropriate behaviour, and 
reduced participation in social and occupational activities.  Schizophrenia is generally a 
progressive and lifelong illness requiring on-going (possibly life-long) maintenance 
treatment to reduce the incidence of psychotic relapse. 
 
Schizophrenia affects about 1% of the adult population worldwide (Torrey, 1987; Rupp 
and Keith, 1993).  After much debate, it now seems clear that the incidence, as well as 
the prevalence, of schizophrenia is higher in males and in disadvantaged communities 
(Aleman et al., 2003; McGrath et al., 2004). 
 
Cost of schizophrenia 
Since schizophrenia is a chronic illness with frequent instances of relapse, it is not 
surprising that treatment costs for this condition are high: “probably the most expensive 
psychiatric disorder” (Andreasen, 1991). 
 
While health care spending accounts for about 10% of GDP (Gross Domestic Product) in 
many developed countries (Wasylenki, 1994), the direct costs alone for the treatment of 
schizophrenia account for between 1.5 and 3% of the total health care budget (Rupp and 
Keith, 1993; Roullion et al., 1997; De Hert et al., 1998b; Meerding et al., 1998), yet the 
latest published data available reveal that expenditure on pharmacotherapies accounts 
for only 2 to 6% of the total cost of care for all psychotic illnesses in developed countries 
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(Salize and Rössler, 1996; Genduso and Hakey, 1997; Rouillon et al., 1997; Masand and 
Berry, 2000; Hansen et al., 2006). 
 
In the United States the total estimated cost of schizophrenia was US$ 33 billion in 1990 
(Rice and Miller, 1992), but by 2002 the cost of schizophrenia was estimated to be 
US$62.7 billion, with $22.7 billion in direct health care cost ($7.0 billion outpatient, $5.0 
billion drugs, $2.8 billion inpatient, $8.0 billion long-term care).  The total direct non-
health care costs, including living cost offsets, were estimated to be $7.6 billion.  The 
total indirect costs were estimated to be $32.4 billion.  The indirect cost due to 
unemployment is the largest component of overall schizophrenia costs (Wu et al., 2005). 
 
In Belgium, the total direct costs are estimated to account for 1.9% of national health 
expenditure, which means that the average expenditure on a schizophrenia patient is 
more than ten times the health care costs of the average citizen (De Hert et al., 1998b). 
 
The SANE/Access Economics report into the costs of schizophrenia in Australia (Magnus 
et al., 2005) sets the annual direct cost at A$661 million, or A$18,000 per person with 
schizophrenia.  The estimated transfer costs of the illness included A$190 million of lost 
tax revenue of patients and carers and A$274 million in welfare payments.  Thus the 
total estimated cost to Australia of schizophrenia ranged from A$1.15 billion (Magnus et 
al., 2005) to A$1.44 billion (Carr et al., 2003) in 2001.  These costs are heavily skewed 
towards acute care.  However, acute care cost is under extreme pressure and the level 
of care offered is increasingly unacceptable.  The avertable burden, although claimed to 
be less than in other disorders, could still be substantially addressed through improved 
adherence to treatment guidelines, medical accessibility and overall quality of care. 
 
Reducing the burden 
Although the acute treatment of schizophrenia is frequently favourable, the actual 
outcome in schizophrenia in the real world is poor with low compliance rates, frequent 
relapses, rehospitalisations, social and occupational impairment and a high risk of suicide 
(Jobe and Harrow, 2005; Leucht and Heres, 2006).  This study aimed to assess whether 
an intensive, evidence-based seminar could successfully inform psychiatrists of the best 
current clinical practices and change their prescribing habits.  If successful in this regard, 
it would contribute to reducing the burden that patients, their relatives, medical services, 
society and economies bear at present.  By improving knowledge, attitudes and 
behaviour and treatment, this burden can be decreased and at the same time improve 
the quality of life of sufferers. 
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 In order to meet this challenge, psychiatrists and public health organisations throughout 
the world have spent considerable resources on improving treatment outcomes for 
schizophrenia sufferers. International treatment guidelines (APA, 1997; PORT guidelines: 
Lehman et al., 1998; Texas Algorithm: Chiles et al., 1999; NICE, 2002; APA, 2004; 
Royal Australian and New Zealand College of Psychiatrists, 2005) as well as expert 
consensus statements (Kissling et al., 1991; Sartorius et al., 2002; Kane et al., 2003) 
have published recommendations on several key issues for the optimal treatment of 
schizophrenia. 
 
In the age of the internet and globalisation, one would assume that since new knowledge 
based on recent research is rapidly disseminated, changes in clinical management 
incorporating new information would occur more rapidly than in the past.  However, 
there seems to be a distinct unwillingness on the part of many clinicians to adopt new 
treatment guidelines.  Recommendations are often applied at random or have limited 
effect on treatment practices (Cabana et al., 1999).  According to Kissling et al. (1994), 
there is a lack of international or even national consensus – standards of psychiatric care 
vary across the world, within specific countries and even within hospital wards. 
 
1.2   The Lundbeck Institute 
The Lundbeck Institute is situated in Skodsborg, north of Copenhagen, in Denmark.  
Recognising the importance of psychiatric disability and the potential for vastly improved 
care for patients suffering from psychiatric and neurological disorders, as well as support 
for their relatives, the Danish pharmaceutical company H. Lundbeck A/S allocated 
substantial resources and personnel to found the Lundbeck International Neuroscience 
Foundation, which directs and monitors the activities of the Lundbeck Institute.  The 
Lundbeck Institute is committed to improving the quality of life of patients suffering from 
psychiatric and neurological disorders, by increasing awareness and recognition of these 
disorders; and, through education, to improving the treatment of these patients by 
providing objective educational seminars and workshops, treatment tools and 
publications (Lundbeck International Neuroscience Foundation Statutes, 1998; Joubert, 
1999). 
 
All the Institute’s educational activities, once approved by the Foundation, are 
implemented in close co-operation with the Lundbeck Institute Faculty, made up of 
prominent international opinion leaders within psychiatry, neurology and patient interest 
groups.  This arrangement ensures the objectivity and quality of the education provided. 
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Evidence-based seminars 
The main educational activity of the Lundbeck Institute is the presentation of evidence-
based seminars.  The seminars create a forum where psychiatrists, neurologists and 
other mental health workers can meet and discuss their knowledge, share experience 
and review relevant evidence-based literature, in plenary and groupwork sessions. 
 
Currently the Institute presents seminars covering four main disorders: schizophrenia, 
mood disorders, dementia and anxiety disorders.  Each seminar lasts five days with five 
participants from five different countries in attendance.  By the end of 2006 the Institute 
will have presented 121 seminars in total, attended by more than 2800 psychiatrists and 
neurologists from 62 different countries (The Lundbeck Institute, data on file). 
 
1.3   Schizophrenia seminars – integrating science and art 
The Lundbeck Institute has presented schizophrenia seminars since August 1997.  The 
title of the seminars is: Evidence based medicine in schizophrenia: sharing 
responsibilities for improved care.  The material presented at the seminars 
comprises a large collection of literature related to various aspects of schizophrenia and 
its treatment.  This literature is presented and discussed at each seminar, with the aim 
of reaching group consensus on diagnosis, acute and maintenance treatment, 
psychoeducation and the quality of care.  The seminars mainly involve groupwork, where 
a group consists of a participant from each of the five countries attending.  The rationale 
is that facilitating discussion on available literature, international treatment guidelines 
and the sharing of experience encourages consensus (Joubert, 1999) and enhances 
effective learning (Rutherford and Ahlgren, 1991). 
 
For the purposes of this study data from the first 16 schizophrenia seminars, attended by 
408 psychiatrists from 29 countries including Western and Central Europe, South Africa, 
Israel, Canada, Australia and New Zealand, were used. 
 
Questionnaires 
Two weeks prior to attending the seminars, all participants are requested to complete a 
pre-seminar questionnaire (see Appendix 1, page 135) to evaluate their knowledge of, 
and attitudes to, schizophrenia and their practice in treating schizophrenia patients.  The 
data, collected anonymously, are retrieved and displayed on a country-by-country basis.  
These are used during the seminar introduction and discussions to emphasise the 
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differences in treatment habits in the respective countries, or even within a specific 
country. 
 
Two follow-up post-seminar questionnaires are sent to the participants, the first two 
weeks after (see Appendix 2, page 151) and the second six months after (see Appendix 
3, page 158) attending the seminar.  The data presented in this paper were the 
accumulated data and comparative results from the pre- and post-seminar 
questionnaires of the participants of the first 16 schizophrenia seminars. 
 
Each participant is also requested to complete case studies, two for the pre-seminar 
questionnaire and again two for the 6-month post-seminar questionnaire (see 
appendices 1 & 3).  Examples of specific schizophrenia patients are given and the 
participants are asked to find similar patients in their practice and then complete the 
case, reporting on the actual treatment of the case. 
 
The pre-seminar data reveal significant differences in the knowledge and attitudes of the 
attending psychiatrists.  On a few key issues there are five- or six-fold differences 
between the answers given by the participants within a given group, particularly 
regarding optimal doses of the conventional antipsychotics and the duration of treatment 
for first- and multi-episode schizophrenia patients.  These pre-seminar knowledge 
discrepancies form a starting point for the discussions in which the new literature and 
international treatment guidelines are discussed until the participants reach an evidence-
based conclusion, preferably by consensus. 
  
From the outset certain goals are set as measures of successful outcome for the 
seminars.  These include a significant reduction in the dose of the conventional 
antipsychotics used in the treatment of the acute phase, the use of an evidence-based 
dose for the minimum effective dose in relapse prevention, an increase in the treatment 
duration for multi-episode schizophrenia patients and an increase in the overall 
knowledge of the psychiatrists.  With a view to achieving these goals, evidence-based 
literature and international guidelines were selected which could be incorporated in the 
seminar to increase psychiatrists’ awareness of and knowledge about these data. 
 
Effective learning 
The model of teaching at the Institute is designed to enhance effective learning.  
Teaching and learning are not the same thing, but are closely inter-related.  Effective 
teaching takes into account the background and prior knowledge of the students, the 
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methods of teaching used and how to best integrates these into new thinking and 
behaviour. 
 
A systematic Cochrane review on CME for medical professionals review the types of 
education provided and their effect on improving health care (Thomson et al., 2001).  
They reviewed 32 studies involving from 13 to 411 health professionals (total N= 2995) 
that were judged to be of moderate or high quality.  For interventions that combined 
workshops and didactic presentations, there were moderate or moderately large effects 
in 12 comparisons (11 of which were statistically significant).  In seven comparisons of 
didactic presentations, there were no statistically significant effects.  They conclude that 
interactive workshops result in moderately large changes in professional practice while 
didactic sessions alone were unlikely to change professional practice.  These data have 
been replicated showing that interactive techniques are the most effective at 
simultaneously changing physician knowledge and patient outcomes (Davis et al., 1992; 
Davis et al., 1999; Bloom, 2005).  This format of education is reflected by the seminars 
presented by the Lundbeck Institute. 
 
One of the cornerstones of effective education is when new knowledge is integrated into 
existing knowledge through understanding and deeper analysis.  Therefore an 
understanding of the students’ prior knowledge is essential.  The method of delivery of 
the new information should be such that this encourages integration of new and older 
knowledge.  Concrete examples may be required where after the student learns to link 
this information through abstract thinking to their prior knowledge. 
 
Strategies in effective education involve creating curiosity, encouraging active 
participation, presenting evidence for statements, reformulating the new information, 
preferably in a team approach, and integration into new thinking and behaviour 
(Rutherford and Ahlgren, 1991). 
 
Newly learnt information is lost very quickly with the passage of time (Andrade et al., 
2003).  This phenomenon is regarded as normal, but data to support this seem elusive.  
The Research Institute of America (RIA) has found that 33 minutes after completion of a 
course, students retain only 58% of the material covered in the class.  By the second 
day, 33% is retained, and three weeks after the course, only 15% of the knowledge 
delivered is retained (RIA, 1990).  Separate studies conducted by Neil Rackam seem to 
support these findings, in which he has reported that 87% of the learning from any given 
classroom workshop to salesmen is lost within 30 days, if not followed by a coaching 
intervention with the participants’ manager (Rackham, 1998). 
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 The Lundbeck Institute seminars attempt to achieve effective learning by following the 
strategies listed above.  Prior knowledge is gathered with the pre-seminar 
questionnaires, showing differences in pre-seminar thinking and behaviour raises 
curiosity.  After the evidence-based data are presented the participants work in groups 
to answer case-based questions with the new literature at their disposal.  Each group is 
asked to present their answers to the full seminar group and then the new data are 
discussed.  Once the participants return home after the seminar, they are actively 
encouraged to use the new-gained integrated information by doing educational 
workshops in their work settings. 
 
The design of the seminars therefore takes into account background knowledge, 
encourages questions, debate and new thinking, attempts to integrate the new 
information into current thinking and then encourages further analyses and integration 
when the participants present their own education sessions. 
Seminar content 
The five-day-seminar includes presentations and discussions of most major topics of 
management of schizophrenia, first in a plenary discussion, followed by groupwork.  
Each group is assigned a task relating to the topic of the day.  The group is asked to 
review the literature and discuss their varying experiences in the groupwork sessions.  
The groups then return to the plenary session where the results of each groupwork are 
presented to the rest of the participants.  These answers are then discussed, with the aid 
of a moderator, to allow all participants to present their views.  The moderator’s task is 
to try to encourage the group to address unanswered questions on schizophrenia 
management.  When the discussions or recommendations fall outside the framework of 
international treatment guidelines, the moderator's role is to emphasise the use of these 
guidelines and evidence-based medicine.  If the group still wishes to recommend a 
treatment option outside the guidelines, they are asked to provide scientific reasons 
supporting the use of these treatment options. 
 
The topics for each session during the seminar focus on the most important aspects of 
management: acute treatment, maintenance treatment, the new generation 
antipsychotic medications, psychoeducation, and the care pathway in schizophrenia and 
ensuring the quality of care provided.  Central themes throughout the week include 
antipsychotic medication, side effects, remission criteria, relapse and psychotherapeutic 
interventions (Joubert, 1999). 
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The discrepancies in the data collected from the pre-seminar questionnaire are used to 
show differences in knowledge, attitude and behaviour of the psychiatrists present, and 
these form the basis of the discussions. 
 
The treatment principles used are those set out in international treatment guidelines and 
expert consensus meetings. These include: 
• Optimal dose of haloperidol for the treatment of psychosis 
• Minimum effective dose of haloperidol in relapse prevention during long-term 
treatment 
• Recommended treatment duration for first- and multi-episode schizophrenia. 
 
Members of the Lundbeck Institute Faculty, including Dr Werner Kissling (München, 
Germany), Professor John Kane (New York, USA), Professor Nina Schooler (Washington, 
USA), Professor Anthony Hale (Canterbury, UK) and Professor Wolfgang Fleischhacker 
Innsbruck, Austria) wrote the content and approved the format of the programme.  The 
European Committee for Accreditation (ECA) has evaluated and accredited the 
programme, judging it to be unbiased and of high academic standard. 
 
Dr André Joubert (the author of this dissertation) has presented and moderated the 
seminars since their inception in 1997. 
 
Psychopharmacological treatment principles 
During the seminars the treatment principles of the relevant psychiatric disorders are 
addressed, including diagnosis, choice of pharmacotherapy, dose of medication, side 
effects, treatment duration, follow-up visits and all relevant psychosocial interventions 
such as structured psychotherapy, psychoeducation or social skills training.  For the 
purpose of this introduction to the seminars, the treatment principles not relevant to this 
study will only be addressed briefly, while more detailed attention will be given to the 
relevant principles to highlight the topics addressed and the relevant evidence-based 
data presented during the seminars. 
 
Diagnosis 
In this study it was assumed that the diagnosis of schizophrenia had been confirmed, the 
psychiatrist had considered physical and other psychiatric comorbidity, substance abuse 
and suicidality.  Hospital admission and the indication for ECT use should also have been 
considered. 
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 Optimal treatment is important in the early phase of schizophrenia as the severity of the 
symptoms tend to contribute to severe deterioration in the first 5 years of the illness, 
contributing to sustained disability and burden (Robinson et al., 2005), and 10% of 
suicides by schizophrenia patients occur within the first 10 years of schizophrenia being 
diagnosed (Linszen et al., 1998).  Once the diagnosis has been confirmed there are 
several decisions that need to be made concerning the treatment of the psychosis, 
including the choice of the class of antipsychotic, the optimal dose and the initial 
treatment duration. 
 
Choice of pharmacotherapy 
Psychopharmacological treatments form the cornerstone of both acute and maintenance 
therapy for schizophrenia.  The discovery of chlorpromazine in the mid 1950s 
revolutionized the treatment of schizophrenia.  The blockade of central D2 receptors by 
the conventional antipsychotics was thought to be the key.  The new generation of 
antipsychotics have effects on various other receptors such as those of the 5HT2A 
system.  However, while these other receptor binding properties may modify the side-
effect profiles and possibly broaden the spectrum of efficacy, D2 antagonism appears to 
remain central to antipsychotic action (Carlsson 1995; Seeman 2000), but with new 
evidence of extrasynaptic dopaminergic activity (Carlsson and Carlsson, 2006). 
 
Antipsychotic drugs are effective in treating the positive symptoms of schizophrenia 
(hallucinations and delusions), but less effective for the negative and neurocognitive 
symptoms.  Approximately 60% of patients treated with antipsychotic drugs achieve full 
or near-full remission of their positive symptoms.  However, many patients continue to 
experience significant negative symptoms and cognitive impairment (Bilder et al., 2002; 
Lambert and Castle, 2003). 
 
Several factors seem to be important in selecting a drug, such as previous response to 
an antipsychotic, available modes of administration (oral versus depot or long-acting), 
patient and relative preference, side effects and cost (APA, 2004).  The preference of the 
psychiatrist seems to be a major factor in the selection of a drug.  There are also 
regional differences in the availability of the new generation antipsychotics and their 
appropriate use (Emsley et al., 1999). 
 
Expectations of remission, recovery, rehabilitation and reintegration are now much 
higher.  Until recently, there was little evidence for greater efficacy of one antipsychotic 
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over another in schizophrenia subgroups, except for clozapine in treatment resistant 
schizophrenia (Kane and Marder, 1993) and also in those with active suicidal ideation 
(Meltzer, 2005). However, a recent important, but methodologically flawed study 
comparing the efficacy and safety of new generation antipsychotics found a significant 
advantage, in terms of lower rates of discontinuation for lack of efficacy, for olanzapine 
20mg/day compared to risperidone, quetiapine, ziprasidone and perphenazine 
(Lieberman et al., 2005). 
 
Choice of medication in the acute treatment phase 
For several years there has been debate on whether conventional or novel antipsychotic 
drugs should be used as first-line treatment in first-episode psychosis or in continuing 
care of multi-episode patients (Geddes et al., 2000; Kapur and Remington, 2000; 
Lieberman et al., 2003).  On the one hand, some suggested that new generation 
antipsychotics might be no more effective and only marginally better tolerated than 
haloperidol (Geddes et al., 2000) when control for the effect of the often excessively 
high dose of haloperidol is exercised.  Others believed that efficacy and tolerability are 
clearly different (Davis et al., 2003). 
 
A Cochrane Review found haloperidol to be effective – however, so toxic that “given the 
choice, people with schizophrenia may wish to start another antipsychotic with less 
likelihood of causing parkinsonism, akathisia and acute dystonias” (Joy et al., 2001). 
 
Until recently most definitive meta-analyses favour new generation drugs over 
conventional antipsychotics on efficacy and tolerability grounds (Davis et al., 2003), 
though other authors remain somewhat more sceptical (Geddes, 2004) or reported 
modest superiority (Leucht et al., 2003). 
 
In the past two years new data have been published which, for the first time, have 
compared the efficacy and tolerability of the newer and older antipsychotic drugs, 
namely the CATIE (Lieberman et al., 2005), SOHO (Haro and Salvador-Carulla, 2006) 
and CUtLASS (Jones et al., 2006) studies.  These studies have been keenly anticipated 
and have been widely publicised.  From subsequently published commentaries, their 
data have unfortunate flaws, which have not produced convincing outcomes, but have 
led to strong opinions being penned in the scientific and commercial press. 
 
The CATIE study (Lieberman et al., 2005) produced advantages for the new generation 
antipsychotic olanzapine, but was prescribed at unusually high doses.  Perfenazine, a 
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conventional antipsychotic seemed to produce good efficacy and comparable side effects, 
even EPS.  However, patients with current or a history of EPS, often considered to be a 
“more difficult to treat” sub-population of schizophrenia patient were not “randomised” 
to this drug.  There is evidence that patients with TD may represent a subgroup with a 
more severe and refractory course of illness (Ascher-Svanum et al., 2006).  Patients 
with TD were excluded from any analysis involving perphenazine, potentially eliminating 
an important subset of patients.  Furthermore, a significant disconnect appears between 
the low rating scale scores and the high patients’ discontinuation due to EPS.  
 
The SOHO study (Haro and Salvador-Carulla, 2006) showed an advantage for the new 
generation drugs olanzapine and clozapine over other drugs.  The new generation 
antipsychotics were associated with a lower frequency of EPS and anticholinergic use 
than conventional antipsychotics, with the lowest frequency for clozapine-, quetiapine- 
and olanzapine-treated patients, at around 10%.  The new generation antipsychotics 
exhibited a lower risk for tardive dyskinesia than the conventional antipsychotics. 
 
In contract the CUtLASS study (Jones et al., 2006) seemed to show no advantage for the 
new generation drugs, based on the primary outcome of Quality of Life.  Patient 
randomisation was not blinded and the number of patients on individual drugs resulted 
in an underpowered analysis. 
 
Neither overly broad generalization nor wholesale rejection (or worse, cherry-picking) of 
study findings is helpful.  Each study is a piece of the puzzle that answers a clinical 
question.  As we try to develop more effective treatments for tomorrow (CATIE and 
CUtLASS reinforce the urgent need to do so), only a balanced understanding and 
individualized application of our data repository on existing treatments can optimize 
outcomes for persons with schizophrenia today (Tandon et al., 2006). 
However, the CATIE and CUtLASS studies reinforce several points of agreement (Tandon 
et al., 2007): 
• Actual benefits of new generation antipsychotics over conventional antipsychotics 
may be exaggerated; all new generation antipsychotics are not uniformly more 
effective and/or safer than conventional antipsychotics; 
• Clozapine is more efficacious than other agents in otherwise treatment-refractory 
patients; 
• Non-clozapine new generation antipsychotics provide a modest and inconsistent 
greater efficacy than conventional antipsychotics with reference to negative 
symptoms, cognition, and mood; differential EPS and related neuroleptic adverse 
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effects (dysphoria, neuroleptic-induced deficit syndrome, bradyphrenia) 
substantially explain such differences; and new generation antipsychotics 
generally have a lower liability than conventional antipsychotics to cause EPS; 
• Different antipsychotic agents present different challenges in terms of balancing 
efficacy and safety/tolerability and there is considerable individual variability in 
antipsychotic response and vulnerability to specific adverse effects. 
• Given broadly similar efficacy but significantly different adverse-effect profiles, it 
is important to use an effective antipsychotic that does not cause a significant 
adverse effect in each patient; "significant adverse effect" is determined by 
patient vulnerability, preference, and ultimately by which adverse effect the 
patient develops. 
The expert guidelines (Kane et al., 2003) suggest tailoring the choice of antipsychotics to 
primary symptoms of the psychosis.  In the case of a first-episode psychosis patient with 
predominantly positive symptoms, they recommend the use of risperidone, while they 
recommend either risperidone or aripiprazole for patients with predominantly negative 
symptoms. 
 
There may still be a place for conventional antipsychotic drugs when all newer options 
have failed, especially in cases where long-acting (depot) use is justified.  However, this 
is debatable as a long-acting new generation agent is now available.  The better-
tolerated new generation antipsychotics seem fully justified as first line treatment on 
clinical and humane grounds, despite their higher cost (Sartorius et al., 2002; Royal 
Australian and New Zealand College of Psychiatrists, 2005), particularly so in first-
episode psychosis, where the patient’s first experience with an antipsychotic may have a 
profound impact on his/her attitude towards medication use in the future (McGorry, 
2002). However, a new profile of side effects has now emerged with the new generation 
antipsychotics.  Referred to as the “Metabolic Syndrome”, these effects are on weight 
gain, glucose dysregulation and dyslipidaemia and have now been recognised as serious 
clinical problems, particularly with olanzapine and clozapine, and to a lesser extent with 
risperidone and quetiapine (Lieberman et al, 2005). 
 
The 2004 American Psychiatric Association (APA) guidelines suggest the following 
principles in deciding between conventional and new generation antipsychotic drugs: 
 
• Consider second-generation antipsychotics as first-line medications because of 
the decreased risk for extrapyramidal side effects and tardive dyskinesia 
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• For patients who have had prior treatment success or who prefer conventional 
agents, these medications are useful and for specific patients may be the first 
choice 
• New generation antipsychotics may have superior efficacy in treating global 
psychopathology and cognitive, negative, and mood symptoms 
• With the possible exception of clozapine for patients with treatment-resistant 
symptoms, antipsychotics generally have similar efficacy in treating positive 
symptoms. 
 
Few international treatment guidelines discuss the choice of medication.  The Royal 
Australian and New Zealand College of Psychiatrists schizophrenia guidelines (2005) 
suggest the first line use of atypical antipsychotic medication on the basis of better 
tolerability and reduced risk of tardive dyskinesia.  This is particularly strongly 
recommended for first-episode patients where the superior tolerability makes the new 
generation agents the first, second and third line choice.  However, the guidelines warn 
against the associated potential of serious medium to long-term side effects for which 
patients must be carefully monitored. 
 
The UK’s NICE guidelines also recommend the use of new generation antipsychotic 
medication on the basis of better tolerability and reduced risk of tardive dyskinesia 
(NICE, 2002). 
 
The most comprehensive review, by the World Psychiatric Association (WPA), highlights 
all published data providing evidence for the use of the new generation antipsychotics 
(Sartorius et al., 2002). 
 
The Hungarian guidelines (1996) emphasise the importance of monotherapy. 
 
Choice of medication in the maintenance treatment phase 
The choice of antipsychotic for the maintenance phase of treatment is linked to several 
factors, predominantly the availability of the medication in depot- or long-acting form, 
and patient preferences and compliance. 
 
Compliance (adherence/concordance) is of major concern, especially in the maintenance 
phase of schizophrenia management.  Previously the depot conventional antipsychotics 
were seen as the solution to the lack of compliance to oral medications. 
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Even though there is little evidence that the new generation antipsychotics are more 
efficacious than the conventional antipsychotic medications in the acute treatment of 
positive symptoms, they seem to be more effective in relapse prevention (Csernansky, 
2002).  Also, the new generation antipsychotics demonstrate a clear advantage over the 
conventional antipsychotic agents because of the decreased risk of potentially serious 
side effects (Kapur et al., 2004; Gaebel et al., 2005).  Furthermore, data have suggested 
greater efficacy for negative and cognitive symptoms (Purdon, 1999; Bilder et al., 2002). 
 
Recent expert guidelines (Kane et al., 2003) suggest the use of most of the new 
generation antipsychotics in the maintenance phase of treatment, as well as any long-
acting medication. 
 
The Australian guidelines mention the option of conventional antipsychotic medications 
for relapse prevention only in low doses, where they may still have a role in an ever 
smaller proportion of patients (Royal Australian and New Zealand College of 
Psychiatrists, 2005). 
 
It needs to be remembered that, for many countries across the globe, access to the new 
generation antipsychotics is restricted. In these countries, judicious use of the older 
agents may also provide a better outcome for patients (Emsley et al., 1999). 
 
The dose of antipsychotic medication 
Over the past 50 years there has been a worldwide trend for markedly excessive 
antipsychotic doses to be used both in the acute and maintenance phases, and also as a 
behavioural control measure.  This trend has contributed to a great deal of unnecessary 
suffering and avoidable burden on individuals.  
 
Establishing the optimal dose for the treatment of acute psychosis is important, as there 
is a dose-response curve up to a maximum response for antipsychotics (Davis et al., 
1989).  After this point, higher doses afford no further improvement and may even 
decrease response efficacy (Baldessarini et al., 1988). 
 
Functional neuro-imaging with Positron Emission Tomography (PET) studies with 
haloperidol have shown a direct association between striatal D2-receptor occupancy and 
antipsychotic efficacy, hyperprolactinaemia and the emergence of extrapyramidal side 
effects (EPS) (Farde et al., 1992).  This suggests a haloperidol therapeutic window linked 
to D2-receptor occupancy, with antipsychotic response starting at 60% occupancy and 
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EPS emerging at occupancy levels above 80% (Kapur et al., 2000).  Therefore, careful 
titration of the haloperidol dose may achieve an antipsychotic effect without the 
emergence of EPS side effects.  The McEvoy et al. (1991) “neuroleptic threshold” study 
found an effective dose of haloperidol to be 3.7 mg/day.  This was in line with an earlier 
report by Farde et al. (1992) that a dose of 2 mg of haloperidol resulted in 70% D2-
receptor occupancy, suggesting that this could be the optimal dose.  These data are 
consistent with the results of the Zimbroff et al. study (1997), which reported modest 
efficacy, yet significant EPS in the 4mg haloperidol arm of the study. 
 
These and other data support the more recent trend to use lower doses of haloperidol, 
including acute phase trials (van Putten et al., 1990; McEvoy et al., 1991; Zimbroff et 
al., 1997; Emsley et al., 1999; Zhang-Wong et al., 1999; Oosthuizen et al., 2001, 
McEvoy, personal communication, 2006), maintenance phase studies (Eklund and 
Forsman, 1991), blood level monitoring (Coryell et al., 1998) and neuro-imaging studies 
(Kapur et al., 1996a and 1996b; Remington and Kapur, 1999; Kapur et al., 2000). 
 
However, not all the evidence supports the use of low-dose conventional antipsychotics, 
with some suggesting poorer efficacy for low-dose oral (Zimbroff et al., 1997) or depot 
medication (Kane and Marder, 1983; Marder et al., 1996).  An optimum dosage range of 
10-15 mg/day haloperidol has been proposed (Baldessarini, 1988). 
 
A Cochrane meta-analysis (Waraich et al., 2002) found that low doses of haloperidol (3-
7.5 mg/day) “did not clearly result in loss of efficacy” and had a lower rate of 
development of clinically significant extrapyramidal adverse effects than at higher doses 
of >7.5-15 mg/day. 
 
An evidence-based review of randomised antipsychotic trials, (Davis and Chen, 2004) 
found no evidence that higher doses of antipsychotics were more effective than low 
doses, suggesting that doses as low as 3.3 mg of haloperidol could be an effective dose. 
 
Several recommendations suggest using conventional antipsychotics at a dose close to 
the “EPS threshold” (i.e. the dose that will induce extrapyramidal side effects with 
minimal rigidity detectable on physical examination) (APA 2004).  Expert consensus 
suggests a haloperidol dose as low as 2.5 mg/day (Kissling et al., 1991). 
 
The recommended optimal dose of haloperidol for the treatment of acute psychosis in 
schizophrenia varies from 3-20 mg/day (Hungary), 5-14 mg/day (Baldessarini et al., 
1988), 11-19 mg/day (Davis et al., 1989), 6-15 mg/day (Dixon et al., 1995), 5-20 
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mg/day in the PORT and other guidelines (Marder, 1996; APA, 1997; Lehman et al., 
1998; APA, 2004; Netherlands), and “not higher than 20 mg/day” (Denmark).  Other 
studies suggest ultra-low doses of 1-2 mg/day (McEvoy et al., 1991; Oosthuizen et al., 
2001; Oosthuizen et al., 2004) while others have until relatively recently studied doses 
as high as 60 mg/day (Rifkin et al., 1991) and even 200 mg/day (Chang et al., 1994). 
 
However, all haloperidol data should be seen in light of the warning from Oosthuizen et 
al. (2004) on the use of low dose haloperidol in first-episode psychosis.  They reported 
an incidence of probable or persistent tardive dyskinesia of 12.3% (n=57), despite a 
mean dose of haloperidol of 1.68 mg/day. 
 
The results of the CATIE study where the conventional antipsychotic perphenazine was 
compared to several other new generation antipsychotics (Lieberman et al., 2005) have 
contributed to the debate.  Although efficacy was broadly similar, perphenazine was 
associated with increased, but not significant, discontinuation due to EPS (it should be 
remembered that patients with tardive dyskinesia at baseline were not randomised to 
the perphenazine group).  A recent meta-analysis showed insignificant differences in EPS 
between new generation antipsychotics, other than clozapine, and low potency 
conventional comparators (Leucht et al., 2003).  The CATIE study results confirmed this. 
 
The high-potency antipsychotics such as haloperidol are known to cause more EPS than 
the low-potency drugs such as chlorpromazine (Leucht et al., 2003).  In the haloperidol 
versus new generation antipsychotic studies, the use of higher haloperidol doses may 
have lead to a bias that favours the newer drugs due to haloperidol-induced EPS 
(Haddad and Dursun, 2006).  Further research is required to study low dose, low 
potency conventional antipsychotics such as chlorpromazine or even perphenazine, 
rather than haloperidol, as the comparator versus new generation antipsychotics. 
 
The recommended doses for the new generation antipsychotics range as follows: 
aripiprazole 10–30 mg/day, clozapine 150–600 mg/day, olanzapine 5–30 mg/day, 
quetiapine 300–800 mg/day, risperidone 2–8 mg/day, and ziprasidone 120–200 mg/day 
(PORT, Lehman, 1998; Stein et al., 1999) while the APA guidelines recommend clozapine 
300-400 mg/day, risperidone 4-6 mg/day, olanzapine 10-20 mg/day and quetiapine 
150-750 mg/day (APA, 1997). 
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Minimum effective antipsychotic dose in relapse prevention 
The principle of the “minimum effective dose” of an antipsychotic is the lowest dose of a 
drug at which there is no significant increase in the risk of relapse, and the risk of side 
effects is minimal.  This is usually applied during the maintenance phase of treatment.   
 
A Cochrane review (Bollini et al., 1994) of the antipsychotic neuroleptic dose for 
maintenance management of schizophrenia concluded that there was no benefit from 
doses higher than 375 mg/day of chlorpromazine or the equivalent of such a dose in the 
case of other antipsychotics (7.5 mg/day of haloperidol).  It should be noted that 
adequate studies on lower doses could not be found. 
 
Few guidelines recommend haloperidol doses for maintenance treatment.  Those that do 
have suggested not more than 5 mg/day (Danish Psychiatry Association, 1989), or 2.5-
10 mg/day (Netherlands Schizophrenia Foundation, 1996). 
 
Antipsychotic side effects 
The risk of side effects seems to drive the choice of medication.  Intolerable side effects 
can lead to the premature discontinuation of drugs and result in an increase in 
potentially damaging relapses of acute symptoms of schizophrenia (Marder, 1998).  As 
concluded in the CATIE study: “Selecting an antipsychotic involves a trade-off between 
efficacy and a range of side effects, the relative importance of which are likely to vary in 
different consultations” (Haddad and Dursun, 2006; Lieberman et al., 2005). 
 
PET studies have shown haloperidol D2-receptor occupancy of over 80% using 4 and 6 
mg/day, which is associated with significant EPS-side effects (Farde et al., 1992).   
 
The risk of tardive dyskinesia is significantly higher when conventional drugs are used 
and the levels of extrapyramidal symptoms (EPS) remain high, even with low dose 
conventional agents such as haloperidol (Oosthuizen et al., 2004).  The new generation 
antipsychotic drugs are better tolerated and produce fewer motor side effects, including 
tardive dyskinesia – a definite advantage. 
 
However, some of the newer drugs have potentially serious side effects of their own, 
such as hypotension and seizures (clozapine), prolactin elevation (risperidone, 
amisulpride), sedation (quetiapine, olanzapine, clozapine) and perhaps more importantly 
weight gain (olanzapine and clozapine) (Singh, 2005).  The emergence of endocrine and 
cardiovascular side-effects, called the Metabolic Syndrome, characterized by weight gain, 
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increased triglycerides and total cholesterol and impaired glucose tolerance (Meyer, 
2001), could restrict the long-term use of certain new generation antipsychotics (McEvoy 
et al, 2005).  In the recently published CATIE study, olanzapine was associated with 
significantly greater increases in glycosylated haemoglobin, cholesterol and triglycerides 
than the other drugs even after adjustment for treatment duration, with ziprasidone 
being associated with an improvement on all three parameters (Lieberman et al., 2005; 
McEvoy et al., 2005; Haddad and Dursun, 2006). 
 
Duration of antipsychotic treatment 
Treatment duration usually refers to the duration of treatment once the patient’s 
symptoms are in remission.  Another important duration is the time one should wait to 
notice a response after starting an antipsychotic drug, as well as how long to wait before 
deciding that a drug has insufficient or no effect. 
 
Time to antipsychotic treatment response 
The criteria that should be reviewed prior to judging that there has been non-response 
to a specific drug are an adequate dose and adequate treatment duration, with 
confirmed compliance.  It had long been assumed that the onset of antipsychotic action 
is delayed, and that these agents take several weeks to exhibit an effect.  In their review 
of the literature, Keck et al. (1989) reported that the effects of most drugs are only 
significantly superior to a placebo after 3 weeks of treatment (Abse et al., 1960; 
Schooler et al., 1976; Johnstone et al., 1978).  However, this result is usually a mean of 
all the different response times in the study subjects, and thus includes the patients who 
will not respond at all.  If non-responders were removed from the dataset and another 
retrospective analysis performed the mean response time would be significantly shorter 
– as demonstrated in depression studies (Parker et al., 2000; Posternak and 
Zimmerman, 2005; Mitchell, 2006; Robinson, 2007).  Recently, evidence has emerged 
showing in fact that the onset of antipsychotic action is rapid, with most of the 
antipsychotic effect occurring within the first few weeks of treatment (Agid et al., 2003; 
Kapur et al., 2005; Leucht et al., 2005; Li et al., 2006), with more improvement 
occurring in the first few days than in any other later period of equal duration and 
producing 68% of total annual improvement achieved within the first four weeks (Leucht 
et al., 2005).  This relates particularly to multi-episode patients, while in first-episode 
psychosis some patients may take much longer to respond to treatment (Emsley et al., 
2006). 
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One set of guidelines (Kane et al., 2003) considered 3–6 weeks an adequate 
antipsychotic trial, but suggested waiting until 4–10 weeks before making a major 
change in treatment regimen if there was a partial response.  They recommended trying 
to improve response by increasing the dose of the medication before switching to a 
different agent. 
 
The conclusion can be made that patients respond within days, although full remission of 
schizophrenia symptoms usually occurs slowly over many weeks. Guidelines still suggest 
that treatment with a specific antipsychotic agent should be continued for at least four to 
six weeks before concluding that there has been non-response to the drug, but as seen 
in the depression and schizophrenia data above, this guideline may soon change.  Leucht 
et al. (2007) has just completed a review of antipsychotic trials showing that continuing 
treatment for four to six weeks seems to delay effective outcomes. They conclude that 
patients with no improvement of symptoms during the first 2 weeks of treatment are 
unlikely to respond at week 4 and may benefit from a change of treatment (Leucht et 
al., 2007). 
 
Relapse prevention 
Long-term maintenance treatment, or relapse prevention, encompasses the topics of 
indications for maintenance treatment, oral versus depot/long-acting administration of 
the drugs, minimum effective dose and treatment duration for first- and multi-episode 
patients. 
 
Treatment duration after remission for first-episode psychosis 
For first-episode psychosis the treatment guidelines vary from 2-3 months in Denmark, 
to 6 months in Sweden, to at least two years in the Netherlands.  Most suggest 1 to 2 
years of antipsychotic treatment before considering reducing the dose (Kissling et al., 
1991; Texas Algorithm: Chiles et al., 1999; APA practice guidelines, 2004; Practice 
guidelines for Sweden, France, Hungary, Denmark and the Netherlands). 
 
The latest guidelines from the United Kingdom suggest that if a patient is in full 
remission and remission is sustained for 12 months the medication may be stopped 
gradually, with close follow up (NICE, 2002). 
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The guidelines from Australia for first-episode psychosis patients suggest that sustained 
and comprehensive intervention should be provided for the initial 3-5 years (Royal 
Australian and New Zealand College of Psychiatry treatment guidelines, 2005). 
 
However, there are clear data that stopping treatment even after one year of 
maintenance treatment in first episode patients leads to symptom re-emergence in 78% 
of patients in the first year and 96% within two years after discontinuation (Gitlin et al., 
2001). 
 
These data should provide strong evidence for significantly longer maintenance 
treatment durations in schizophrenia than the current guidelines, possibly advocating 
unlimited treatment duration (Zipursky, 2002). 
 
Treatment duration after remission for multi-episode schizophrenia 
In this instance the recommended treatment duration is at least 5 years (Kissling et al., 
1991; APA, 1997 and 2004; France; the Netherlands).  For patients with severe 
relapses, histories of violence and/or aggression and/or suicide the recommendation is 
for life-long continuous antipsychotic relapse prevention.  The Danish guidelines (1996) 
suggest 3-5 years of sustained remission before the dose is reduced. 
 
However, due to the lower incidence of EPS side effects with the use of the new 
generation antipsychotic drugs, the abandonment of the differentiated treatment 
duration for first- and multi-episode patients has been suggested (Robinson et al., 
2005).  The potential irreversible loss of functional impairment associated with the first 
relapse, possibly outweighs the risk of long-term side effects with the new generation 
antipsychotic drugs.  However, this risk-benefit decision should, on one hand consider, 
EPS, in particular the high-potency conventional antipsychotics, but also, on the other, 
the Metabolic Syndrome with the long-term use of some of the new generation 
antipsychotics (McEvoy et al., 2005). 
 
Psychosocial interventions 
While the focus of this thesis is on pharmacological interventions, it needs to be 
remembered that an holistic approach to treatment is recommended as prescribing 
medication alone is not likely to achieve the best outcome. Other psychosocial 
interventions play a critical role in the management of schizophrenia. Under-
development of quality systems of care and failure to provide intensive and 
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comprehensive psychosocial interventions to complement drug treatment have resulted 
in limited improvement in functioning and quality of life for schizophrenia patients, while 
predicting and preventing suicide remains poor (Roos et al., 1992). 
 
Psychoeducation 
The use of psychosocial interventions, such as psychoeducation, and drug management 
programmes, in addition to maintenance antipsychotic medication, reduces the risk of 
psychotic relapse (Linszen et al., 1998).  The value of psychoeducational psychotherapy 
in the optimal treatment of schizophrenia has been shown (Kissling et al., 1996; 
Buchkremer et al., 1997), as have the principles of “Shared Decision Making” (Hamman 
et al., 2003) 
 
A Cochrane review of studies employing psychoeducation found that compared to 
standard care alone, the addition of psychoeducation improved outcome and compliance 
(Pekkala and Merinder, 2004).  The number needed to treat (NNT) with psychoeducation 
in addition to standard care was 9.  However, while still supporting psychoeducation as 
good clinical practice, the recent National Institute for Clinical Excellence guidelines were 
ambiguous in their evaluation of the evidence, (NICE, 2002). 
 
1.4   Haloperidol – historic rise and fall in dose 
Haloperidol (initially known as R1625) was synthesized by Bert Hermans at the Janssen 
Laboratories, in Belgium, on 11 February 1958.  Animal tests, started two days later, 
suggested to Paul Janssen and his colleagues that this butyrophenone drug would be of 
great interest as its action was similar to, but much more powerful, than that of 
chlorpromazine. 
 
Five weeks after its synthesis, haloperidol was provided to a psychiatrist, Dr C. Bloch, in 
Brussels.  He gave an intravenous injection of two milligrams of haloperidol to a few 
patients suffering from delirium tremens (Janssen, 1989; Niemegeers, 1989).  In a letter 
Bloch described his first patient as “a young woman of 25 years old with a good physical 
condition who presented an emotional crisis (hypermotricity).  A slow injection of 1ml 
was immediately followed by a slight sedation and three minutes later by drowsiness.  
Three hours later, the sedative reaction was still present, but to a lesser extent.  Her 
blood pressure decreased from 120/70 to 95/70 mmHg while her heartbeat went from 
25X4 (excitation) to 19x4 (sedation)” (Granger and Albu, 2005). 
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The first article on R1625, originating in Liège, was published in Acta Neurologica et 
Psychiatrica Belgica, and entitled “R1625: a new symptomatic treatment of psychomotor 
agitation” (Divry et al., 1958).  In this study of 18 agitated patients, the authors 
concluded that haloperidol was a “powerful sedative of agitation” and “the excellence of 
the sedative action of R1625 upon psychomotor agitation is such that this drug has 
become of common usage (in the same year as its synthesis!) in our hospital 
department”.  There was no mention of neurological effects. 
 
In their second publication (Divry et al., 1959), entitled: “Study and clinical 
experimentation of R1625 or haloperidol, a new neuroleptic and neurodysleptic”, they 
reported “the brilliant effects obtained intravenously in the symptomatic treatment of 
agitation have led us to continue the experiment … The first results published here are 
enough to show, as we had guessed during episodic injections, that R1625 is not a basic 
sedative but a genuine neuroleptic” (Granger and Albu, 2005). 
 
The subsequent clinical studies confirmed that this new agent was particularly effective 
in the treatment of delusions and hallucinations.  In 1960, 15 reports were published in 
Acta Neurologica and Psychiatrica Belgica.  Since those initial experiments hundreds of 
studies have followed. 
 
In a review of haloperidol efficacy the randomised studies showed a clinically significant 
reduction in psychotic symptoms over placebo after 6 months of treatment when 
compared to placebo (Joy et al., 2001).  
 
Of interest to the present study are the varying dosages of haloperidol that have been 
prescribed over the decades.  Dosing seemed to have started very low (Divry, 1958 and 
1959;), peaked at 100mg/day or more and now returned to the initial doses of 2-4 mg 
(seminar data). 
 
Several studies have reported the use of very high haloperidol doses of 75 mg (Paquay 
and Brasseur, 1976) and 60 mg per day, where the ‘tolerance was always good’ 
(Lavagna et al., 1976).  McCreadie and McDonald (1977) reported in the British Journal 
of Psychiatry on a 3-month, double-blind, chlorpromazine-controlled trial, high dosage 
haloperidol study using 100 mg haloperidol daily in drug resistant schizophrenia in-
patients.  “Serious extrapyramidal side effects were not seen at high doses.  However, 
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the majority of patients on haloperidol showed deterioration in ward behaviour, possibly 
related to drowsiness”.1 
 
Meanwhile, across the Atlantic, rapid neuroleptization was rampant with doses of 1-
30mg being used, with a maximum daily dosage of 100 mg (Donlon et al., 1979). 
  
In a randomised study comparing haloperidol low dose (mean: 20 mg/day) to high dose 
(mean: 58 mg/day) the authors reported no difference in efficacy or side effects and 
concluded “Administration of higher oral haloperidol doses cannot be recommended as a 
standard procedure” (Modestin et al., 1983). 
 
As recently as 1989, a Greek study reported the effective use of haloperidol doses up to 
60 mg per day, which were associated with a significant decrease in serum testosterone 
levels in 15 male patients (Rinieris et al., 1989). 
 
In 1991 Rifkin et al. reported a 6-week study where 87 patients were randomized to 
receive 10, 30 or 80 mg/day of haloperidol.  Survival analysis showed no differences 
among the three treatments, side effects were minimal in all three treatment groups 
with no differences among the groups.  They suggested that haloperidol dosages higher 
than 10 mg/day for most patients have no additional beneficial effect in the treatment of 
acute or exacerbated schizophrenia (Rifkin et al., 1991).   
 
By 1993 there was a “trend towards lower neuroleptic dosing in the treatment of 
psychosis” but there were still patients receiving doses of 40-80 mg/day.  In their study 
Remington et al. (1993), reported on a successful dose-lowering study.  A similar study 
in Canada saw mean doses successfully reduced from 62 to 30 mg/day (Leblanc et al., 
1994).  Similar results were later reported by Volavka et al. (2000). 
 
However, in 1994, a study in Taiwan (Chang et al., 1994) reported on the treatment of 
60 schizophrenia patients with high to very high doses of 40-200 mg/day haloperidol.  
The researchers noted, “All patients safely tolerated the high haloperidol dosages and 
only five patients had extrapyramidal side effects that were unresponsive to 
anticholinergic medication”.  They also added that therapeutic improvement was not 
observed in each patient. 
                                          
 
1 A personal observation: The highest reported dose of haloperidol suggested by a seminar 
participant was in 1998, from a British psychiatrist who surprised us all by stating that he routinely 
used 150 mg/day of haloperidol for his acutely psychotic patients, without serious side effects. 
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 Illustrating the dangers of excessively high doses of haloperidol, a case report described 
a severely agitated patient who received 80 mg of intravenous haloperidol: “The results 
of the electrocardiogram were consistent with torsade de pointes and showed a 
prolonged QTc interval of 610 milliseconds.  Magnesium sulphate controlled the 
arrhythmia, … but bravery and persistence prevailed and the patient received one 
additional 80 mg haloperidol dose six hours after the arrhythmia-triggering dose, without 
reoccurrence of torsade de pointes (total dosage 915 mg over 7 days).  Haloperidol was 
then discontinued” (O’Brien et al., 1999). 
 
In a sudden turn around, a dose of 4 mg/day of haloperidol was found to be as effective 
as a dose of 10 and 40 mg (Stone et al., 1995).  In 1997 Zimbroff et al. published a 
sertindole versus haloperidol versus placebo-controlled study.  This study has been 
called “the haloperidol dose finding study” because doses of 4, 8 and 16 mg of 
haloperidol were randomly assigned.  Efficacy was similar for the three groups, although 
side effects were significantly reduced in the 4 mg group, but this group still had 
significantly more side effects than the placebo group (Zimbroff et al., 1997).  This 
raised the question of whether there is an effective yet EPS-free haloperidol dose. 
 
In contrast to most earlier studies, Oosthuizen et al. (2001) from South Africa reported 
an open label, dose-finding study in 35 patients with first-episode psychosis, employing 
ultra-low haloperidol doses.  After 12 weeks, 16 patients (55%) had stabilized on 1 
mg/day or less, and 29 (83%) were stable on a mean dose of 1.78 mg/day.  There were 
no significant differences in mean EPS ratings between baseline and 12 weeks.  Ultra-low 
doses of haloperidol were found to be effective and well tolerated in first-episode 
psychosis.  This study replicated one of the core messages from McEvoy et al. (1991), 
that low dose haloperidol can be effective if the initial dose is maintained for a sufficient 
period of time to allow the medication to take full effect.  In a further randomised, 
double-blinded study Oosthuizen et al. compared 20 patients treated with 2 mg/day 
haloperidol against 20 patients treated with 8 mg/day haloperidol.  There were no 
differences in efficacy between the groups, while there were significantly fewer EPS in 
the 2 mg/day group (Oosthuizen et al., 2004). 
 
The first dose of haloperidol given in 1958 was 1 mg.  In the subsequent years the dose 
gradually increased to exceed 100 and 150 mg per day, but was also studied in a dose 
as high as 200 mg per day.  Since the beginning of the 1990s the dose has rapidly 
declined again to the latest studies showing significant effect with a low level of side 
effects at approximately 1-2 mg per day. 
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 In short, lower haloperidol doses may be as effective as the higher dose ranges and 
result in fewer adverse effects (Waraich et al., 2002). 
 
1.5   Evidence-based medical education 
Psychiatry, as with other branches of medicine, has changed profoundly over the last few 
decades, with continual advances and changes in available information in the field of 
schizophrenia.   
 
The rate of change in medical technology is now so fast that it is estimated that 50% of 
all knowledge is out of date within 5 years; therefore, the need for doctors and allied 
professionals to remain informed about the latest management techniques is greater 
than ever (Souery and Mendlewicz, 1995). 
 
These changes include the new data on the epidemiology of disorders, adaptation of 
diagnostic criteria, refinement of diagnostic categories, aetiological changes, recent 
attention to early intervention strategies in prodromal stages of the disease, replacement 
of the conventional antipsychotics with the new generation drugs as well as the re-
introduction of clozapine for treatment resistant cases.  Regular introduction of new 
antipsychotics, changes in dosing recommendations, the mass discharge of many 
patients from long-term in-patient care, the greater recognition of the need to 
supplement physical treatment with more active psychosocial interventions for both the 
patient and particularly for the family (Singh, 2005), and then publication and updating 
of international treatment guidelines have also occurred.  All these factors make it 
essential that psychiatrists be kept informed of updates and changes, preferably from 
scientifically reliable sources. 
 
Evidence-based medicine (EBM) is the conscientious, explicit, and judicious use of 
current best evidence in making decisions about the care of individual patients, which 
implies clinicians integrate individual clinical expertise with the best available external 
clinical evidence from systematic research (Sackett et al., 1996). 
 
In recent years there has been an understandable and growing focus on the importance 
of Evidence-based Medicine (EBM).  Clinicians still fail to adequately recognise that in the 
case of burdensome psychiatric disorders they should practise high quality medicine; 
they should be able to justify their decision-making under all (or nearly all) 
circumstances, while still applying judicious economic efficiency (Stein et al., 2002). 
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 Goldner and Bilsker described evidence-based medicine, and its role in education, in 
their seminal paper in 1995 (Goldner and Bilsker, 1995).  Evidence-based psychiatry 
requires that psychiatrists base their clinical decision-making not so much on lecture-
styled training or traditional treatment practice (which is not necessarily the same as 
clinical experience) as on high-quality research evidence. 
 
However, in psychiatry there are still large knowledge caveats creating important 
residual clinical uncertainties.  Among these is the role of new generation antipsychotics, 
the duration of treatment before a patient is considered non-responsive and the 
prioritisation of strategies when non-response occurs.  However, answers to any of the 
questions regarding optimal treatment in psychiatry require several large, but simple, 
randomized trials. 
 
Implementing EBM primarily requires a practical, problem-based method of learning that 
allows clinicians to keep up with the ever-increasing research data and new literature to 
ensure that important research findings can be integrated into clinical practice so that 
patients benefit from the best possible care (Geddes and Carney, 2001).  The successful 
introduction of evidence-based practice into psychiatry will require the acquisition and 
sustained application of new skills.  These include the ability to read and select credible 
research results, grasp basic standard statistical methods and understand the 
applicability of these data to their practise of psychiatry. 
 
Psychiatrists seem to recognise the need for EBM.  In a survey of psychiatrists in 
Scotland (Lawrie et al., 2000), only 40% of respondents thought their practice was 
evidence-based.  They contended that a lack of time was the greatest barrier to 
implementing evidence-based psychiatry.  As many as 70% of psychiatrists and General 
Practitioners (GPs) in South Africa felt there was a need for regular EBM updates in 
psychiatry (Siegfried et al., 2003).  It also seems there is increasing acceptance of EBM 
amongst psychiatrists and GPs alike (Geddes and Carney, 2001). 
 
Policy makers should be using EBM in compiling clinical practice guidelines, to assist, not 
to enforce, clinical decision-making.  In the UK, the National Institute of Clinical 
Excellence (www.nice.org.uk) has been charged with this task. 
 
It is also vital to understand that EBM is an evolutionary and dynamic process.  Many 
current EBM guidelines are based on relatively old data and outdated methods of 
consensus development.  Continual review and updating are required, as well as local 
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adaptation prior to implementation.  Stein et al. (2002) highlighted potential pitfalls of 
applying guidelines from developed countries in developing countries. 
 
Keeping abreast of change in a world of increasing information is difficult in itself.  In 
psychiatry we are fortunate to be in an exciting field with rapid advances in our 
understanding of psychiatric disorders and the possible underlying mechanisms in the 
brain.  Coupled to that is an expectation that we are able to deliver improved, and often 
more rapid, outcomes, with improved quality of life for our patients.  To achieve this, 
psychiatrists need to be able to evaluate, select and implement best-practice principles 
in the care of their patients through continual education that draws on the latest 
research and most recent publications. Evidence-based medicine is vital. 
 
1.6   Current literature on the effects of Continued Medical Education 
 
Clinical education: 
“the science, the art, and the heart of medicine” 
                                (Atchley, 1959) 
 
“Hippocrates (b. c. 460 BC, island of Cos, Greece ― d. c. 377, Larissa, Thessaly) appears 
to have travelled extensively in Greece and parts of Asia Minor practicing his art and 
teaching his pupils” (Atchley, 1959).  This description possibly illustrates the separation 
on the one hand between the art and practice of medicine, and on the other hand, the 
science and teaching of medicine.  Medical education with its clinical decision-making is 
no doubt one of the areas where science and art are intricately interwoven.  Atchley 
(1959) describes clinical teaching as a synthesis of “the science, the art” which then 
becomes “the heart of medicine”. 
 
The conflict between the art and science of medical practice has always posed problems 
for medical education (Weatherall, 2006).  Medical curricula have changed radically in an 
attempt to develop the best students into the best doctors they can be.  When the great 
English physician, Thomas Sydenham, returned to England after the Civil War to study 
medicine at Oxford, he was not impressed with what he saw. He is believed to have said 
that “It was better to send a man to Oxford to learn shoe-making than to practise 
medicine!” (Weatherall, 2006). 
 
The question is how science, medicine and medical practice integration are related to the 
crucial issue of the character of medicine (Labisch, 2000), particularly as a result of the 
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explosion of medical information and the changes brought about in international medical 
curricula in the past 20 years.  Since the beginning of the previous century there have 
been several major changes in the way medicine is taught, from a basic science 
approach in the early 20th century, to organ-based approach started at Case Western 
Reserve University and, more recently, a problem-based approach, first started at 
McMaster University in Montréal, Canada. 
 
During the recent decades of development it has become clear that medicine will never 
become a pure science, not even an applied science (Labisch, 2000), despite the 
tremendous increase in our scientific understanding of the biological underpinning of 
psychiatric disorders.  To benefit from expanding scientific data, however, further 
education has become necessary to keep clinicians up to date.  Continued Medical 
Education (CME) was formalised as a method to maintain or even improve trained 
clinicians’ knowledge and skills. 
 
Changes resulting from CME have been studied in various settings.  The attitudes to and 
participation in CME activities, for GPs and psychiatrists, as well as the effect or result of 
CME are of particular interest to this study. 
 
Two Danish groups have reported on attitudes to, and participation in, CME activities in 
General Practice in Denmark.  The first publication was an audit of 369 GPs who were 
asked to record their perceived need for training in relation to individual consultations.  
They identified a need for further education in 16% of all consultations.  Psychiatry, 
community medicine and musculoskeletal diseases were the areas of medicine where the 
greatest need was identified (Hansen et al., 1999). 
 
The second paper reported on participation in CME activities by GPs.  The audit found 
that GPs spent approximately 96 hours per year on CME.  In addition they spent 90 
hours per year reading textbooks, journals and the Internet, and also 12 hours per year 
in small group-based CME.  The nearly 200 hours per year spent on education exceeded 
the requirements of their medical organisation (Nielsen et al., 2002). 
 
A similarly positive attitude to implementing continuing medical education (CME) was 
reported from a survey of psychiatrists in southern Transvaal (a region in the Transvaal 
province in the pre-1994 South Africa).  Sixteen of the 40 psychiatrists in the survey 
responded.  All 16 felt CME was necessary, and most favoured symposia, lectures and 
congresses activities.  While nearly everyone read journals in psychiatric and non-
psychiatric fields, group journal reviews, as a form of CME, were categorically rejected.  
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Most respondents were, however, prepared to contribute time and effort to earn CME 
accreditation (Freed and Miller, 1979). 
 
The real effects of education have often been discussed and remain highly emotive and 
controversial.  The Internet, international medical journals, congresses and symposia 
offer a wealth of educational possibilities for psychiatrists and other clinicians after their 
initial training.  However, this field remains difficult to research comprehensively, and 
few attempts at doing so have been published. 
 
Recognising that depression is frequently unrecognised and under-treated, and there is a 
need to increase the knowledge and skills of primary care physicians regarding 
management of depression, Kutcher et al. (2003) initiated a brief educational 
intervention.  They evaluated 68 GPs pre- and post- educational programme where the 
doctors were trained in depression and its management.  In their study doctors 
demonstrated high baseline knowledge of depression, yet 75% of them still had better 
scores following the programme.  Their study demonstrated that a short, simple 
educational programme could enhance the participants’ knowledge of depression.  
However, an increase in knowledge alone did not necessarily translate into a change in 
practice behaviour. 
 
Updating knowledge will not ensure improved treatment.  This will happen only if the 
clinicians put the new information into practice and follow the recommended treatment 
guidelines.  A study was undertaken in the Texas public mental health system of 
psychiatrists’ adherence to depression medication algorithms after being educated on the 
algorithm with regard to outcome measures, prescribing patterns (correct medications, 
therapeutic dosing, dosage increases and appropriate medication changes), and visit 
frequency (Bettinger et al., 2004).  The results showed consistently high adherence to 
appropriate drug regimens at appropriate dosages.  Although there was extensive 
variation in many other outcome measures, it appeared possible to implement 
medication algorithms in the mental health services that could improve the quality of 
care provided. 
 
Finally, a study of the effect of psychiatry residency training demonstrated changes in 
knowledge and measured change in prescribing habits.  Alexander et al. (1983) studied 
the effects of pharmacology education in psychiatry services at a Veterans 
Administration centre.  They conducted a retrospective prescription review of 
psychopharmacologic treatment methods, before and after education, related to multiple 
daily dosages, polypharmacy, prophylactic anticholinergic use, and drug use in alcohol 
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withdrawal.  They found that teaching resulted in the use of psychotropic medications 
that were more in line with recommendations in the literature presented.  It appears that 
education can lead to improved treatment planning and prescription. 
 
From these studies it is possible to conclude that GPs and psychiatrists generally seem to 
exhibit a positive attitude towards CME, participate at least as well as is required, often 
apply the new information to their practice, and that the education does in fact change 
their prescribing habits. 
 
1.7   Study objectives 
The overall objective of this study was to understand the effect of education in changing 
treatment habits, attitudes and behaviour among participants attending schizophrenia 
seminars presented by the Lundbeck Institute in Denmark.  In this respect, the study 
was descriptive in nature.  Explanations of the changes, or lack of changes, in behaviour 
are also presented.  What was of particular interest was whether variation existed in 
these changes in different seminar participants and why some participants changed their 
behaviour and others did not. 
 
To summarise: the question was firstly whether knowledge, attitudes and behaviour 
were affected by the seminar, and secondly, to explore variation/differences in changes 
among participants. 
  
The study focused on the three domains of change in knowledge, attitude and behaviour.  
These three areas were studied by means of measuring change in the following topics 
within schizophrenia treatment: 
• Haloperidol doses prescribed 
- Effective dose in the acute treatment of psychosis 
- Minimum effective dose in the relapse prevention phase 
• Duration of treatment 
- First-episode patients 
- Multi-episode patients 
• Drug-class used 
- Conventional versus new generation antipsychotic drugs 
 
The domains of change were studied by analysing the effects of the seminar using 
participant questionnaires, two weeks before the seminar, compared with two weeks and 
six months after the seminar.  The three areas were primarily analysed by looking at the 
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changes between the pre-questionnaire and the 6-months questionnaire for each 
variable.  
 
Additionally, it was important to be aware that change in behaviour was not always 
needed.  For example, learning was not needed where the psychiatrist treated patients 
within the desired ranges before the seminar.  Therefore, the focus on change was not 
an entirely valid reflection of the success of the seminar.  This was a major reason for 
focusing on variation in results, by identifying the effect of the seminar on those 
participants who needed to change behaviour versus those who did not need to change. 
 
Structure 
The structure of this study follows the two-fold purpose of description and explanation.   
• Chapter 3 presents the results in the key areas of learning. 
• Chapter 4 reports on the changes in behaviour, together with a short discussion 
of the relevant test-statistics and whether the changes in knowledge, attitude and 
behaviour could be attributed to the seminar. 
• Chapter 5 addresses the variables that could influence learning. 
• Chapter 6 tries to explain the changes described in chapters 3 and 4. 
• Chapter 7 performs bi-variate and multivariate tests of the different explanations.  
 
Overall the study focused on changes in knowledge, attitude and, ultimately, reported 
behaviour after participation in the seminars, and how these changes could be explained.  
In order to measure these changes the questionnaire data were used.  The assumption 
was that changes in answers from the pre-seminar questionnaire to the 6-months 
questionnaire could be ascribed to the seminar.   
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Chapter 2 Methods 
 
2.1   Subjects – recruitment and selection 
This study measured data collected prospectively from 408 psychiatrists from 29 
countries who attended the first 16 schizophrenia seminars.  The Lundbeck Institute in 
Denmark from August 1997 hosted these seminars until October 2001. 
 
The sample of participating countries and psychiatrists was neither random nor 
representative.  There was no standard recruitment process in place; the psychiatrists 
were selected to attend the seminars in different ways in various countries and each 
country used different criteria in their selection/invitation procedure.  In some countries 
psychiatrists were invited by the local Lundbeck office, in other countries a local 
psychiatric organisation or representative office selected the participants, while in yet 
other countries participants were nominated or they applied personally to a selection 
committee.  The selection process of the attendees is clearly a significant limitation in 
the design of the study. 
 
The number of psychiatrists from each country was also not a representative sample of 
the country’s psychiatry specialists.  This represents a major limitation to the study data, 
particularly that the data cannot be extrapolated to reflect the standard and quality of 
care in the different countries. 
 
However, it is possible to assume that those who attended these “evidence-based 
medicine” seminars were psychiatrists more interested in benefiting from further 
education in their field, or in education as a whole.  Were this the case, this fact may 
indeed strengthen the results of this study, since these psychiatrists, already interested 
in evidence-based education, may be following these principles closely and therefore be 
less likely to learn and change practise due to the seminar. 
 
2.2   Demographics 
The pre-seminar questionnaire collected data about participants’ demographics.  Not all 
participants answered the questionnaire, nor did all who responded answer all questions.  
However, 95.5% (390 of the 408) did supply at least some of their demographic data. 
 
The demographics-Table 1 lists the number of participants from the different countries. 
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Demographics-Table 1: 
Country of origin of seminar participants  
 Seminar participants    
(n=408) 
Australia         15   3.7% 
Austria         20   5.0% 
Belgium          26   6.4% 
Canada           5   1.2% 
Czech republic         10   2.5% 
Denmark         25   6.0% 
Estonia           5   1.2% 
Finland         15   3.7% 
France         20   5.0% 
Germany         30   7.4% 
Greece         18   4.4% 
Hungary         15   3.7% 
Ireland           3   0.7% 
Israel           5   1.2% 
Italy         29   7.1% 
Luxembourg           1   0.3% 
Macedonian           2   0.5% 
Netherlands         22   5.4% 
New Zealand         17   4.2% 
Norway         23   5.6% 
Poland          15   3.7% 
Russia           5   1.2% 
Slovakia           5   1.2% 
Slovenia           5   1.2% 
South Africa         15   3.7% 
Spain         20   5.0% 
Sweden         10   2.5% 
Switzerland         15   3.7% 
United Kingdom         12   3.0% 
Total       408 (100%) 
 
 
The pre-seminar questionnaire asked participants about their primary place of work. The 
results are presented in Table 2. 
 
Demographics-Table 2: 
Workplace of respondents in pre-seminar dataset 
 Pre-dataset        
(n=386) 
University Hospital  140  36.3% 
District or General Hospital    93  24.1% 
Private Practice     7    1.8% 
Specialised Psychiatric Hospital  132  34.2% 
Other    14    3.6% 
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Other demographic data collected included years of experience in psychiatry, number of 
patients seen per month and the percentage of those patients who had been diagnosed 
with schizophrenia.  Again, not all seminar participants returned the questionnaire, or 
answered all questions. 
 
Demographics-Table 3: 
Other demographics of pre-seminar dataset 
Pre-seminar dataset Mean Std. Deviation 
Years of experience in psychiatry (n=390) 13.3 years         7.42 
Number of patients seen per month (n=390) 79.0 patients       67.80 
Percentage of patients with schizophrenia (n=229) 37.3%       24.24 
 
The available demographic data of the seminar participants was limited to the 
information deemed important to measuring the effect of education.  We did not collect 
data on other traditional study demographics such as age, gender, social or financial 
background.  Although one cannot assume that these factors do not have an effect on 
education, it should be borne in mind that this was a population of psychiatrists where 
these factors should not influence the standard of knowledge or the quality of care 
provided to schizophrenia patients.  However, this may not be true, and should be seen 
as a limitation in the design and interpretation of this study. 
 
Only the paired data was used for analyses. i.e. only the data  of the respondents who 
returned both the pre-seminar questionnaire and the 6-month post-seminar 
questionnaire.  The respondent numbers and the validity of the paired respondents’ data 
are addressed in Chapter 4, section 4. 
 
2.3   Assessment measures and questionnaires 
Participants attending the seminars were sent a pre-seminar questionnaire (Appendix 1, 
page 135) in the month preceding their attendance.  This questionnaire elicited the 
psychiatrist’s baseline knowledge and attitude, as well as their treatment practice in two 
case studies. The two cases are used to differentiate the “intended behaviour”, as 
measured by the questions, from the “actual behaviour”, which is recorded in the case 
studies of two patients.  After attending the seminar, the participants were first sent a 2-
week follow-up questionnaire (Appendix 2, page 151) and then a 6-month post-seminar 
questionnaire (Appendix 3, page 158).  The data for this study were collected from the 
returned questionnaires. 
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The questionnaires were designed to collect many different data, including participant 
demographics (years of experience in psychiatry, practice setting, patient load), 
knowledge questions relating to schizophrenia (relapse rates, suicide rates), and its 
treatment (optimal doses, treatment duration, choice of drug), as well as questions 
aimed at evaluating attitudes to the disease and its diagnosis and treatment (duration 
before a non-response judgement, psychoeducation, and quality management).  These 
data were collected anonymously but could be linked to a participant’s number or 
nationality.  The differences in treatment habits and attitudes in the various countries, or 
even within a specific country formed the basis for the discussions at the seminars. 
 
2.4   Ethical considerations  
Ethical approval was not sought for this study.  According to the regulations of the Office 
for Human Research Protection in the United States (with which the Committee for 
Human Research of the Faculty of Health Sciences, University of Stellenbosch is 
registered), retrospective studies such as this one are exempt from full ethics review, as 
long as they involve the study of existing records, and the information was collected and 
recorded in such a manner that subjects cannot be identified, directly or through 
identifiers linked to the subjects. 
 
Written informed consent was not obtained from the participants in this study.  However, 
before participants were asked to complete the questionnaires they were fully informed 
of the nature of the questionnaire and the fact that the information obtained was to be 
used to assess the effectiveness of the seminar in a later analysis.  They were also 
informed that their responses would remain anonymous.  Care was taken to preserve 
the anonymity of the participants.  No identifying details were requested in the 
questionnaire.  Details were entered into the database according to a participant 
number. 
 
2.5   Statistical methods 
All statistical analyses were conducted with the help of a biostatistician. Differences 
between the pre-seminar dataset and the 6-months post-seminar dataset were analysed 
by using either a paired samples t-test or cross-tabulation and McNemar test. 
 
The two datasets (the pre-seminar and the 6-months post-seminar) may be described as 
dependent because the respondents of the 6-months and pre-seminar questionnaire 
were theoretically the same, even though not everybody who filled in the pre-seminar 
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questionnaire filled in the 6-months post-seminar questionnaire.  The paired samples t-
test was therefore adequate because the test is designed to take account of the 
dependency between the groups. 
 
The paired t-test was approached circumspectly because the 6-month dataset might not 
have the same distribution of respondents as the pre-seminar dataset.  There could be a 
problem if, for instance only the "good learners" filled in the 6-months post-seminar 
questionnaire (see below).  However, as the next sections show, this was not the case, 
so the paired samples t-test could be used.  The test compares the means on a given 
variable e.g. duration of treatment. 
 
Furthermore, this study also included variables that cannot be quantified, e.g. the factors 
influencing the selection of the antipsychotic drug-class used.  In order to analyse 
changes in the drug-class used, cross-tabulation tables were made of the class of drug in 
the pre-seminar and the 6-months post-seminar dataset. A test was also performed to 
determine whether respondents’ changed answers, i.e. determining whether “learning” 
had occurred (meaning the seminar had an effect).  To ascertain whether the differences 
in the cross-tabulation tables or between the binary categorical variables were 
significant, McNemar's test was used.  This test determines whether the answers in the 
pre-dataset equal the answers in the 6-months dataset.  The test is especially good at 
detecting changes in answers due to experimental intervention (e.g. a seminar) in a 
before-and-after design. 
 
The changes in haloperidol prescribing behaviour were investigated using multivariate-
dummy-regression (see chapters 6 and 7). 
 
Regression analysis investigates the relationship between a single dependent variable 
e.g. change in haloperidol dose, and several independent variables e.g. nationality, years 
of experience, caseload, workplace. The objective is to use the independent variable(s), 
whose values are known, to predict a single specified dependent variable. 
 
Dummy variables are a way of adding the values of a nominal or ordinal variable to a 
regression equation.  The value of each categorical independent variable with the 
exception of one is entered as a dichotomy.  For instance, to test whether a difference 
exists between Norway, Denmark and Sweden, the nominal variable "Country" creates a 
set of dummy variables.  (Denmark = 1 if the unit is from Denmark, otherwise 0; 
Norway = 1 if the unit is from Norway, otherwise 0)  One class must be left out to 
prevent perfect multicolinearity in the model (in our example Sweden is left out). 
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 In these analyses the dummy variable was given the value 1 if the respondent was on 
the outside of the target before the course.  For example, a respondent might 
recommend 10 months treatment of first-episode schizophrenia before the course.  This 
respondent’s recommendation is below the internationally recommended target.  If the 
dummy variable was significant, the duration of treatment recommended by participants 
would change in a significantly different way from those whose recommendations were 
above the target.  However, it would still not be clear whether the change was in the 
intended direction.  When the dummy is positive, it indicates that those who were below 
the target before the seminar increased the duration of their treatment after the 
seminar. 
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3.1 Haloperidol doses 
3.2 Duration of treatment  
3.3 Drug–class used 
3.3.1 Intended drug-class 
3.3.2. Actual drug-class used 
3.4 Summary 
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Chapter 3 Results 
3.1   Haloperidol doses 
The haloperidol dose was analysed in respect of both the most effective haloperidol dose 
to treat acute episodes of schizophrenia and the minimum effective haloperidol dose that 
could be prescribed without increasing the relapse risk. 
 
Table 1: Mean of respondents’ selected effective haloperidol dose to treat acute 
schizophrenia, before and 6 months after attending the schizophrenia seminar 
 
n=122, paired samples t-test: t=3.03; p=0.003  
 Mean Std. Deviation 
Before the seminar 8.6 mg/day 5.3 
6-months after the seminar                7.4 mg/day 3.6 
 
The results in Table 1 indicate a difference in the selected effective haloperidol dose by 
respondents before the seminar and 6-months after the seminar i.e. it dropped from 8.6 
mg/day to 7.4 mg/day, more in line with the internationally recommended effective 
haloperidol dose of approximately 5 mg/day. Despite a big standard deviation, the 
difference is statistically significant (p=0.003).   
 
The large standard deviation indicated a degree of variation amongst respondents.  Also, 
many respondents recommended the internationally accepted effective dose before the 
seminar and therefore did not need to change (“learn”). Thus it was more useful to 
evaluate the change in dosing regime of participants who recommended a haloperidol 
dose above 5 mg/day i.e. needed to “learn”.  Such an analysis focused more directly on 
the learning effect of the seminar, removing the effect of those who were already using 
the recommended dose beforehand.  The analysis, which allows isolation of the 
behaviour of the participants using a dose above 5 mg/day before the seminar, is a 
simple cross-tabulation of the dose before the seminar and 6-months after the seminar. 
 
Table 2:  Effective haloperidol dose to treat acute schizophrenia:  actual 
numbers and percentage of total respondents above or below 5 mg/day pre- 
and post-seminar 
  Use of haloperidol 6-months after the 
seminar  
  Above 5 mg/day Below 5 mg/day 
Above 5 mg/day   59*   (49.6%)**   22   (18.5%) Use of haloperidol 
before seminar Below 5 mg/day   13   (10.9%)   25   (21.0%) 
n=119, * number of respondents, ** percentage of total respondents 
McNemar test of changes p = 0.176  
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Table 2 shows that 49.6% of the respondents selected a dose above 5 mg/day before 
the seminar and after the seminar, 21% chose below 5 mg/day before and after the 
seminar, while 18.5% chose above 5 mg/day before the seminar and below 5 mg/day 
after 6 months.  However, 10.9% moved in the other direction - from below 5 mg/day 
before the seminar, to above 5 mg/day after the seminar.  Therefore, even though 
significant change in the “magnitude” of pre- and post-seminar dosing behaviour 
occurred, the “direction” of these changes was not statistically significant. 
 
Of interest is that close to half the psychiatrists knew the “correct” dose before the 
seminar - therefore not needing to “learn”, whereas 50% did need to “learn”.  More 
interestingly, 18.5% who selected above 5 mg/day before the seminar chose below 5 
mg/day after the seminar (“learned”), whereas 10.9% moved in the opposite direction 
i.e. “unlearned”.   
 
These results indicate that the seminar did not have a uniform effect on the participants. 
(i.e. changes did not all occur in the one direction; some went from above 5 mg/day to 
below and vice versa, while others did not change at all).  The McNemar test of changes 
yielded a p-value of 0.176 indicating that the changes in effective haloperidol dose to the 
internationally recommended dose of below 5 mg/day were not significant.  This is 
somewhat surprising because Table 1 shows that the haloperidol dose was significantly 
reduced on average from before the seminar to after the seminar.  Consequently, it 
seems as if the knowledge of participants changed in the intended direction, though the 
change was not statistically significant in respect of the below 5 mg/day target. 
 
Table 3: Mean of respondents’ selected minimum effective haloperidol dose for 
schizophrenia relapse prevention, before and 6-months after attending the 
seminar 
 Mean Std. deviation 
Before the seminar 4.9 mg/day 3.9 
6-months-after the seminar                4.1 mg/day 2.9 
n=96, paired samples t-test: t = 1.79; p=0.076 
 
The internationally accepted recommended minimum effective haloperidol dose is 
approximately 2-3 mg/day. Results in Table 3 show that the average minimum effective 
dose selected by respondents before the seminar was 4.9 mg/day, and after the seminar 
4.1 mg/day; this was not considered a statistically significant change (p=0.076). 
However, there was wide variability in responses, as evidenced by the substantial 
standard deviation and may explain why this difference was not considered significant.   
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The factors behind the apparent variation in learning among participants are analysed in 
Chapter 5. 
 
Since many psychiatrists knew the minimum effective dose before the seminar, it was 
therefore again useful to evaluate behaviour of the participants who recommended a 
haloperidol dose above 3 mg/day before the seminar. 
 
Table 4: Minimum effective haloperidol dose in schizophrenia relapse 
prevention: numbers and percentage of total respondents above or below         
3 mg/day before and 6-months after the seminar 
  Haloperidol dose 6-months after the 
seminar  
  Above 3 mg/day Below 3 mg/day 
Above 3 mg/day 37* (39.8%)**  19 (20.4%) Haloperidol dose 
before the seminar Below 3 mg/day  7   (7.5%) 30 (32.3%) 
n=93; * number of respondents, ** percentage of total respondents 
McNemar test of changes p = 0.031  
 
Table 4 shows that 39.8% of the respondents were above 3 mg/day before the seminar 
and 6-months after the seminar, while 32.3% recommended 3 mg/day or less both 
before the seminar and 6-months after the seminar.  More interestingly, 20.4% who 
were above 3 mg/day before the seminar were below after the seminar, whereas only 
7.5% moved in the opposite direction.  Note that before the seminar nearly 40% of the 
psychiatrists were using the recommended minimum effective dose of haloperidol, 
therefore not needing to “learn”, whereas 60% did need to “learn”.  Of importance was 
that 20.4% of the participants moved (“learned”) in the intended direction.  This change 
was statistically significant.  Analysed in terms of the 3 mg/day target, significant 
changes occurred in the behaviour of the participants.  However, the change was not 
necessarily due solely to effects of the seminar – as explained in Chapter 4. 
 
To conclude, significant changes occurred with regard to both the selected effective dose 
and the selected minimum effective dose of haloperidol, 6-months after the seminar.  
However, establishing that changes in haloperidol dosing behaviour pre- and post-
seminar occurred is not evidence that the seminar was responsible for these changes. 
This is examined in the following chapters.   
 
3.2   Duration of treatment 
The internationally accepted recommended minimum duration of treatment for first-
episode schizophrenia patients is 18 months.   
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Table 5: Mean selected duration of treatment before the seminar and 6-months 
after the seminar, for first-episode schizophrenia patients 
 Mean Std. deviation 
Before seminar  16.7 months 10.9 
6-months-after the seminar                17.5 months   7.9 
n=124, paired samples t-test: t = 0.86; p=0.39  
 
The selected duration of treatment for first-episode schizophrenia patients increased 
after the seminar towards the recommended minimum treatment period of 18 months.  
However, the magnitude of the change was not statistically significant.  
 
The wide variation in the answers, reflected in the large standard deviation, could 
indicate that the effect of the seminar (change in knowledge and behaviour) was 
influenced by certain characteristics of the respondents.  Changes in behaviour may be 
due to specific characteristics of the psychiatrists.  One hypothesis is that the effect of 
the seminar was different for psychiatrists with few years of experience compared with 
those of many years experience.  Potentially, psychiatrists with less experience can learn 
more than psychiatrists with many years of experience i.e. who have entrenched 
treatment practices.  This hypothesis is tested in Chapter 6.  Other variables that may 
affect the influence of the seminar are described in Chapter 5. 
 
The internationally recommended minimum duration of treatment of multi-episode 
schizophrenia patients is 60 months.   
 
Table 6: Mean selected duration of treatment before the seminar and 6-months 
after the seminar, for multi-episode schizophrenia patients 
 Mean Std. Deviation 
Before the seminar 38.7 months 19.4 
6-months-after the seminar                45.9 months 17.8 
n=120, paired samples t-test: t = 4.81; p < 0.0001  
 
Table 6 indicates that treatment behaviour had altered significantly 6-months after the 
seminar (p < 0.0001), increasing from 38.7 months pre-seminar to 45.9 months post 
seminar.  However, there was considerable variation in the responses after the seminar 
(sd = 17.8). 
  
It is not immediately apparent why the selected duration of treatment of multi-episode 
patients changed significantly 6-months after the seminar, whereas the selected 
treatment duration for first-episode schizophrenia patients did not change significantly.  
However, the substantial variation in the answers after the seminar suggests that there 
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may be subsets of participants who changed their prescribing habits significantly.  
Further understanding of this variation is explored in Chapter 6 by analysing respondent 
characteristics to explain the differences in learning of the psychiatrists. 
 
3.3   Drug-class used 
The last of the three areas of interest concerns the selected antipsychotic drug-class.  In 
this study, antipsychotics were categorised into two groups: conventional and new 
generation. The conventional antipsychotics included haloperidol, flupenthixol, 
zuclopenthixol, perphenazine, trifloperazine and sulpride.  The new generation 
antipsychotics included risperidone, olanzapine, quetiapine, ziprasidone, amisulpiride, 
clozapine and sertindole. 
 
Two different types of behaviour were analysed concerning the drug-class - intended 
(i.e. as measured by the differences in knowledge in the pre-seminar questionnaire and 
the post-seminar questionnaire) and actual (i.e. as measured by the differences in 
treatment options chosen in the case reports in the pre-seminar and post-seminar 
questionnaires).  The interest was in determining firstly whether a difference existed in 
the intended drug-class used before and after the seminar, and secondly, whether the 
actual drug-class used also changed after the seminar.  Finally, the correlation between 
the intended and actual drug-class used was investigated.  
3.3.1 Intended drug-class used before and 6-months after the seminar 
The intended drug-class was analysed in respect of both first-episode and multi-episode 
schizophrenia patients. 
 
Table 7: “Intended” drug-class used before and 6-months after the seminar for 
first-episode schizophrenia patients: total number and (percentage of total) 
  Drug-class used 6-months after the 
seminar  
  New Generation  Conventional 
New Generation 55*    (55%)**   6    (6%) Drug-class used 
before the seminar Conventional 23      (23%) 16    (16%) 
n=100, * number of respondents, ** percentage of total respondents 
McNemar test of changes p = 0.003 
 
Table 7 shows that 55% of the participants intended to use new generation 
antipsychotics before the seminar and 6-months after the seminar and 16% used 
conventional antipsychotics before the seminar and 6-months after the seminar.  In total 
71% of the participants did not change their preferred drug-class.  Of the remaining 
29%, 23% substituted conventional with new generation antipsychotics, while 6% 
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intended to swap from new generation antipsychotics before the seminar to conventional 
6-months after.  
 
These changes in intended drug-class for treatment of first-episode schizophrenia 
patients were significant (p=0.003).  However, they were not necessarily due to the 
effects of the seminar.  Chapter 4 analyses whether certain pre-conditions are fulfilled. 
 
Table 8: “Intended” drug-class used before and 6-months after the seminar for 
multi-episode schizophrenia patients: total number and (percentage of total) 
 
  Drug-class used 6 months after the 
Seminar 
  New Generation Conventional 
New Generation 48*  (50.5%)**        5  (5.3%)      Drug-class used 
before the seminar Conventional 21    (22.1%)    21  (22.1%)    
n=95, * number of respondents, ** percentage of total respondents 
McNemar test of changes p = 0.003  
 
Table 8 shows that 72.6% of the respondents did not change their intended behaviour 6-
months after the seminar when treating multi-episode schizophrenia patients; 50.5% 
used new generation both prior to and 6-months after the seminar and 22.1% used 
conventional drugs prior to and 6-months after the seminar.  The remaining 27.4% 
changed their behaviour: 22.1% moved from conventional drugs to new generation 
drugs, while 5.3% changed in the opposite direction. 
 
These changes in intended drug-class for treatment of multi-episode schizophrenia 
patients 6-months after the seminar were highly statistically significant (p=0.003). 
3.3.2 Actual drug-class used before and after the seminar 
Actual changes in drug-class used were assessed by asking the delegates how they 
would manage an acute patient (see appendices 1 & 3, patient case 1, pages 147 & 166) 
and a chronic (multi-episode) patient (patient case 2, pages 149 & 168). 
 
Table 9: Actual drug-class used before and 6-months after the seminar for 
acute phase of schizophrenia: total numbers and (percentage of total) 
  Drug-class used 6-months after the 
seminar  
  New Generation Conventional 
New Generation 22* (45.8%)**    6   (12.5%)     Drug-class used 
before the seminar Conventional 10   (20.8%)    10 (20.8%)    
n=48, * number of respondents, ** percentage of total respondents 
McNemar test of changes p = 0.45  
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Table 9 shows that two-thirds of the psychiatrists did not change the drug they used 
(45.8% and 20.8%), while 20.8% changed from a conventional to a new generation 
drug, and 12.5% changed from a new generation to a conventional drug.  It is important 
to note that the changes were not only in the direction of new generation drugs as was 
the case of intended behaviour towards first-episode patients (see Table 7, page 62). 
 
Only 48 respondents completed the information about patient 1 before the seminar and 
after the seminar.  Consequently conclusions derived from Table 9 need to be 
interpreted with caution. 
 
Table 10: Actual drug-class used before and 6-months after the seminar for the 
treatment of chronic schizophrenia patients: total number and (percentage of 
total) 
  Drug-class used 6-months after the 
seminar  
   New Generation Conventional 
New Generation 12* (47.7%)**    5  (7.7%)     Drug-class used 
before the seminar Conventional 8     (30.8%)     1  (3.8%)     
n=26, * number of respondents, ** percentage of total respondents 
McNemar test of changes p = 0.109  
 
Table 10 shows more consistency in the changes compared with Table 9.  Approximately 
50% of the respondents did not change behaviour, 30.8% changed from conventional to 
a new generation drug, while 7.7% changed from conventional to a new generation 
drug.  Overall there was a clear trend towards the new generation drugs.  However, the 
differences did not meet statistical significance, possibly due to the low number of 
respondents. 
 
The results indicated that no statistically significant change occurred in the actual drug-
class used from before to after the seminar, as assessed by case report responses.  This 
contrasts with the analysis of the intended drug-class; a significant number of 
respondents intended to use new generation antipsychotics 6-months after the 
seminar.  Therefore a difference seems to exist between intended and actual behaviour, 
indicating actual use does not always follow intention.  To test this assumption, Table 11 
compared the intended versus actual selected antipsychotic for treating a multi-episode 
schizophrenia patient (patient 1).   
 
If there were no difference in intended and actual behaviour, 100% of the cases would 
be in either the cell “new generation/new generation” or in the cell 
“conventional/conventional”.   
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Table 11: Intended drug-class and actual drug-class used for case “Patient 1” 
before the seminars: total number and (percentage of total).  
  Drug-class intended 
  New Generation Conventional 
New Generation 47* (40.2%)**    11   (9.7%)    Drug-class used 
for patient 1 Conventional 31   (26.2%)    28  (23.9%)    
n=117, * number of respondents, ** percentage of total respondents 
Chi-square test of independence: p = 0.004 
 
The analysis in Table 11 confirms that the intended medication choice was not 
necessarily the same as the actual choice; approximately 37% of the respondents 
exhibited inconsistent behaviour.  However, these differences are not significant. In 
statistical terms the actual behaviour is dependent upon the intended behaviour because 
the Chi-square is below 0.05. In other words the null hypothesis (H0) assuming 
independence between intended and actual behaviour is rejected.  
 
(The McNemar test of difference was not used in this instance, as the test compares 
whether the difference is significant in a particular direction and not whether differences 
exist overall.  The latter is the most relevant when consistency is analysed, whereas the 
former is relevant when the effect of a seminar is analysed.) 
 
3.4   Summarising changes in selected haloperidol dose, duration of treatment 
and antipsychotic class used 
The preceding sections have analysed the changes in behaviour before the seminar and 
6-months after the seminar concerning haloperidol dose prescribed, duration of 
treatment and drug-class used.  In all three areas some, but not all of the prescribing 
behaviour changed significantly 6-months after the seminar compared with the situation 
before the seminar. Respondents’ selected duration of treatment of first-episode 
schizophrenia patients did not change significantly 6-months after the seminar.  The 
same was to a certain extent the case with the effective haloperidol dose.  Furthermore, 
and perhaps more interestingly, the actual drug-class used did not change significantly 
from before the seminar to 6-months after the seminar despite the significant change 
occurring in the intended drug-class (bearing in mind the small sample size used for the 
analysis).  If the significant change in the intended drug-class was due to the seminar, it 
would appear that the seminar had more effect on the intended behaviour than on the 
actual behaviour.  
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Although significant changes in haloperidol prescribing behaviour were observed, factors 
other than Institute seminar attendance may be responsible.  These factors are 
discussed in the next chapter. 
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Chapter 4 Changes in prescribing behaviour due to evolving knowledge 
over time 
4.1 Haloperidol doses 
4.2 Duration of treatment 
4.3 Drug–class used 
4.4 Number of study respondents and validity of paired data 
4.5 Summary 
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Chapter 4 Changes in prescribing behaviour due to evolving knowledge 
over time 
The main purpose of this study was to research changes in knowledge, attitude and 
prescribing behaviour after participation in an educational seminar.  The descriptive part 
of this study was presented in Chapter 3, where it was determined that changes in 
haloperidol prescribing behaviour did actually occur. The important question yet to be 
addressed was whether the changed behaviour, 6-months after the seminar, could be 
attributed wholly or partly to seminar learning.  Several factors other than the seminar 
may be responsible for these changes. 
 
In order to conclude that the seminar had an effect, a necessary condition was that a 
difference existed between the answers given before the seminar and the answers given 
after the seminar.  However a difference is not a sufficient condition for concluding that 
the seminar had an effect.  For example, changes in policies, international treatment 
guidelines and marketing might occur and influence the psychiatrists’ knowledge and 
attitudes.  It would be incorrect to ascribe such changes to the effects of the seminar if 
this proved to be the case. 
 
Accordingly, two factors of importance concerning the responses before the seminar and 
6-months after the seminar were analysed in this chapter.  These were the changes in 
the background knowledge of the psychiatrists over time, and dataset differences 
between respondents of the pre-questionnaire and the 6-month-questionnaire. 
 
Development in knowledge  
It is a fair assumption that the knowledge of participants concerning the treatment of 
schizophrenia might change over time.  In this section the possible effect of changes in 
background knowledge from August 1997 (when the first seminars were presented) until 
2001 (when the last of the seminars included in this study was presented) were studied.  
A significant difference between delegate responses over time regarding the pre-seminar 
dataset and the 6-months dataset would suggest that the changes in haloperidol 
prescribing behaviour described in Chapter 3 were not necessarily a direct result of the 
seminar, but were due, at least in part, to changes in background knowledge.  In order 
to test this, two analyses were performed.  
 
One analysis compared the mean pre-seminar questionnaire responses of each seminar 
group over the time course of the seminars i.e. from 1997 to 2001. If there were no 
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differences between the first eight and the last eight seminars, then it could be 
concluded that the participants’ background knowledge did not change over the years of 
the seminars.  
 
As there was no control group in this study, the pre-seminar data of the participants in 
the later seminars will be regarded as the control group for the participants in the earlier 
seminars  (in other words, the pre-seminar data of the 1999 seminar participants acted 
as the control group for those who participated in 1998.  Hence most pre-seminar 
datasets containing data from the first 18 pre-seminar questionnaires act as the control 
for the last seminar in this study.)  Thus, background changes in treatment principles 
were evaluated by comparing the pre-seminar data of the earlier participants with the 
pre-seminar data of later participants. 
 
The second analysis compared the knowledge of delegates 2-weeks and 6-months after 
the seminar. This test also focused on the development in background knowledge among 
the participants.  However, this analysis used only the data of those participants’ who 
filled in both the 2-week and the 6-months post-seminar questionnaires.  One would 
expect that the effect of learning derived from a seminar declined after 6 months.  
Bearing this in mind, if knowledge remained unchanged or even increased, this could 
indicate changes in background knowledge.  These changes in knowledge could, in turn, 
change behaviour.  Both analyses tested whether any changes occurred in the key areas 
of interest: haloperidol dose prescribed, duration of treatment and drug-class used. 
 
4.1 Haloperidol doses 
Analysis of pre-seminar questionnaire responses over time 
In figures 1 and 2 the variation in the average effective haloperidol dose and the 
average minimum effective dose, respectively, before the seminars, was plotted. 
 
While Figures 1 and 2 indicate the trend of a slight decrease in the mean haloperidol 
dose chosen by each seminar group over time (suggesting small changes in general 
background learning took place), the scatter of results makes this interpretation 
tenuous.   
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Figure 1: Variation in the average effective haloperidol dose for treating acute 
schizophrenia, before the various seminars 
 
The mean result for the pre-seminar selected effective haloperidol dose for each seminar group was plotted 
against sequential seminars (i.e. from earliest to latest). The line of best fit for individual points was 
determined using the method of least squares 
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Figure 2: Variation in average minimum effective haloperidol dose for 
schizophrenia relapse prevention, before the various seminars 
 
The mean result for the pre-seminar selected minimum effective haloperidol dose for each seminar group was 
plotted against sequential seminars (i.e. from earliest to latest). The line of best fit for individual points was 
determined using method of least squares.  
0
2
4
6
8
10
0 5 10 15 20
Course number
A
ve
ra
ge
 m
in
im
um
 h
al
op
er
id
ol
 d
os
e 
m
g/
da
y
 
 
Further investigation was performed by comparing the average pre-seminar haloperidol 
dose selected by delegates attending the first 8 seminars conducted (“earlier” seminars) 
and those attending the last 8 seminars conducted (“later” seminars) – see Tables 12 
and 13. 
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Table 12: Mean selected effective haloperidol dose before the seminar for the 
“earlier” seminars and the ” later” seminars 
 Mean Std. Deviation 
Earlier seminars 9.6 mg/day 6.9 
Later seminars  9.2 mg/day 6.3 
n=377, Independent samples t-test: t=0.59; p=0.556  
 
 
Table 13: Mean selected minimum effective haloperidol dose before the seminar 
for the ” earlier” seminars and the” later” seminars 
 Mean Std. Deviation 
Earlier seminars 5.4 mg/day 5.9 
Later seminars  5.3 mg/day 5.9 
n=294, Independent samples t-test: t=0.23; p=0.82  
 
Results shown in Tables 12 and 13 confirm there were no statistically significant 
differences between earlier and later seminars in the pre-seminar average selected 
effective haloperidol dose (p=0.556), or in the pre-seminar average selected minimum 
effective haloperidol dose (p=0.82). 
 
Therefore, no significant systematic difference in effective or minimum effective 
haloperidol dose selected pre-seminar occurred during the time period over which the 
seminars were conducted.   Therefore, according to these results the changes both in 
effective haloperidol dose and the minimum effective dose from before the seminar to 6-
months after the seminar were not likely due to changes in the background knowledge of 
psychiatrists. 
 
However, the result was slightly different when the percentage of psychiatrists selecting 
a dose below the recommended target of 5 mg/day before the seminars were compared. 
 
Figure 3 shows that the percentage of seminar respondents who selected a dose of 
haloperidol below the 5 mg/day target for the effective haloperidol dose was influenced 
by the number of the seminar, i.e. when the seminar was held. 
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Figure 3: Variation in the percentage of respondents who recommended a 
haloperidol dose below 5 mg/day, before the seminar 
Plot of the percentage of pre-seminar respondents who selected an effective haloperidol dose below 5mg/day 
versus sequential seminars, earliest to latest.  The line of best fit for individual points was determined using 
method of least squares.  
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The trend-line indicates that the percentage of psychiatrists who selected a haloperidol 
dose below 5 mg/day, increased over time.  These data could therefore explain why the 
mean effective haloperidol dose was significantly lower 6-months after the seminar, even 
though the shift towards the recommended target of below 5mg/day was insignificant 
(see Chapter 3, Tables 1 & 2, page 58). 
 
Table 14: Effective haloperidol dose selected before the seminar 
(earlier and later seminars) 
  Seminar time 
  Earlier seminars Later seminars 
Above 5 mg/day  75.3%  66.8% 
Below 5 mg/day  24.7%  33.2% 
Use of haloperidol 
dose before the 
seminar  (100%) (100%) 
n=377, Chi-square test of independence p = 0.045 
 
Table 14 analyses the data to determine whether there was a systematic difference 
between the earlier seminars and the later seminars concerning respondents who viewed 
less than 5 mg/day of haloperidol as the effective dose.  In the earlier seminars, 75.3% 
of respondents were above the target compared with 66.8% in the later seminars.  This 
difference is statistically significant (p=0.045).  It indicates that changes in knowledge 
about the effective haloperidol dose took place over time.  It then follows that the 
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significant change in the average effective haloperidol dose (see Table 1, page 58) could 
be attributed to a higher percentage of participants in later seminars already selecting 
less than 5 mg/day pre-seminar i.e. a change in background knowledge and not 
necessarily a change due to the effect of the seminar. 
 
Figure 4 relates to the minimum effective haloperidol dose.  It plots the change in the 
percentage of respondents who were below the 3 mg/day target (the recommended 
minimum effective dose discussed at the seminars), pre-seminar. 
 
Figure 4: Variation in the percentage of respondents that recommended a 
minimum effective haloperidol dose below 3 mg/day, pre-seminar in the 
various seminars 
Plot of the percentage of pre-seminar respondents who selected a minimum effective haloperidol dose below 
3mg/day versus sequential seminars, earliest to latest.  The line of best fit for individual points was determined 
using method of least squares.  
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Figure 4 demonstrates there was no systematic change over time in the percentage of 
those who prescribed below 3 mg/day: the trend-line is almost horizontal. The results in 
Table 15 confirm this i.e. there was no statistically significant difference found between 
the pre-seminar minimum effective haloperidol dose selected by “earlier” versus “later” 
seminar attendees, indicating no significant “background” learning took place. 
 
Table 15:  Pre-seminar selected minimum effective haloperidol dose for 
“earlier” and “later” seminar groups 
  Seminar time 
  Earlier seminars Later seminars 
Above 3 mg/day 62.4% 59.2% 
Below 3 mg/day 37.6% 40.8% 
Use of haloperidol 
dose before the 
seminar  (100%) (100%) 
n=294, Chi-square test of independence p = 0.331 
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To summarise, it seems that the effective haloperidol dose changes related to the 
time when the seminar course was given.  However, this conclusion did not hold true for 
the minimum effective haloperidol dose.  Therefore, the overall change in the 
selected effective haloperidol dose was most likely due to changes in background 
knowledge rather than an effect of the seminar, whereas change in the selected 
minimum effective dose after the seminar was probably not due to changes in 
background knowledge. 
 
Analysis of changes in responses from 2-weeks after to 6-months after seminar 
attendance 
This section analyses whether changes occurred in responses between 2-weeks after and 
6-months after the seminar.  
 
Table 16: Mean selected effective haloperidol dose 2-weeks and 
6-months after seminar attendance 
 Mean Std. deviation 
2-week post-seminar   7.51 mg/day 5.08 
6-months post-seminar  7.27 mg/day 3.55 
n=115, Paired samples t-test: t=0.50; p=0.616 
 
Table 16 shows that there was no statistically significant change in the mean selected 
effective dose between 2-weeks and 6-months after the seminar (p=0.616). General 
background learning cannot be said to take place in this respect.   
 
Table 17: Mean selected minimum effective haloperidol dose 2-weeks 
and 6-months after seminar attendance 
 Mean Std. deviation 
2-week-post-seminar 4.13 mg/day 2.5 
6-months-post-seminar 4.14 mg/day 2.9 
n=106, paired samples t-test: t=0.004; p=0.997  
 
Results in Table 17 indicate no significant difference in the mean selected minimum 
effective haloperidol dose from 2-weeks after to 6-months after the seminar (p=0.997) 
i.e. general background learning does not seem to take place.  Accordingly, this indicates 
that the changes in selected minimum effective dose from before the seminar to 6-
months after the seminar were most likely due to the seminar itself, and not to the 
effects of “background” learning. 
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The seminars recommended an effective dose of haloperidol of 5 mg/day and a minimum 
effective dose of 3 mg/day.  It is therefore of interest to know whether changes occurred 
in respect of this target during the period from 2-weeks after the seminar to 6-months 
after the seminar. 
 
Table 18: Selected effective haloperidol dose 2-weeks after and 6-months after 
the seminar: total number and (percentage of total) 
  Use of haloperidol 6-months after the 
Seminar 
  Above 5 mg/day Below 5 mg/day 
Above 5 mg/day 128*  (43.5%)**   31  (10.4%)    Use of haloperidol 
2-weeks after the 
seminar  
Below 5 mg/day 33      (11.3%)    102 (34.8%)   
n=294, * number of respondents, ** percentage of total respondents 
McNemar test of changes p = 0.841  
 
Table 19: Selected minimum effective haloperidol dose 2-weeks after and 6-
months after the seminar: total number and (percentage of total) 
  Use of haloperidol 6-months after the 
Seminar 
  Above 3 mg/day Below 3 mg/day 
Above 3 mg/day 114*  (38.7%)**   50  (17.0%)    Use of haloperidol 
2-weeks after the 
seminar 
Below 3 mg/day 30     (10.4%)    100 (34.0%)   
n=294, * number of respondents, ** percentage of total respondents 
McNemar test of changes = 0.194  
 
Results in Tables 18 and 19 indicate no significant systematic changes occurred with 
respect to selected effective and minimum effective haloperidol doses in the period 2 
weeks post to 6 months post the seminar (p=0.841 and p=0.194 respectively). 
 
To summarise: analysis of questionnaire responses for selected effective haloperidol 
dose over the time course seminars have been held indicated that background learning 
or changes in knowledge occurred; later seminar participants tended to recommend a 
lower effective dose.  However, no change occurred in the selected effective dose during 
the period from 2-weeks after the seminar to 6-months after the seminar.  Despite this, 
a general learning process seems to take place over time.  Therefore, the change in the 
magnitude of selected effective haloperidol dose before and after the seminar (from 
8.6mg/day to 7.4mg/day, described in Chapter 3) were probably not due to effects of 
the seminar, but to general “background” learning.  The opposite conclusion was reached 
when considering the selected minimum effective dose where general learning did not 
seem to occur.  This was confirmed by an absence of changes between the groups 
before the seminar, as well as by comparing the change 2-weeks after the seminar with 
the change 6-months after the seminar.  The finding is similar for both measures – 
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average dose or dichotomised between below or above 5 mg/day.  These findings 
suggest that the seminars change participants’ knowledge on minimum effective 
haloperidol dose. 
 
In conclusion, the above analyses lend validity to ascribing the changes in selected 
minimum effective haloperidol dose 6-months after the seminar, to the seminar itself. 
The significant change in the magnitude of the selected effective haloperidol dose was 
unlikely due to effects of the seminar alone; instead general background learning 
seemed to take place, which could in part account for this change. 
 
4.2   Duration of treatment 
Analysis of pre-seminar questionnaire responses 
 
Figure 5: Variation in average selected duration of treatment before the 
seminar for first- episode schizophrenia patients 
Plot of mean pre-seminar average duration of treatment (in months) for first-episode schizophrenia patients by 
each seminar group versus seminar course number over time (earliest to latest).  The line of best fit for 
individual points was determined using method of least squares.  
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Results in Figure 5 indicate that no systematic learning took place; the trend-line is 
horizontal.  The lack of “background” learning was confirmed when the average duration 
of treatment for the first 8 seminars (earlier seminars) and the last 8 seminars (later 
seminars) was compared.  In Table 20, the difference between the two groups of 
seminars is reported. 
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Table 20: Mean selected duration of treatment for first-episode schizophrenia 
patients (“earlier” and “later” seminars) 
 Mean Std. deviation 
Earlier seminars  16.03 months   9.46  
Later seminars 15.87 months 11.24 
n=351, Independent samples t-test: t=0.25; p=0.80  
 
Results in Table 20 indicated that no statistically significant difference existed between 
the mean selected duration of treatment for first episode schizophrenia patients for 
“earlier” versus “later” seminar attendees (p=0.80).  
 
The same conclusion was reached when results for selected duration of treatment for 
multi-episode patients were analysed.  From Figure 6 it can be seen that no significant 
systematic learning appeared to take place.  The trend-line had a minimally positive 
skew.  A substantial amount of variation exists between the groups. 
 
Figure 6: Variation in average duration of treatment for multi-episode 
schizophrenia patients, before the seminar 
 Plot of mean pre-seminar duration of treatment (in months) for multi-episode schizophrenia patients by each 
seminar group versus seminar course number over time (earliest to latest).  The line of best fit for individual 
points was determined using method of least squares.  
  
0
10
20
30
40
50
60
0 5 10 15 20
Course number
D
ur
at
io
n 
of
 tr
ea
tm
en
t (
m
on
th
s)
 
 
The lack of learning was confirmed when a comparison was made of the average 
selected duration of treatment of the first 8 seminars (earlier seminars) and the last 8 
seminars (later seminars).  Table 21 reports the difference between the two groups of 
seminars. 
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Table 21: Mean selected duration of treatment for multi-episode schizophrenia 
patients, “earlier” and “later” seminars 
 Mean Std. Deviation 
Earlier seminars  34.47 months 19.42 
Later seminars 38.22 months 19.78 
n=340, Independent samples t-test: t=1.76; p=0.08  
 
The difference in the selected duration of treatment between later and earlier seminars 
was approximately 4 months.  Despite this rather large change, the difference between 
the groups was not considered statistically significant (p=0.08).  There was substantial 
variation within the groups (refer to respective standard deviations). 
 
In summary, the analyses of responses provided before the seminars showed that no 
systematic difference existed between the earlier seminars and the later seminars 
concerning the selected duration of treatment.  In this respect the difference in duration 
of treatment from before the seminar to 6-months after the seminar was probably not 
due to development in background knowledge. 
Analysis of changes in responses from 2-weeks after to 6-months after seminar 
attendance 
The above conclusion was re-confirmed when the responses 2-weeks after the seminar 
and 6-months after the seminar were analysed. 
 
Table 22: Mean selected duration of treatment for first-episode  
schizophrenia patients, 2 weeks and 6-months after the seminar 
 Mean Std. Deviation 
2-weeks-dataset – Duration of treatment  17.94 months 8.93 
6-months-dataset – Duration of treatment  17.80 months 9.10 
n=117, paired samples t-test: t=0.22; p=0.83  
 
 
Table 22 shows that no significant difference existed between the 2-week dataset and 
the 6-months dataset concerning recommended duration of treatment for first-episode 
schizophrenia patients (p=0.83). 
 
Table 23: Mean selected duration of treatment for multi-episode  
schizophrenia patients, 2 weeks and 6 months after the seminar 
 Mean Std. Deviation 
2-weeks-dataset - Duration of treatment  48.17 months 17.45 
6-months-dataset - Duration of treatment  47.47 months 17.50 
n=113, paired samples t-test: t=0.47; p=0.64  
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Table 23 also shows that no significant change occurred in the recommended duration of 
treatment for multi-episode patients, in the period from 2 weeks to 6 month after the 
seminar (p=0.64).   
 
To summarise, no learning or changes in knowledge seemed to take place regarding 
selected duration of treatment, either when pre-seminar questionnaire responses were 
analysed or when questionnaire responses from 2-weeks after and 6-months after the 
seminar were analysed.  This conclusion is independent of the schizophrenia subtype: 
first-episode or multi-episode. 
 
In conclusion, these results support the hypothesis that the significant changes in 
respondents’ selected duration of haloperidol treatment 6-months after the seminar can 
be ascribed to the effects of the seminar. 
 
 
4.3   Drug-class selected 
New Generation versus Conventional antipsychotic 
The emergence of the new generation of antipsychotic drugs from the early 1990s and 
during the early stages of seminar presentation clearly led to significant knowledge 
changes occurring apart from the seminars.  It was therefore necessary to assess 
whether the changes in choice of drug-class 6 months after the seminar could be 
ascribed to the seminars. 
 
Analysis of questionnaire responses pre-seminar 
Figure 7 reports the average percentage of respondents before each seminar who 
intended to use new generation drugs treating first-episode schizophrenia patients.  This 
figure shows a clear upward trend over time. 
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Figure 7: Variation in the percentage of respondents who used new generation 
drugs for treating first-episode schizophrenia patients, before the seminar 
 
Plot of the percentage of each seminar group who chose new generation antipsychotics for treating first-
episode schizophrenia patients pre seminar versus seminar course number over time (earliest to latest).  The 
line of best fit for individual points was determined using method of least squares.  
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The positive skew of the trend line in Figure 7 clearly indicates an increase in the 
percentage of respondents choosing new generation antipsychotics.  
 
This trend was confirmed when the difference between earlier and later seminars was 
analysed.  Table 24 reports the comparison of drug-class between earlier and later 
seminar attendees. 
 
Table 24: Pre-seminar selected antipsychotic drug-class used for first-episode 
schizophrenia patients by “earlier” (first 8) vs “later” (last 8) seminar 
attendees 
  Seminar time 
 n= 304 Earlier seminars Later seminars 
New Generation  55.1%  74.1% 
Conventional  44.9%  25.9% 
Drug-class used 
for first-episode 
patients 
 (100%) (100%) 
n=304, Chi-square test p = 0.001  
 
In the earlier seminars 55.1% used new generation drugs, whereas 74.1% used new 
generation drugs in the later seminars.  This result is highly significant (p = 0.001) and 
suggests that the changes in drug-class selected before the seminar to 6-months after 
the seminar were due to developments in the background knowledge and behaviour of 
psychiatrists.  
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Figure 8 indicates that the selection of new generation drugs for treating multi-episode 
schizophrenia patients also increased over time. 
 
Figure 8: Variation in the percentage of respondents who chose new generation 
drugs for treating multi-episode schizophrenia patients, before the seminar 
Plot of the percentage of each seminar group who used new generation antipsychotics to treat multi-episode 
schizophrenia patients pre seminar attendance versus seminar course number over time (earliest to latest).  
The line of best fit for individual points was determined using method of least squares.  
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While the tendency is less marked than was the case for first-episode patients (Fig 7), 
the differences between earlier and later seminars seem to be considerable.   
 
 
Table 25: Pre-seminar selected drug-class used for multi-episode schizophrenia 
patients by “earlier” versus “later” seminar attendees 
  Seminar time 
  Earlier seminars Later seminars 
New Generation  59.0%  67.1% 
Conventional  41.0%  32.9% 
Drug-class used 
for multi-episode 
patients  (100%) (100%) 
n=300, Chi-square test = 0.09 
 
While the percentage of respondents choosing the new generation drugs in multi-episode 
patients increased from 59% in the earlier seminars to 67.1% in the later seminars, this 
did not reach statistical significance.  The possibility of a type II error here (concluding 
that no difference exists between earlier seminars and later seminars when in fact there 
is a difference) needs to be kept in mind, as the p value is close to significant.  
Considering the difference in the numbers of respondents selecting the new generation 
drugs at earlier and later seminars, and the probability of conducting a type II error, it is 
reasonable to conclude that a difference exists between earlier and later seminars 
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regarding the drug-class i.e. in spite of background changes in the choice of 
antipsychotic over time, there is still evidence to suggest that the seminars had a 
significant effect in changing the antipsychotic choice. 
 
In summary, the analysis of questionnaire responses completed before the seminars has 
shown that changes occurred over time concerning chosen antipsychotic drug-class for 
both first- and multi- episode schizophrenia patients, with the selection of the new 
generation antipsychotics becoming more common.  This was most likely due to general 
background knowledge developments rather than to effects of the seminar. 
 
Analysis of response changes from 2-weeks after to 6-months after seminar 
attendance 
 
However, the above conclusion was not supported by the analysis of the changes in 
response from 2-weeks to 6-months post-seminar for first- and multi-episode 
schizophrenia patients. 
 
Table 26 shows the respondents’ selection of drug-class used for first-episode 
schizophrenia patients 2-weeks after and 6-months after the seminar. 
 
Table 26: Drug-class (conventional or new generation) selected for first-
episode schizophrenia patients by delegates 2 weeks and 6 months after the 
seminar: total number and (percentage of total) 
  Drug-class used 6-months after the 
Seminar 
  New Generation Conventional 
New Generation 75*   (73.5%)**      5   (4.9%)     Drug-class used 
2-weeks after 
seminar 
Conventional  6     (5.9%)     16   (15.7%)    
n=102, * number of respondents, ** percentage of total respondents 
McNemar test of changes p = 1.0  
 
As can be seen from Table 26, 73.5% of the psychiatrists chose new generation drugs 
both 2-weeks and 6-months after the seminar, and 15.7% used conventional drugs 2-
weeks and 6-months after.  Therefore, 89.2% of the respondents did not change their 
opinions regarding drug-class for treating first-episode schizophrenia patients.  In 
general the behaviours seem to have stayed the same. 
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Table 27: Drug-class (conventional or new generation) selected 2 weeks and 6 
months after the seminar for multi-episode schizophrenia patients: total 
number and (percentage of total) 
  Drug-class used 6-months after the 
Seminar 
  New Generation Conventional 
New Generation 61*  (61.0%)**      7  (7.0%)     Drug-class used 
2-weeks after 
seminar 
Conventional 15   (15.0%)    17   (17.0%)   
n=100, * number of respondents, ** percentage of total respondents 
McNemar test of changes p = 0.134  
 
Table 27 shows that 78% did not change drug-class between the 2-week and the 6-
months-questionnaire when treating multi-episode schizophrenia patients, while 15% 
moved from conventional to new generation drugs and 7% moved from new generation 
to conventional drugs.  Compared to Table 26, slightly more psychiatrists seem to have 
changed behaviour, but this result was not statistically significant.  It would appear, 
therefore, that the behaviour of respondents in terms of drug-class selected 2 weeks 
after the seminar and 6 months after the seminar did not change significantly.  
 
In contrast to the analysis performed on pre-seminar data, no change in background 
knowledge seemed to take place from 2-weeks after to 6-months after the seminar.  
This difference in results between the analysis comparing earlier and later participants 
and the above analysis might be due to at least two factors.  Firstly, only participants 
who answered both the 2-week and the 6-months questionnaire were included in the 
analysis.  The dataset of answers 2-weeks after and 6-months after the seminar were 
subsets of the pre-seminar dataset i.e. not all participants who filled in the pre-seminar 
questionnaire completed either the 2-week post or 6-month post questionnaires.  
Secondly, the learning from a seminar usually declines over time, but the opposite 
seems to be the case in Tables 26 and 27.  The reason could be that there was still a 
general learning process taking place, which could cancel out the decline in the effect of 
the learning, thereby preventing the decline in knowledge after the seminar. 
  
The conclusion was that the background knowledge and behaviour of psychiatrists 
changed significantly over the time that elapsed before the different groups attended the 
seminars.  The consequence was that the differences in the drug-class selected before 
the seminar and 6-months after the seminar could not be ascribed purely to the effect of 
the seminar. 
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Choice of antipsychotic agent before and 2-weeks after the later seminars 
The above results suggest that the effect of the seminar only partially explained the 
observed changes in preference of antipsychotic class used for treatment.  This section 
examined whether the seminars played a role in the changes at all; specifically whether 
there was a significant difference in the drug-class selected pre- and 2-weeks post 
seminar, using only the data for the “later” (last 8) seminars.  If a difference existed, it 
might indicate that the seminars had some effect on the psychiatrists’ knowledge, 
behaviour and attitude to the new generation drugs.  The analysis of the previous data 
indicated that the participants at later seminars possibly experienced “background” 
learning about the use of new generation drugs to a greater extent than the earlier 
participants.  If there were a difference in drug-class used after later seminars, this 
would indicate that the seminar did have an effect, despite changes occurring in 
background knowledge). Changes between the pre-seminar dataset and the 2-week 
post-seminar dataset were compared because this provided the best chance to detect 
direct effects of the seminar for the following reasons: firstly, the amount of background-
learning change that could happen in the period of a month (2 weeks before the seminar 
and 2 weeks after the seminar) would be minimal, and secondly, the effect of a seminar 
normally declines rapidly.  If there was no significant difference in the selected drug-
class used 2-weeks post-seminar compared with the selected drug-class used 2-weeks 
pre-seminar, there would probably be no significant difference 6-months post seminar. 
 
Table 28 represents the change in responses for selected drug-class used for first-
episode schizophrenia patients from 2-weeks pre-seminar to 2-weeks post-seminar as 
analysed for the “later” i.e. last 8 seminars only.  
 
Table 28: Selected drug-class (conventional or new generation) used for first-
episode schizophrenia patients before and 2-weeks after the seminar, using 
only responses from the last 8 seminars  
  Drug-class used 2-weeks after the 
Seminar 
  New Generation Conventional 
New Generation  62*   (72.1%)**    6   (7.0%)     Drug-class used 
before the 
seminar 
Conventional  10    (11.6%)    8    (9.3%)    
n=86, * number of respondents, ** percentage of total respondents 
McNemar test of changes p = 0.45  
 
The results of Table 28 indicate that 18.6% of the respondents changed their behaviour, 
of whom 11.6% changed from a conventional drug to a new generation drug.  This 
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indicates that the drug-class selected did not change significantly as a result of the later 
seminars. 
 
In comparison, when the results of the earlier seminars are included, about 30% had 
changed drug-class after 6-months (see Table 7, page 62), of whom 23% had changed 
from conventional to new generation antipsychotics.  These figures indicate that change 
to new generation agents decreased over time i.e. over time, more and more 
respondents used new generation antipsychotics prior to attending the seminars. 
 
Figure 9 plots the percentage of participants who changed from selecting conventional to 
new generation antipsychotics for first-episode patients 2-weeks after the seminar. 
 
Figure 9: Variation in the percentage of respondents over the time course of 
seminars who changed from selecting conventional antipsychotics before the 
seminar to new generation antipsychotics 2 weeks after the seminar (for first-
episode patients) 
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The trend-line indicates that the percentage change from conventional to new generation 
antipsychotics decreased as the seminar-number increased, i.e. as time passed.  
However, results from the first two seminars seem to account for most of the variation.  
It could also be that the percentage change from conventional to new generation drugs 
was fairly stable across the period.  To better investigate whether the seminars had the 
desired effect of increasing the percentage of new generation antipsychotics chosen, it 
would be more correct to examine the effect of the seminar by separately analysing 
those respondents who used conventional drugs before the seminar. 
 
Figure 10 shows the percentage of respondents at each seminar included in this study 
who changed from conventional to new-generation anti-psychotics.  It is important to 
 85 
note that the percentages may not be valid as the number of respondents from which 
the percentages are derived is small (n=49). 
 
Figure 10: Variation in the percentage of respondents that change from 
conventional to new generation drugs at various seminars for treating first-
episode schizophrenia patients, from before the seminar and 2 weeks after the 
seminar 
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In Table 29 the drug-class used for multi-episode schizophrenia patients was reported 
before the seminar and 2-weeks after the later seminars. 
 
Table 29: Drug-class (conventional or new generation) used before the seminar 
and 2-weeks after the seminar for multi-episode schizophrenia patients 
(Percentage of later seminar answers) 
  Drug-class used 2-weeks after the 
Seminar 
  New Generation Conventional 
New Generation 73,5%   (58)   4,9%    (4) Drug-class used 
before the seminar Conventional   5,9%    (5) 15,7%   (12) 
n=79, McNemar test of changes = 0.65  
 
Only 5.9% changed from conventional to new generation drugs.   As was seen with the 
drug-class for first-episode schizophrenia patients, the drug-class used for multi-episode 
schizophrenia patients did not change either when the later seminars were analysed. 
 
By comparison, from before the seminar to 6-months after the seminar, when all 
seminars were included, about 22.1% of the participants changed from conventional to 
new generation drugs (see Table 8, page 63). 
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Figure 11 shows the average percentage of participants at different seminars who 
changed from conventional drugs to new generation drugs 2-weeks after the seminar in 
cases where multi-episode schizophrenia patients are treated. 
 
Figure 11: Variation in the percentage of respondents at different seminars who 
changed drug-class from conventional to new generation drugs 
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Figure 11 shows there was a great deal of variation between seminars in the average 
percentage of respondents who changed from conventional to new generation drugs.  
Despite this, the trend-line seems to indicate that the percentage who changed to new 
generation drugs became progressively smaller as time passed, i.e. the effect of the 
seminars became progressively less and less. 
 
To conclude, the seminars did not seem to have any significant effect on the drug-class 
used in the short-term when the “later” seminars were analysed; hence the change in 
drug-class from before the seminar to 6-months after all the seminars could not be 
attributed to the effects of the seminar.  The reasons are, firstly, that differences 
occurred in the drug-class used over time; participants at “later” seminars tended to use 
more new generation drugs before the seminar compared to those at “earlier” seminars.  
This indicated that a change towards new generation drugs was a general feature and 
did not result from effects of the seminar itself.  Secondly, there was no significant 
change in drug-class from before to 2-weeks after the “later” seminars.  Further, a lower 
percentage of psychiatrists changed to new generation drugs in the “later” seminars 
compared with the “earlier” seminars.  Given these data it seemed many participants 
(72% used new generation drugs before the seminar) had already made the change to 
new generation drugs before the “later” seminars.  Therefore the seminar could not have 
had a significant effect on the drug-class used.  However, based on the significant effect 
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that could be demonstrated, changes in the drug-class used did seem to occur as a 
result of attendance at the “earlier” seminars. 
 
4.4   Number of study respondents completing questionnaires 
Even though the level of knowledge concerning duration of treatment and haloperidol 
dose seems to be more or less identical during the period of investigation, the number of 
respondents in the different datasets might influence the results.  
 
Not all of the 408 seminar participants answered to all questionnaires.  Furthermore, the 
number of participants who filled in the pre-questionnaire and the 6-months 
questionnaire differed: 386 participants filled in the pre-questionnaire and 139 filled in 
the 6-months questionnaire.  The participants who completed the questionnaires may 
not have been representative of the entire sample.  For example, it may be possible that 
only the general hospital employed psychiatrists filled in the 6-months questionnaire.  
Let us assume that general hospital employed psychiatrists are better learners compared 
to those employed in a university hospital. Therefore, it would mean that only the good 
learners (i.e. those from the general hospitals) filled in the 6-months-questionnaire.  
This would bias results in favour of seminar learning having a greater effect on changes 
to haloperidol prescribing behaviour than were the case. Therefore, a paired comparison, 
where only responses of participants who filled in both questionnaires (pre- and 6-
months post-seminar), was used in this study.  Therefore, if learning ability or 
willingness to learn was connected to certain characteristics of the psychiatrist, it was 
important to make sure that the characteristics of respondents who filled in both 
questionnaires also reflected the characteristics of those who only filled in the pre-
seminar questionnaire i.e. it was important to determine whether there were any data-
set differences.   Otherwise, the conclusions of the paired analyses might prove invalid.  
 
Characteristics of respondents used to detect differences between the two-datasets were 
workplace, years of experience, number of patients and country of origin (see tables 31-
34).  If no differences were detected between the two datasets, then differences in 
knowledge and behaviour, before the seminar and 6-months after the seminar, could not 
be due to specific characteristics of the psychiatrists comprising each dataset. 
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Table 30: Workplace of pre-seminar and 6-months post-seminar respondents 
 Pre-dataset   
(n=386) 
6-months-dataset   
(n=139) 
University Hospital    36.3%       37.4% 
District or General Hospital    24.1%       25.9% 
Private Practice      1.8%         1.4% 
Specialised Psychiatric Hospital    34.2%       30.9% 
Other      3.6%         4.3% 
Chi-square test = 0.95  
As can be seen from Table 30, no significant difference between the two datasets existed 
in terms of the workplace of the respondents. 
 
Clinical experience is perhaps a doctor’s most trusted tool.  This certainly could influence 
knowledge and clinical care.  Table 31 compares the clinical experience of participants in 
the pre-seminar dataset and the 6-month post-seminar dataset. 
 
Table 31: Years of experience practising psychiatry for respondents 
in the pre-seminar and 6-monthpost-seminar dataset 
 Mean Std. Deviation 
Pre-dataset                        (n=390) 13.3 years 7.42 
6-months-dataset               (n=144) 14.5 years 7.46 
Independent samples t-test: t=1.64; p=0.09  
 
Results in Table 31 indicate no significant difference in the average years of psychiatric 
experience among respondents of the pre-seminar and 6-months post-seminar dataset. 
 
Workload (patient numbers per month) determines the time a doctor can spend with a 
patient, in turn influencing the quality of care and treatment practises.  Table 32 
explores this. 
 
Table 32: Number of patients treated per month by respondents 
in the  pre-seminar and 6-month post-seminar dataset 
 Mean Std. deviation 
Pre-dataset                        (n=390) 79.0 patients 67.8 
6-months-dataset               (n=144) 80.6 patients 70.9 
Independent samples t-test: t=0.17; p=0.82  
 
No significant difference in the average number of patients seen per month by 
respondents of the pre-seminar and 6-months post-seminar questionnaire was detected 
(p=0.82).  
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Psychiatrists from 29 different countries attended the seminars.  It is quite possible that 
the two datasets exhibited a high knowledge variation in different countries of origin 
because not all countries have the same knowledge, training and interest in 
schizophrenia.  Table 33 shows that similar percentages of participants from the various 
countries were represented in the pre-seminar dataset and the 6-months post-seminar 
dataset. 
 
Table 33: Country of origin of respondents in the pre-seminar and 
6-months post-seminar dataset 
 
 
 
Pre-seminar-dataset  
(n=382) 
6-months-dataset    
(n=157) 
Australia      15    3.9%      6    3.8% 
Austria      20    5.2%      7    4.5% 
Belgium       23    6.0%    12    7.6% 
Canada        5    1.3%      0       0% 
Czech Republic      10    2.6%      6    3.8% 
Denmark      23    6.0%      9    5.7% 
Estonia        5    1.3%      3    1.9% 
Finland      12    3.1%      7    4.5% 
France      18    4.7%      9    5.7% 
Germany      28    7.3%    11    7.0% 
Greece      16    4.2%      4    2.5% 
Hungary      15    3.9%      7    4.5% 
Ireland        3    0.8%      2    1.3% 
Israel        5    1.3%      0       0% 
Italy      29    7.6%    10    6.4% 
Luxembourg        1    0.3%      1    0.6% 
Macedonian        0       0%      1    0.6% 
Netherlands      20    5.2%      8    5.1% 
New Zealand      17    4.5%      6    3.8% 
Norway      23    6.0%    11    7.0% 
Poland       12    3.1%      6    3.8% 
Russia        5    1.3%      0       0% 
Slovakia        5    1.3%      3    1.9% 
Slovenia        3    0.8%      0       0% 
South Africa      15    3.9%      6    3.8% 
Spain      20    5.2%      6    3.8% 
Sweden      10    2.6%      5    3.2% 
Switzerland      13    3.4%      6    3.8% 
United Kingdom      11    2.9%      5    3.2% 
Total    382  (100%)  157  (100%) 
Chi-square test = 0.976  
 
For the analyses conducted in chapter 6, it was vitally important that the two datasets 
should be similar in terms of country of origin of the participants.  For the purpose of 
analysis, participants were clustered into three groups of countries on the basis of 
similarity of knowledge in the pre-seminar questionnaires.  The groups were arranged in 
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descending order i.e. Group 1 countries had the highest proportion of “correct answers” 
whereas the Group 3 countries had the lowest proportion. 
 
These groups are listed below: 
 
Table 34:  Countries listed by their allocated country-groups 
Group 1 Group 2 Group 3 
Canada Denmark Greece 
Australia Sweden Germany 
South Africa France Britain 
Netherlands Belgium Spain 
Norway Switzerland Eastern-European-countries 
New Zealand Ireland Italy 
 Austria  
 Finland  
 
Table 35 reports the percentage representation of each country-group within the pre-
seminar and the 6-months post-seminar datasets. 
 
Table 35: Country of origin in the pre-seminar dataset and the 6-months post-
seminar dataset, reported in terms of the country-groups  
 Pre-dataset           
(n=382) 
6-months-dataset   
(n=157) 
Group 1 countries  27.5%  26.8% 
Group 2 countries  30.9%  33.8% 
Group 3 countries  41.6%  39.5% 
 (100%) (100%) 
Chi-square test = 0.805  
 
Table 35 shows that there were no significant differences in the country-group 
distribution in the two datasets (p=0.805). 
 
4.5   Summarising the effect of developments in knowledge over time and 
differences between datasets - can differences observed before and after the 
seminar be ascribed to the beneficial effects of the seminar?  
It was important to investigate whether advances occurred in the level of general 
schizophrenia knowledge among psychiatrists – “background” knowledge change.  If 
knowledge advanced over time, the difference in responses of the pre-seminar 
questionnaire and the 6-months post-seminar questionnaire (presented in Chapter 3) 
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could be the result of changes in this background knowledge rather than the result of 
seminar attendance. 
 
Accordingly, a comparison of the knowledge and behaviour of the participating 
psychiatrists (relating to the variables of most interest to the study) was made between 
the “earlier” and the “later” seminars and between the responses in the two-week post-
seminar and 6-months post-seminar questionnaires. 
 
Results of these analyses showed that only the minimum effective dose selected by 
psychiatrists before they attended the seminars did not change over time, indicating   
that changes observed after the seminar were not due to changes in background 
knowledge.  However, the changes in the selected effective dose of haloperidol after 
the seminar were probably, at least in part, due to changes in background knowledge.  
The percentage of respondents prescribing below 5 mg/day pre-seminar increased over 
time, even though there were no changes between 2-weeks after and 6-months after the 
seminar. 
 
The analyses of changes in recommended duration of treatment showed that no 
significant differences were found between “earlier” seminars and “later” seminars.  
Furthermore no changes occurred between 2-weeks after the seminar and 6-months 
after the seminar.  Therefore, it was likely that changes in selected duration of treatment 
for first- and multi-episode schizophrenia patients pre-seminar to 6-months post-
seminar were not due to changes in background knowledge. 
 
Furthermore, the intended drug-class used changed between the earlier seminars and 
the later seminars.  Despite the fact that the intended drug-class used was quite stable 
from 2-weeks after to 6-months after the seminar, substantial changes occurred in the 
drug-class used over time by psychiatrists before they attended i.e. new generation 
antipsychotics were gradually more commonly chosen as the preferred drug before the 
seminars.  Section 4.3 (see Table 28) showed that there was no significant change in 
favour of the new generation antipsychotics two weeks after the later seminars.  The 
change in favour of new generation antipsychotics, 6 months after all the seminars, was 
probably due at least partly to development in the background knowledge of 
psychiatrists and not solely due to the beneficial effects of the seminars.  The change in 
actual antipsychotic class chosen over time was not investigated because no significant 
change occurred 6 months after the seminar. 
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The data-set comparison performed to eliminate the possibility that characteristic 
differences between the pre-dataset and the 6-months-datasetmight be responsible for 
any post-seminar haloperidol prescribing behaviour change showed there were no 
significant differences in the key characteristics of workplace, years experience, number 
of patients seen per month and country of origin. Therefore, the post-seminar changes 
described in Chapter 3 were unlikely a result of these factors.  
 
Consequently, it would seem that changes in responses concerning the selected 
minimum effective haloperidol dose and selected duration of treatment were neither due 
to increases in the background knowledge of psychiatrists nor differences between the 
pre-seminar and 6-month post-seminar datasets used for analysis.  The inference is that 
changes in responses concerning these two areas (minimum effective haloperidol dose 
and duration of treatment) could be ascribed to effects of the seminar. 
 
Conversely, the changes in the effective haloperidol dose post seminar were probably 
due at least in part to changes in the background knowledge of psychiatrists.  Changes 
in the intended drug-class used by later seminar participants seem to be minimal at best 
and could not be attributed to the seminars.  However, these changes occurred far more 
significantly in earlier seminar participants, and these changes do seem to be an effect of 
attendance at the early seminars. 
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Chapter 5 Variables that could influence outcomes 
 
In Chapter 3, changes in haloperidol prescribing behaviour post-seminar were 
investigated, with significant change in several key areas noted. In Chapter 4, some of 
these changes in prescribing behaviour were partly attributed to respondent 
“background” learning (not solely an effect of seminar attendance). The likelihood of 
dataset differences between pre-seminar and 6-months post-seminar respondents being 
responsible for any change was discounted. Thus it was concluded that the changes in 
selected minimum effective haloperidol dose and selected duration of treatment were the 
only changes in haloperidol prescribing behaviour likely to be directly related to seminar 
attendance.  The following two chapters investigate why some seminar attendees 
changed behaviour (i.e. what attendee traits or characteristics made them more likely to 
change haloperidol prescribing behaviour) by looking at the effect nationality, years of 
work experience, patient caseload and workplace environment had on changes in 
selected minimum effective dose and selected duration of treatment.  
 
Changes were analysed only with respect to the minimum effective haloperidol dose and 
duration of treatment.  The variation in drug-class used and effective haloperidol dose 
was not analysed, as these differences before and after the seminars can probably not 
be ascribed to an effect of the seminars. 
 
5.1   Country of origin 
It is likely that different countries have different approaches to psychiatry. This in turn 
might impact on the learning abilities and potential of the participants through differing 
knowledge levels, training provided and ethics.  By way of example, a Dutch psychiatrist 
may be more "open" to new ideas and knowledge compared to a psychiatrist from 
Greece. The difference in learning – and possibly change in behaviour – may therefore 
be due to a difference in “learning culture”.  Also, the Dutch may have a “psychiatry 
culture” that focuses on fewer patients but higher quality treatments, whereas the 
Greeks may focus on more quantitative aspects. These differences in “learning-culture” 
and “psychiatry culture” may result in more openness to new ideas among Dutch 
psychiatrists.  As a result the Dutch may learn more at the seminars than the Greek 
psychiatrists.  On the other hand, the Dutch may know more than the Greeks before 
they attend the seminar; therefore a comparison of the changes in behaviour between 
Dutch and Greek psychiatrists may demonstrate that the Greeks learn more. 
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In order to test the hypothesis of the effect of different countries of origin/cultures, the 
next chapter compares changes in behaviour between different cultures of psychiatry 
controlled for the answers before the seminar (the knowledge before the seminar is 
taken into account).  The countries have been categorised into groups reflecting different 
levels of knowledge in the pre-seminar questionnaires (“psychiatry culture”) (See Table 
34, page 91). 
 
5.2   Years of experience 
Other factors could possibly affect the changes in prescribing behaviour that were 
observed after the seminar.  The number of years the psychiatrists have practised could 
influence their way of practice and their ability, interest, or even need, to learn.  An 
experienced psychiatrist might be more conservative in the treatment habits compared 
to a younger psychiatrist.  On the other hand, the more experienced psychiatrist might 
have greater knowledge compared to the young psychiatrist, meaning that the 
experienced psychiatrists could not learn as much from the seminar. 
 
In order to take the level of knowledge into account, the pre-seminar answers are 
controlled for level of knowledge when changes in behaviour are analysed.  As an 
example, if the effective haloperidol dose is given as below 5 mg/day before the 
seminar, it is deemed that the participant cannot “learn” much.  When this is not taken 
into account, the result might be that number of years of experience does not influence 
the effect of the seminar – changes in knowledge and behaviour.  The following section 
compares changes in behaviour between less and more experienced psychiatrists, 
controlling for level of knowledge in the answers before the seminar. 
 
5.3   Workplace 
The workplace setting can influence learning.  By example, before attending a seminar, a 
psychiatrist from a specialised psychiatric hospital might have superior knowledge of 
schizophrenia management and may therefore have less opportunity to learn from the 
seminar, as compared to a psychiatrist who works at a general hospital, who perhaps 
does not treat schizophrenia patients on a regular basis.  As in testing the previous 
hypotheses, the level of knowledge before the seminar needs to be taken into account. 
 
5.4   Average number of patients treated per month 
The number of patients treated by the psychiatrist may influence both the 
knowledge/experience of the psychiatrist as well as the time available to see each 
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patient.  A psychiatrist with many patients might have less time for keeping up to date 
with the literature compared to a psychiatrist with few patients.  On the other hand, 
psychiatrists with fewer patients might have less experience treating patients compared 
to psychiatrists with many patients.  In this sense it is difficult to conclude a priori what 
effect having many patients might have on changes in behaviour.  However, as in testing 
the previous three hypotheses, the level of knowledge before the seminar needs to be 
taken into account, as it is a fair assumption that the participants' knowledge varied 
before the seminar. 
 
In the next chapter the effect of the average number of patients seen by the psychiatrist 
on the changes in behaviour is analysed.  The number of patients was considered in 
terms of the total number of patients per month, the number of schizophrenia patients 
seen per month, and percentage of patients who have a schizophrenia diagnosis.  
Several indicators are used to obtain a more valid assessment of the work-load and area 
of specialisation of the particular psychiatrist. 
 
5.5   Summary 
Having established that i) changes in haloperidol prescribing behaviour post-seminar 
actually do occur ii) some of these changes are attributable to “background” learning by 
participating psychiatrists and iii) the pre- and post-seminar datasets used in this study 
are comparable, it was important to further investigate the nature of the variation in the 
changes in prescribing behaviour of the different participants at the seminars.  The next 
chapter tests whether the variation can be understood with reference to: country of 
origin, workplace, and years of experience and number of patients seen. 
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Chapter 6 Exploring variations in results 
 
The tests of the explanatory-power of the above hypotheses concerning the nature of 
the variation in changes to haloperidol prescribing behaviour focus on the minimum 
effective haloperidol dose and duration of treatment.  The variations in drug-class used 
and effective haloperidol dose were not analysed because these prescribing changes 
post-seminar were most likely due to factors other than the learning effect of the 
seminar (see Chapter 4).  The testing of the above explanations of change was two-
tiered. 
 
Firstly, there was a need to test whether the individual variables e.g. years of 
experience, caseload, nationality, or workplace could explain the variation in dependent 
variables e.g. duration of treatment, minimum effective dose.  As an example, the 
association between years of experience and changes in duration of treatment was 
tested, controlled for by duration of treatment prescribing behaviour before the seminar.  
A dummy-variable2 was constructed in order to take account of the knowledge before 
the seminar.  Dummy variables are a way of adding the values of a nominal or ordinal 
variable to a regression equation.  Each value of the categorical independent except one 
is entered as a dichotomy. 
 
In the current analysis, the dummy variable was created in such a way that it had the 
value 1 if the respondent was on the wrong side of the target i.e. below the 
recommended duration of treatment or above the recommended minimum dosage 
before the seminar e.g. a respondent might recommend 10 months treatment of first-
episode schizophrenia patients before the seminar.  This respondent is deemed below 
the target of 18 months, and for the purpose of analysis is assigned the value of 1, 
compared with a respondent recommending a value above 18 months who is assigned 
the value of 0. This enables regression analysis to be performed.  If, after analysis, the 
dummy variable then is found to be significant, the interpretation is that those selecting 
below the recommended target duration of treatment pre-seminar changed behaviour in 
a significantly different way compared to those above the target pre-seminar.  The 
duration of treatment is said to be increased when the regression coefficient of the 
dummy variable is positive, indicating that those below the target pre-seminar increased 
                                          
 
2 A dummy-variable is a variable with 2 values: 0 or 1. In this sense the variable is on interval 
(numerical)-level and can consequently be used in regression-analysis.  Categorical variables 
cannot be used in normal regression-analysis.  Categorical variables like country of origin are 
instead often transformed into dummy-variables.  
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their duration of treatment in comparison to the reference group i.e. those selecting 
above the target pre-seminar.  In other words, an important objective of the seminar 
has been fulfilled - a change in the prescribing behaviour of those participants below the 
target pre-seminar occurred, i.e. “learning” occurred where “learning” was required. 
 
Secondly, in addition to the dummy-variable, interaction-variables were also 
constructed.  Interaction exists when the association between e.g. changes in haloperidol 
dose and number of patients is altered as the haloperidol dose before the seminar 
changes.  The number of patients and the haloperidol dose before the seminar are said 
to interact, which means that the association between number of patients and changes 
in haloperidol dose is conditioned by the haloperidol dose before the seminar.  An 
example could be that the changes in behaviour are especially related to the situation 
where the psychiatrist prescribes a dose above the target dose of haloperidol (in this 
case higher than 5 mg/day) and has many first-episode schizophrenia patients.  Put 
differently, the haloperidol dose changes especially among those psychiatrists who are 
above the target before the seminar and see many first-episode schizophrenia patients.  
If this is the case, interaction exists between the number of first-episode schizophrenia 
patients and the haloperidol dose before the seminar.  The test described below shows 
that this was the case. 
  
When the effect of the individual variables had been tested individually using simple 
regression analysis (through including the dummy-variables and interaction-variables) all 
the variables (country of origin, years of experience, workplace and number of patients) 
were put into a multivariate analysis.  A so-called multiple-dummy-regression was 
performed.  This implies that the effects of all the different hypotheses on changes in 
behaviour (e.g. duration of treatment and experience) are taken into account at the 
same time.  The advantage is that a spurious3 correlation, such as between duration of 
treatment and years of experience could be detected more easily.  It may be that a 
given relationship between duration of treatment and country of origin was the effect of 
the numbers of years of experience.  By way of example, Greek psychiatrists may have 
more years of experience compared to other countries, which may be why the country of 
origin (incorrectly) seems to explain changes in the duration of treatment, whereas years 
of experience offers the explanation for the change in duration of treatment. 
 
                                          
 
3 A relationship between two variables is said to be spurious if both variables are dependent on a 
third variable, so that the association disappears when the third variable is controlled.  
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6.1   Country of origin    
In order to test whether the country of origin made a difference to the learning or 
changes in prescribing behaviour of a participant, the countries were categorised into 
groups the same as those used in Chapter 4 (see Table 34, page 91).  A dummy-variable 
was constructed to control for the knowledge before the seminar.  In the case of country 
of origin, two dummy-variables were constructed; Dummy group 1 and Dummy group 2.  
To make the results more readable, the interaction variables were only reported if they 
contributed significantly to the explanation. 
 
6.1.1 Country of origin and changes in duration of treatment 
 
Table 36: Regression analysis of the association between participant’s country 
of origin and changes in the selected optimal duration of treatment for first-
episode schizophrenia patients 
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -5.624  0.002 
Dummy group 1 -2.001 -0.081 0.371 
Dummy group 2  1.077  0.048 0.604 
Dummy below 18 months 
of treatment before the 
seminar 
10.513  0.472 0.000 
Explained variation R2 = 24.1%                                                          n=116 
 
Results in Table 36 show that country of origin had neither a direct effect (see regression 
coefficients) nor an indirect effect through interactions with other variables on the 
changes in selected duration of treatment of first-episode schizophrenia patients. 
Instead, changes in duration of treatment post-seminar were explained with reference to 
the length of treatment recommended before the seminar.  Respondents who selected 
below the target of 18 months before the seminar increased their recommended duration 
of treatment by approximately 5 months (i.e. 10.51 months - 5.62 months) more 
compared with respondents who were above 18 months before the seminar. 
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Table 37: Regression analysis of the relationship between changes in duration 
of treatment for multi-episode schizophrenia patients and country of origin 
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -2.288  0.416 
Dummy group 1 -0.155 -0.004 0.965 
Dummy group 2 -0.048 -0.001 0.988 
Dummy below 60 months 
of treatment before the 
seminar 
16.295  0.480 0.000 
Explained variation R2 = 23.0%                                                          n=112 
 
Similar to Table 36, Table 37 shows that country of origin again had neither a direct 
effect (see regression coefficients and T-test significance for dummy groups 1 and 2) nor 
an indirect effect (interaction variables insignificant so not included) on changes to the 
duration of treatment of multi-episode schizophrenia patients.  Instead, the changes in 
duration of treatment were again explained by the recommended duration of treatment 
selected before the seminar.  Respondents below 60 months before the seminar 
increased their duration of treatment by 16.3 months in comparison to respondents 
above 60 months pre-seminar. 
 
6.1.2 Country of origin and changes in minimum effective haloperidol dose 
 
Table 38: Regression analysis of the relationship between changes in minimum 
effective haloperidol dose and country of origin 
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant 0.338  0.619 
Interaction dummy group 1 
and above 3 mg/day of 
Haloperidol 
2.429 0.201 0.090 
Interaction dummy group 2 
and above 3 mg/day of 
Haloperidol  
4.651 0.413 0.001 
Dummy above 3 mg/day of 
Haloperidol before the 
seminar  
-4.266  -0.467 0.000 
Explained variation R2 = 16.5%                                                            n=90 
 
The regression model in Table 38 explains 16.5% of the variation in changes in minimum 
effective haloperidol dose.  The recommended dose before the seminar had an effect on 
the changes observed: respondents above 3 mg/day pre-seminar decreased their dose 
compared with those below 3 mg/day pre-seminar.   
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Country of origin also had an effect.  However, this effect was indirect (effects of dummy 
group 1 and dummy group 2 alone not significant so not included in table). The 
interaction between the country-groups and dummy above 3 mg/day were more or less 
significant.  Respondents from a Group 2 country and above the target of 3 mg/day 
before the seminar, increased their haloperidol dose by 4.65 mg/day compared to 
respondents from a Group 3 country who were also above the target before the seminar.  
In other words, the net-effect of the seminar on respondents from a Group 2 country 
was marginal; the effect of being above 3 mg/day was cancelled out by the fact that the 
respondents were from a Group 2 country. 
 
In the case of respondents from a Group 1 country, the interaction was significant on the 
10%-level but not the 5%-level.  Group 1 respondents who were above target before the 
seminar increased their dose, albeit only slightly.  However, the increase was slightly 
less than Group 2 respondents, who increased their haloperidol dose by 2.4 mg/day after 
the seminar, compared to Group 3 respondents who were above the target.  However, 
the general effect of being above the target was not cancelled out, as was the case with 
Group 2 respondents.  Therefore, the seminar still had an effect on Group 1 members in 
the intended direction. 
 
The greatest effect of the seminar was present among Group 3 members.  Those above 
the target before the seminar decreased their haloperidol dose by 4.2 mg/day.  These 
findings were not unexpected; as respondents from Group 3 countries seemed to have 
the greatest need to learn i.e. alter their minimum effective dose of haloperidol 
prescribing habit. 
 
Finally, it is noteworthy that the explained amount of variation in change of minimum 
effective haloperidol dose was considerable when compared to Table 41 below (page 
106); years of experience explained only 5.6% of change, whereas nationality explained 
16.5% (see Table 38 above).  In other words, nationality played a stronger role in 
explaining the changes in selected minimum effective haloperidol dose than psychiatrists’ 
years of experience. 
 
6.2   Years of experience 
This section analysed the correlation between number of years of experience and the 
changes in both duration of treatment and haloperidol dose by performing simple 
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regression analyses, controlling for either the duration of treatment before the seminar 
or the haloperidol dose before the seminar4. 
 
6.2.1 Years of experience and changes in duration of treatment 
Table 39 reports the association between years of experience and changes in duration of 
treatment for first-episode schizophrenia patients, controlled for by the selected duration 
of treatment before the seminars.  A dummy-variable was constructed i.e. for first-
episode schizophrenia patients, the recommended duration of treatment is 18 months; 
therefore the dummy separated the respondents into those who selected above or below 
18 months pre-seminar.  In order to make the results more readable, the interaction 
variable (i.e. effect of the interaction between years experience and pre-seminar 
response) was not reported5 if it did not contribute significantly to the explanation. 
 
Table 39: Regression analysis of the relationship between changes in duration 
of treatment for first-episode schizophrenia patients and years of experience, 
controlled for by selected haloperidol dose pre-seminar  
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -7.798  0.000 
Years of experience  0.115  0.078 0.332 
Dummy below 18 months 
of treatment before the 
seminar 
11.165  0.489 0.000 
Explained variation R2 = 25.5%                                                          n=119 
Dependent variable = duration of treatment  
Independent variable = psychiatrists’ years of experience 
Control group = participants who selected above 18 months duration of treatment pre-seminar 
 
Table 39 shows the interaction-variable did not contribute significantly and was not 
included.  Equally, years of experience alone had an insignificant effect on the changes in 
duration of treatment.  The learning concerning treatment duration was not affected by 
the years of experience of the psychiatrist.  Instead, the treatment duration response 
                                          
 
4 Whether the models meet the assumptions of multiple-regression, and whether multicollinearity 
(the independent variables are highly correlated) could be a problem, were tested - this was not 
the case in any of the models presented.  Visually the plot of the significant variables was tested to 
be linear.  The conditional distribution of the dependent variable was normal.  The distribution of 
the independent variable had constant standard deviation throughout the range of independent 
variables - homoscedasticity is present. 
 
5 The variables are removed from the model by backward selection; therefore, all the variables are 
entered into the model in a block and then removed one at a time.  Firstly to test whether the 
interaction term contributes significantly to the model and thereafter the effects of the main 
effects are tested.  
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before the seminar was relevant.  Respondents, who recommended less than 18 months 
of treatment before the seminars, increased their recommended duration of treatment 
by approximately 11.2 months compared to those respondents who recommended more 
than 18 months of treatment pre-seminar.  The respondents who selected above 18 
months treatment pre-seminar decreased their recommended duration of treatment by 
7.8 months.  In other words, the net-increase of those below the target was 
approximately 3.4 months6. 
 
Analysed this way, the seminar had an effect, which differed from the findings in Chapter 
4.  Those who selected below 18 months treatment before the seminar increased their 
duration of treatment and those who selected more than 18 months treatment pre-
seminar decreased the duration.  In short, the seminar had the intended effect on 
treatment duration for first-episode schizophrenia patients. 
 
The total model – knowledge of the recommended duration of treatment before the 
seminar – explains a quarter (25.5%) of the differences in learning/changes in duration 
of treatment.  This is an impressive proportion. 
 
Table 40 reports the effect of years of experience on the change in duration of treatment 
when the patient is a multi-episode schizophrenia. 
 
Table 40: Regression analysis of the relationship between changes in duration 
of treatment for multi-episode schizophrenia patients and years of experience, 
controlled for by selected duration of treatment pre-seminar 
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -2.132  0.546 
Years of experience  0.015 -0.007 0.937 
Dummy below 60 months of 
treatment 
16.074  0.470 0.000 
Explained variation R2 = 22.1%                                                          n=115 
Dependent variable = duration of treatment 
Independent variable = psychiatrists’ years of experience 
Reference group = participants who selected above 60 months duration of treatment pre-seminar 
 
                                          
 
6 In this special situation, where only the dummy is significant, the constant refers to the changes 
in the duration of treatment of the reference-group.  The constant reports that those above the 
target before decrease their duration of treatment by 7.8 months.  The value of the dummy-
variable is the difference compared to the reference-group.  As those below the target increase 
their duration of treatment by 11 months, the net-increase in duration of treatment of those below 
the target is 3.4 months.  
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Once again, years of experience did not affect the changes in duration of treatment.  
Instead, those respondents who selected below 60 months treatment before the 
seminar, increased their duration of treatment by approximately 16.1 months on 
average compared to those who selected greater than 60 months duration of treatment 
pre-seminar (the reference group).  Those who selected above 60 months of treatment 
pre-seminar decreased their duration of treatment by approximately 2 months (the 
constant).  Consequently, the net-increase of those below the target was 16.1 months - 
2.1 months i.e. approximately 14 months.  This indicated that the seminar had an effect 
on the participants who were most out of line with treatment guidelines.  The whole 
model explains 22.1% of the variation in changes between the respondents. 
 
To summarise, the changes in duration of treatment were not explained by either the 
years of experience of a psychiatrist, nor the interaction between years of experience 
and pre-seminar questionnaire response.  Instead the pre-seminar duration of treatment 
response alone was the best predictor of the duration of treatment after the seminar.  
Participants below the recommended duration of treatment before the seminar increased 
their duration of treatment after the seminar.  Therefore, the seminar altered the 
prescribing behaviour of those most out of line with the recommended standards. 
 
6.2.2 Years of experience and changes in minimum effective haloperidol dose 
 
Table 41: Regression analysis of the relationship between changes in minimum 
effective haloperidol dose and years of experience, controlled for by selected 
pre-seminar dose  
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -0.292  0.803 
Years of experience  0.043  0.071 0.494 
Dummy above 3 mg/day 
before the seminar 
-2.011 -0.221 0.035 
Explained variation R2 = 5.6%                                                              n=91 
Dependent variable = minimum effective haloperidol dose 
Independent variable = psychiatrists’ years of experience 
Reference group = participants who selected below 3 mg/day pre-seminar 
 
Table 41 reports the association between changes in haloperidol dose and years of 
experience explains a total of 5.6% of the variation in changes in haloperidol dose.  This 
is not impressive, when considering that country of origin explained 16.5% of the 
variation in change of minimum effective haloperidol dose (see Table 38, page 102).  
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Nationality plays a much stronger explanatory role with regard to changes in minimum 
haloperidol dose. 
 
Furthermore, changes could not be explained by years of experience.  It seems that the 
haloperidol dose prescribed pre-seminar best explained the changes.  Respondents who 
were above 3 mg/day before the seminar decreased their haloperidol dose by 
approximately 2 mg/day in comparison to the reference group (those who selected 
below 3mg/day pre-seminar). The net-reduction was 2.3 mg/day since those who were 
below 3 mg/day pre-seminar also decreased their dose.  This leads to the conclusion that 
the seminar had the intended effect – a reduction in the haloperidol dose. 
 
6.3   Workplace 
6.3.1 Workplace and changes in duration of treatment 
Workplace was also analysed using regression analysis.  Again dummy-variables were 
made: dummy university employed and dummy district-hospital employed psychiatrists.  
The reference category was respondents employed at specialised hospitals, private 
practices and other venues.  Essentially though, the reference category was limited to 
specialised hospitals as only four respondents were employed at private hospitals or 
other places. 
 
Table 42 reports on whether or not workplace influenced the changes in duration of 
treatment.  
 
Table 42: Regression analysis of the relationship between changes in duration 
of treatment for first-episode schizophrenia patients and workplace 
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -6.538  0.000 
Dummy university 
Employed 
0.770 0.014 0.876 
Dummy district employed 0.315 0.030 0.734 
Dummy below 18 months 
of treatment before the 
seminar 
11.163 0.490 0.000 
Explained variation R2 = 24.3%                                                          n=121 
 
Workplace did not seem to have any effect on changes in behaviour.  Neither university 
employed nor the district-hospital employed psychiatrists differed significantly from the 
reference-category (the specialised hospital employed).  Instead, the variation in the 
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changes of duration of treatment was explained by the pre-seminar selected dose 
responses.   
 
This picture was confirmed when multi-episode schizophrenia patients were analysed in 
Table 43. 
 
Table 43: Regression analysis of the relationship between changes in duration 
of treatment for multi-episode schizophrenia patients and workplace 
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -1.518  0.560 
Dummy university 
Employed 
-1.780 -0.050 0.771 
Dummy district employed -1.013 -0.027 0.586 
Dummy below 60 months 
of treatment before the 
seminar 
15.810 0.289 0.000 
Explained variation R2 = 21.2%                                                          n=117 
 
The table shows that those respondents selecting below the recommended period of 60 
months before the seminar on average increased their duration of treatment by 15.81 
months in comparison to those selecting above 60 months. 
 
In summary the workplace of the respondents did not seem to have any effect on the 
changes in duration of treatment.  This conclusion was valid when both first-episode 
schizophrenia patients and multi-episode schizophrenia patients were analysed.  
6.3.2 Workplace and changes in minimum effective haloperidol dose 
In this section relationships between workplace and changes in the haloperidol dose 
were analysed.  The results are shown in Table 44.  
 
Table 44: Regression analysis of the relationship between changes in minimum 
effective haloperidol dose and workplace  
 Regression 
coefficient  
Beta-
coefficient 
Significance 
(T-test) 
Constant  0.138  0.807 
Interaction district employed 
and above 3 mg/day before 
the seminar 
-3.432 -0.299 0.005 
Interaction university 
employed and above 
3 mg/day before the seminar 
-1.999 -0.178 0.088 
Explained variation R2 = 9.6%                                                              n=92 
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Neither the haloperidol dose before the seminar nor the workplace had any direct effects 
on the changes in the haloperidol dose, so results were not included in Table 44.  
Instead, the interaction between workplace and haloperidol dose before the seminar 
explained 9.6% of the changes in the haloperidol dose. 
 
Table 44 shows that respondents who were above 3 mg/day before the seminar and 
were employed at a district hospital reduced their haloperidol dose by 3.4 mg/day more 
than the reference group.  Put differently, a psychiatrist employed at a district hospital 
who selected above the target of 3 mg/day before the seminar reduced the haloperidol 
dose significantly more compared with a respondent at a specialised hospital who was 
above the target.  Therefore, it seems, a district-employed psychiatrist may be a better 
learner than a psychiatrist employed at a specialised hospital. 
 
Also, university-employed psychiatrists above the target of 3 mg/day pre-seminar also 
reduced the dose of haloperidol more than the respondents in the reference-group 
(“specialised” hospital employed above 3 mg/day pre-seminar).  However, this 
conclusion was less certain (p=0.088) but may suggest that the behaviour of university-
employed psychiatrists did differ from that of the reference-group. 
 
Compared with Table 38 (page 102), where the changes in haloperidol dose were 
explained solely with reference to the responses before the seminar, more change in the 
haloperidol dose is explained in Table 44; in total 9.6% of the change in behaviour was 
understandable in terms of workplace and selected haloperidol dose pre-seminar.  The 
model in Table 44 contributes to a better understanding of the changes in the haloperidol 
dose. 
 
6.4   Estimated number of patients seen per month 
This section analyses the correlations between estimated number of number of patients 
seen by respondents per month and the changes in both the selected duration of 
treatment and haloperidol dose.  A simple regression analysis was performed and 
controlled for either the duration of treatment before the seminar or the haloperidol dose 
before the seminar. 
6.4.1 Number of patients seen and changes in duration of treatment selected 
In Table 45 the association between the changes in the duration of treatment selected 
and the estimated number of patients seen per month is reported with a differentiation 
between the total number of patients and the number of new schizophrenia patients. 
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Table 45: Regression analysis of the association between changes in duration of 
treatment for first-episode schizophrenia patients and estimated number of 
patient seen per month/number and percentage of schizophrenia patients 
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -3.254  0.061 
Number of patients in 
general per month 
 0.003  0.025 0.786 
Number of schizophrenia 
patients per year 
-0.017 -0.051 0.580 
Percentage of patients who 
have schizophrenia 
0.007 0.019 0.838 
Dummy below 18 months 
of treatment before the 
seminar 
8.463 0.446 0.000 
Explained variation R2 = 20.4%                                                          n=104 
 
Table 45 shows that neither the total number of patients per month nor the number or 
percentage of schizophrenia patients affected the changes in duration of treatment.  
Again, the reported duration of treatment in the pre-seminar questionnaire explained the 
changes in behaviour.  Respondents below the 18 months target before the seminar 
increased the duration of their treatment by approximately 8.5 months compared to the 
reference group (respondents selecting above 18 months treatment pre-seminar), who 
in this model decreased their duration of treatment by approximately 3.3 months.  
 
Table 46 shows the same result; neither the estimated number of patients per month 
nor the number or percentage of schizophrenia patients seen showed any association 
with changes in duration of treatment of multi-episode schizophrenia patients. 
 
Table 46: Regression analysis of the association between changes in duration of 
treatment of multi-episode schizophrenia patients and estimated number of 
patients seen per month/number and percentage of schizophrenia patients 
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -0.301  0.927 
Number of patients in 
general per month 
-0.009  -0.042 0.650 
Number of schizophrenia 
patients per year 
-0.024 -0.038 0.680 
Percentage of patients who 
have schizophrenia 
0.016  0.023 0.817 
Dummy below 60 months 
of treatment before the 
seminar 
15.786 0.454 0.000 
Explained variation R2 = 22.1%                                                          n=101 
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As can be seen, a selected duration of treatment below 60 months before the seminar 
resulted in an average increase of 15.8 months of treatment compared with the 
reference-group (respondents selecting above 60 months pre-seminar). 
 
To summarise, neither the total number, nor type of patients seen by a psychiatrist, nor 
the interaction between many patients and a low duration of treatment before the 
seminar, influenced changes in behaviour.  Once again, the pre-seminar selected 
duration of treatment response was the best predictor of how the participant changed 
prescribing behaviour after the seminar. 
 
6.4.2 Number of patients and changes in haloperidol dose 
Table 47 shows the changes in haloperidol dose as influenced by the number of patients, 
differentiated into total number of patients and number of new schizophrenia patients. 
 
Table 47: Regression analysis of the association between changes in minimum 
effective haloperidol dose and number of patients (total and percentage with 
schizophrenia)  
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -0.122  0.840 
Interaction total number of 
patients per month and 
above 3 mg/day before the 
seminar 
0.023 0.389 0.000 
Interaction number of 
schizophrenia patients per 
year and above 3 mg/day 
before the seminar 
-0.080 -0.372 0.001 
Interaction percentage who 
have schizophrenia and 
dummy above 3 mg/day 
before the seminar 
-0.049 -0.309 0.004 
Explained variation R2 = 29.4%                                                            n=85 
 
The model in Table 47 explained 29.4% of the changes observed in haloperidol dose 
prescribing post-seminar.  The haloperidol dose selected before the seminar was no 
longer significantly associated with the changes in dose selected after the seminar, and 
results were not included in Table 47.  Furthermore, a three-way interaction term was 
also tested: interaction between the number of patients, percentage schizophrenia 
patients and dummy below 3 mg/day before the seminar.  This interaction term did not 
contribute significantly to the model, so also was not included in the table.  However, 
despite the fact that no direct effect was apparent from the dose of haloperidol before 
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the seminar, the variable was still important because it interacted with some of the other 
tested variables. 
 
When the beta-coefficients were compared, the most important variables in terms of 
explaining the changes in the haloperidol dose were the interaction between total 
number of patients and haloperidol dose before the seminar.  If the psychiatrist had 
many patients (not only schizophrenia patients) and was above the target before the 
seminar, the participant increased the haloperidol dose after the seminar compared to a 
participant who had fewer total patients and was above the target.  Therefore, the 
number of general patients had a negative effect on the learning of the participants - the 
expectation would be that those above the 3 mg/day target would reduce their dose. 
 
However, the number of patients did not necessarily cause a net increase in the 
haloperidol dose.  The haloperidol dose was reduced by participants who, pre-seminar, 
were above the 3mg/day target, and concurrently had a high percentage or high number 
of schizophrenia patients.  In fact, the higher the percentage of schizophrenia patients a 
participant selecting above 3/mg/day pre-seminar had, the greater the reduction in the 
haloperidol dose.  Similarly, the reduction in haloperidol dose was even greater when a 
participant selecting above 3 mg/day saw a high number of schizophrenia patients, 
regardless of percentage. 
 
To summarise, the seminar would have had a direct effect on participants who were 
above the target haloperidol dose before the seminar, if these participants reduced the 
dose after the seminar independently of their number of schizophrenia patients or 
percentage of schizophrenia patients in general.  However, the effect was not direct.  
Instead, the seminar had a positive learning effect on those participants who were above 
the target before the seminar and either saw many schizophrenia patients in total or had 
a high percentage of schizophrenia patients.  Put differently, the decreased dose change 
in haloperidol was dependent upon whether the participant firstly, selected above the 
target dose of 3 mg/day pre-seminar, and secondly had a high number or percentage of 
schizophrenia patients i.e. psychiatrists who selected above the target before the 
seminar, and either had many schizophrenia patients or a high percentage of 
schizophrenia patients, reduced the haloperidol dose they prescribed.  
 
Also, the haloperidol dose was increased by participants selecting above the 3 mg/day 
target before the seminar but had many patients in total (not specifically schizophrenia 
patients), compared with the participants who were also above the target but saw fewer 
patients.  
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Therefore, the number of patients seen had a negative learning effect in general, but a 
positive learning effect if the patients were predominantly schizophrenia patients. 
 
Finally, a note on the “level of explanation”.  Table 47 (number of patients) explains five 
times as much of the change in the minimum effective haloperidol dose compared to the 
model presented in Table 38 (page 102) (country of origin).  If the workplace of the 
respondents were included as well, the amount of explained variation could perhaps 
increase further - as long as the variables were not highly related.  Inclusion of 
workplace in the model is presented in the multivariate analysis in Chapter 7. 
 
6.5 The association between the individual variables and changes in behaviour - 
tentative explanation of changes 
The previous sections have analysed changes in both duration of treatment and changes 
in the minimum effective haloperidol dose.  The effect of one explanatory variable (e.g. 
years of experience), the behaviour before the seminar (e.g. selecting above or below 3 
mg/day haloperidol) and the interaction variables (e.g. interaction between selecting 
above 3 mg/day pre-seminar and nationality) were tested.  However, all explanatory 
variables, the relevant dummy and the interaction variables were not tested at the same 
time.  The analyses performed thus far can be said to be partial, therefore conclusions 
derived from the analyses are only tentative. 
 
6.5.1 Haloperidol doses - what explains the changes? 
Changes in the haloperidol dose were more complex compared with the changes in 
duration of treatment; more factors were associated with changes in haloperidol dose 
prescribing than just the level of the dose selected before the seminar.  
 
The pre-seminar selected minimum effective dose seems to explain some of the changes 
in haloperidol dosage.  A dose above 3 mg/day before the seminar resulted in a 
reduction of the level after the seminar, accounting for about 6% of the changes in the 
doses.  The equivalent degree of explanation concerning the responses before the 
seminars and changes in duration of treatment was 25%.  Thus, in comparison to the 
explanation of changes in duration of treatment, pre-seminar prescribing behaviour was 
not as important when the changes in haloperidol dose were examined.  Other factors 
were also important. 
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Country of origin, in combination with the minimum effective haloperidol dose before the 
seminars, had an effect on the changes in haloperidol dose.  Respondents from Group 2 
countries, who were above the target, increased the haloperidol dose compared to 
respondents from Group 3 countries who were above the target.  The same was true, 
but to a lesser extent, for respondents from Group 1 countries.  
 
Workplace of the respondents contributed to the understanding of the haloperidol dose 
changes as well.  The effect of workplace interacted with the haloperidol dose selected 
pre-seminar.  District-hospital employed psychiatrists, who were above the target before 
the seminar, reduced their haloperidol dose significantly more than psychiatrists working 
in specialised psychiatric hospitals settings who were also above the target before the 
seminar.  University employed psychiatrists, who were above the minimum effective 
haloperidol target dose pre-seminar, probably also reduced the haloperidol dose 
compared with the reference-group. 
 
Furthermore the number of patients seen by the psychiatrist made a difference.  If the 
total number of patients was high and the psychiatrist recommended a dose above the 
target before the seminar, the dose was even higher after the seminar compared to a 
participant who had fewer patients.  The dose decreased among participants who were 
above the target and had either a high number of first-episode schizophrenia patients or 
a high percentage of first-episode schizophrenia patients.  These interaction-terms do 
not allow room for a direct effect from the dose before the seminar.  
 
The analysis in this section indicated that changes in haloperidol dose were independent 
of years of experience.  Instead, the following factors were of importance: country of 
origin in combination with the dose selected before the seminar, workplace in 
combination with dose selected before the seminar, and number and type of patients in 
combination with dose selected before the seminar.  Chapter 7 analyses whether all 
these factors are simultaneously important. 
 
6.5.2 Duration of treatment - what explains the changes? 
No association was found between changes in duration of treatment and years of 
experience, country of origin, workplace and number of patients.  This conclusion was 
independent of the type of patient being treated i.e. first- or multi-episode schizophrenia 
patients.  Furthermore, the interactions between the pre-seminar duration of treatment 
questionnaire responses and the different variables did not have an effect on changes.  
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In other words, the characteristics of the participants did not explain the difference in 
changes in duration of treatment.  
 
Instead, when the first-episode schizophrenia patient data were analysed, approximately 
25% of the changes in duration of treatment could be understood with reference to the 
selected duration of treatment before the seminar.  Respondents selecting a duration of 
treatment of less than 18 months pre-seminar increased their duration of treatment by 
11 months on average compared with those selecting a duration of treatment above 18 
months pre-seminar, who decreased their duration of treatment by approximately 7.8 
months.  So the net-increase in duration of treatment was approximately 3.3 months by 
participants who selected below the target before the seminar.   
 
The same applied to the multi-episode schizophrenia patient data.  Respondents who 
gave less than 60 months of treatment before the seminar increased their recommended 
duration of treatment substantially after the seminar.  Therefore the seminars had an 
effect on the psychiatrists who were furthest out of line in terms of accepted knowledge 
concerning duration of haloperidol treatment. 
 
To conclude, the selected duration of treatment before the seminar explained 
approximately 25% of the variation in the changes in the duration of treatment post-
seminar; this is more than acceptable. 
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Chapter 7 Multivariate analysis of changes 
7.1 Multivariate analysis of changes in haloperidol dose 
7.2 Multivariate analysis of changes in duration of treatment 
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Chapter 7 Multivariate analysis of changes 
 
The above conclusions rest on several analyses investigating the relationship between 
the two dependent variables (duration of treatment and minimum effective haloperidol 
dose) and one independent variable (e.g. workplace, years of experience) controlled for 
by behaviour before the seminar (e.g. selected haloperidol dose before the seminar) and 
their interaction.  
 
The changes in haloperidol dose may not be due to interaction between workplace and 
haloperidol dose before the seminar.  Instead, it could be that the effect of workplace 
and haloperidol dose before the seminar, on change in haloperidol dose is cancelled out 
by the interaction between the number of patients and the haloperidol dose before the 
seminar.  This may be the case if district hospitals had many first-episode schizophrenia 
patients; the reduction in haloperidol dose used at district hospitals is due to the large 
number of first-episode schizophrenia patients seen at these hospitals compared to the 
other hospitals.  Put differently, working at a district hospital and prescribing a 
haloperidol dose above the target should result in a lower haloperidol dose after the 
seminar, independent of the number of first-episode schizophrenia patients.  The 
multivariate analysis presented in this chapter tests exactly this; whether an effect of a 
variable is present independent of the influence of another variable. 
 
In this chapter all the variables are entered into three distinct models.  The first two 
models explain the changes in duration of treatment concerning first- and multi-episode 
schizophrenia patients, while the last model analyses the changes in minimum effective 
haloperidol dose.  The interaction-variables are also included.  However, the interaction 
between the different independent variables (e.g. years of experience and number of 
patients seen) was not included because of the low number of valid cases, and therefore 
the low statistical significance. 
 
7.1   Multivariate analysis of changes in haloperidol dose 
Table 48 below presents the significant model explaining the changes in minimum 
effective haloperidol dose. All insignificant variables have been omitted. 
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Table 48: Multivariate regression analysis of factors relating to changes in 
minimum effective haloperidol dose 
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant 0.179  0.759 
Interaction number of 
schizophrenia patients per 
year and above 3 mg/day 
before the seminar 
-0.057 -0.264 0.024 
Interaction percentage who 
have schizophrenia and 
dummy above 3 mg/day 
before the seminar 
-0.103 -0.651 0.000 
Interactions total number 
of patients, percentage 
of patients that have 
schizophrenia and dummy 
above 3 mg/day of 
haloperidol before the 
seminar 
0.00057 0.406 0.001 
Interaction dummy above 
3 mg/day of haloperidol 
before the seminar and 
dummy group 1 
2.640 0.198 
  
0.082 
Interaction dummy above 
3 mg/day of haloperidol 
before the seminar and 
dummy group 2 
3.952 0.325 0.002 
Explained variation R2 = 36.0%                                                            n=83 
 
As can be seen, this model is different from any of the other models in Chapter 5.  The 
explanation of changes in haloperidol dose was different when all variables were 
introduced simultaneously. 
 
The model in Table 48 explains 36.0% of the variation in changes in haloperidol dose.  
The best model in Chapter 6 explained 29.4% change (see Table 47, page 111).  In this 
model the explanatory power is increased significantly. 
 
The haloperidol dose decreased among those psychiatrists who were above the target 
of 3 mg/day before the seminar and were either seeing many schizophrenia patients 
numerically or had a high percentage of schizophrenia patients, compared with the 
participants who also were above the target but saw less schizophrenia patients in total 
or percentage-wise.  The seminar had an effect on these participants in the intended 
direction.  
 
Furthermore, the haloperidol dose increased among the respondents who were above 
the target of 3 mg/day before the seminar saw many patients in general, and had a high 
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percentage of schizophrenia patients compared to those participants who were also 
above the target but had fewer patients and a lower percentage of schizophrenia 
patients.  In other words, particularly good learning took place among psychiatrists who 
were above the target before the seminar, who saw many schizophrenia patients 
percentage-wise, but this learning was reduced if the particular participant, in addition, 
saw many patients in total.  Therefore, a high number of patients had a negative 
learning effect in general, but a positive learning effect if these were predominantly 
schizophrenia patients. 
 
When the standardised beta-coefficients were compared, the variables concerning the 
type and number of patients explain most of the variation.  However, country of origin 
was also of importance. 
 
The respondents from Group 2 countries, who selected above the 3 mg/day target 
before the seminar, increased their haloperidol dose compared to respondents from 
group 3 countries, who also were above the target.  The same tendency was present to a 
lesser extent among participants from group 1 countries.  The difference between group 
1 and 3 respondents, who were above the target before the seminar, was minimally 
significant (p=0.08).  In other words, the greatest effect of the seminar was present 
among Group 3 psychiatrists.  These respondents did not increase their haloperidol dose, 
when they were above the target before the seminar.  These findings are not surprising, 
especially when it was considered that Group 3 countries - compared to groups 1 and 2 
– had the greatest need to learn. 
 
In summary, the participants who learned the most had the following characteristics: 
 
They were above the 3 mg/day target before the seminar, 
They saw many schizophrenia patients numerically or percentage-wise 
They had a low patient number in total and 
They were from a Group 3 country. 
 
Finally, a note on the variables that were not significant in the multivariate model.  From 
the model it can be concluded that the dose before the seminar did not directly affect the 
dose after the seminar.  The seminar did not have a direct effect on those participants 
who were above the target-dose before the seminar.  Instead, the seminar has an 
indirect effect on these participants through the interaction variables such as number of 
schizophrenia patients seen. 
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Furthermore, the interaction between workplace and haloperidol dose before the seminar 
did not significantly affect the changes in haloperidol dose, i.e. the association between 
workplace and haloperidol dose selected before the seminar was spurious.  Therefore it 
may be that the district hospitals have many first-episode schizophrenia patients 
compared to other hospitals. 
 
The significant variables explain 36% of the changes in the haloperidol dose, which is 
relatively impressive. 
 
7.2   Multivariate analysis of changes in duration of treatment 
Table 49 reports the multivariate analysis of changes in duration of treatment of first-
episode schizophrenia patients.  All the insignificant variables have been left out. 
 
Table 49:Multivariate analysis of factors relating to changes in duration of 
treatment of first-episode schizophrenia patients 
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -6.273  0.000 
Dummy below 18 months 
of treatment before the 
seminar 
11.209  0.492 0.000 
Explained variation R2 = 24.2%                                                          n=121 
 
Changes in selected duration of treatment were explained by the pre-seminar duration of 
treatment questionnaire response.  Participants below the recommended target of 18 
months for first episode patients increased their duration of treatment by 11.2 months 
on average compared with the respondents who were above the target.  The net-
increase in the duration of treatment of participants below the target-period before the 
seminar was the numerical difference between the constant and the dummy: 4.9 
months7.  In other words, those who were above the target period reduced their 
duration of treatment by 6.27 months on average. 
                                         
 
Duration of treatment recommended before the seminar accounted for 24.2% of the 
changes in duration of treatment.  It is quite unusual for a variable with only two 
categories to explain almost a quarter of all changes.  Normally much more complex 
models are needed in order to explain so much of the variation.  Also here the other 
 
 
7 It is only in the unique situation where the explanation of changes in duration of treatment is 
made up of one dummy-variable, that the constant equals the behaviour of the reference-group. 
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variables did not contribute to the explanation of the changes in duration of treatment; 
they were all insignificant. 
 
The same held true when duration of treatment of multi-episode schizophrenia patients 
was analysed. The result of the multivariate analysis is shown in Table 50. 
 
 
Table 50: Multivariate regression analysis of factors relating to changes in 
duration of treatment for multi-episode schizophrenia patients 
 Regression 
coefficient 
Beta-
coefficient 
Significance 
(T-test) 
Constant -2.348  0.289 
Dummy below 60 months 
of treatment before the 
seminar 
15.667  0.458 0.000 
Explained variation R2 = 21.0%                                                          n=117 
 
Table 50 shows that the respondents who selected below 60-months treatment before 
the seminar increased the duration of treatment by 15.67 months after the seminar 
compared with the respondents above 60-months before the seminar.  The net-increase 
was 13.3 months.  
 
In this case 21% of the changes in duration of treatment of multi-episode schizophrenia 
patients were explained by knowledge of the recommended duration of treatment before 
the seminar.  Even taking the simplicity of this variable into consideration, the change 
was once again quite remarkable. 
 
To summarise, those respondents who were below the recommended duration of 
treatment for multi-episode patients increased their duration of treatment significantly.  
In short those psychiatrists who most needed to learn more - those below the target - 
learned more. 
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Chapter 8 Discussion  
 
The overall objective of this study was to assess the effect of an educational programme 
(i.e. an evidence-based schizophrenia seminar presented by the Lundbeck Institute in 
Denmark) in changing the knowledge, attitudes and treatment habits (behaviour) of 
psychiatrists attending the programme. 
 
Changes directly attributable to the effect of the seminar were identified in respect of 
treatment decisions regarding the minimum effective dose of haloperidol in relapse 
prevention, and treatment durations for first- and multiple-episode schizophrenia 
patients. 
 
Other treatment decisions that changed significantly, but could not be attributed solely 
to the effect of the seminar, were the optimal effective haloperidol dose in acute 
schizophrenia treatment and the drug-class used.  Both of these changes were in the 
desired direction, namely a reduction in the optimal effective haloperidol dose and a 
change from conventional antipsychotics to the new generation antipsychotics.  
Background changes in psychiatrists’ knowledge also contributed to this change in 
knowledge and treatment behaviour. 
 
Additionally, it was shown that not all psychiatrists needed to update their knowledge or 
change their treatment practices; there were many who treated patients within the 
internationally recommended doses and for the optimal duration prior to attending the 
seminar.  Although expected, it was reassuring that this study confirmed that the 
greatest effect in achieving change was seen in psychiatrists who were least 
knowledgeable about recent treatment recommendations and who were furthest from 
treating their patients in line with current treatment guidelines. 
 
The multivariate analyses of changes in minimum effective haloperidol dose and 
treatment duration of schizophrenia patients also indicated that the seminars had an 
effect on the psychiatrists whose knowledge before the seminars was least up to date 
according to international treatment recommendations.  The effect of education was, 
however, dependent upon a number of factors: 
 
• A high estimated number of patients seen in total, 
• A high estimated number of schizophrenia patients, percentage and numerically, 
• The nationality of the psychiatrist. 
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 The effective haloperidol dose decreased among those psychiatrists who were above the 
target before the seminar and were either seeing many schizophrenia patients 
numerically or had a high percentage of schizophrenia patients, compared with the 
participants who also were above the target but saw less schizophrenia patients in total 
or percentage-wise.  However, the haloperidol dose increased among the psychiatrists 
who were above the target before the seminar, saw many patients in general, and had a 
high percentage of schizophrenia patients compared to those participants who were also 
above the target but had fewer patients and a lower percentage of schizophrenia 
patients.  Effective learning was apparent among psychiatrists who selected a dose 
above the target dose before the seminar and saw a large proportion of schizophrenia 
patients, but this learning was reduced if the particular psychiatrist, in addition, saw 
many patients in total.  Therefore, a high caseload was associated with a negative 
learning effect in general, but a positive learning effect if these were predominantly 
schizophrenia patients. This suggested that psychiatrists familiar with treating 
schizophrenia patients were more likely to alter their treatment behaviour, although if 
the total patient number was too great, this was not the case.  
 
The results obtained from comparing the questionnaires completed 2-weeks and 6-
months after the seminar indicated that many of the participants gradually lost newly 
acquired knowledge after attending these seminars.  Although the lack of retention of 
the knowledge was expected (Andrade et al., 2003; RIA, 1990), it remains of concern, 
and indicated that strategies should be developed to address this problem in future.  The 
Institute strongly encourages participants to go back to their home countries and use the 
evidence-based materials provided to present similar local workshops to their colleagues 
and other mental health care workers.  Not only does this assist in disseminating 
evidence-based treatment guidelines, but it also facilitates the retention of new 
information.  However, it appears that this alone is not sufficient and in future, 
consideration should be given to introducing specific post-seminar refresher courses 
(e.g. by e-mail).  Another area of concern was that some (albeit few) delegates actually 
changed their opinions regarding the antipsychotic class and optimal duration of 
treatment in the wrong direction – i.e. from atypical to conventional antipsychotics, and 
to a shorter duration of maintenance treatment.  The reasons for these changes are not 
immediately apparent, and should be the subject of future studies.  
 
New research and information regarding the brain and its diseases make it essential that 
psychiatrists and other clinicians remain regularly updated.  The goal of Continued 
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Medical Education is to use evidence-based medical education to keep doctors abreast of 
latest research and treatment recommendations. 
 
The results presented here provide empirical evidence to suggest that the Lundbeck 
Institute’s evidence-based seminars in the treatment of schizophrenia succeed in their 
overall goal of improving the care of patients with schizophrenia.  Although some 
psychiatrists fail to adhere to international treatment recommendations fully after 
attending the seminar, the results confirm that the participants generally change their 
treatment practices in line with the internationally accepted recommendations. 
 
8.1   Study limitations 
There are several factors in the design of this study that limit its validity. 
 
Selection-bias 
Firstly, the selection of the participating countries and psychiatrists was neither random 
nor representative.  While the dataset offered a unique opportunity to investigate the 
effects of the seminar on psychiatrists from around the world, not all regions of the 
world are represented in the study.  Of particular note is the lack of participants from 
Latin America and Asia, and that 84% of participants originate from the extended 
Europe.  The Institute had no control over which countries were invited, however, 29 
countries are represented.  A fairer distribution of countries may provide a different 
balance. 
 
There were no standard recruitment procedures for the selection of participants.  It was, 
however, recommended that psychiatrists attending the seminar should at least be able 
to understand and converse in basic English, and have an interest in education.  This is 
clearly a substantial limitation of this study and limits the potential applicability of the 
results in various countries. 
 
It is possible that the selection process favoured psychiatrists who were keener about 
the subject and more willing to learn. This would mean that they were more 
knowledgeable than others prior to the seminar, with less to learn.  If that were the case 
then it would strengthen the results of this study.  Showing changes in their knowledge 
and behaviour would be more difficult to achieve for such a group.  However, this is 
purely speculative and no attempt has been made to test the veracity of this statement. 
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Another selection limitation of this study includes the fact that the effect of cultural 
background differences was not addressed in this study.    
 
Lack of a control group 
A second significant limitation is the lack of a control group in this study.  A control 
group would enable quantification of the changes in background knowledge that may 
have explained much of the observed changes – as clearly demonstrated in some of the 
results presented. 
 
To offset the lack of a control group in this study, the pre-seminar data of the 
participants in the “later” seminars were regarded as the control group for the “early” 
seminar participants (e.g. The pre-seminar data of the 1999 seminar participants acted 
as the control group for those who participated in 1998.  Hence many pre-seminar 
datasets contained data from the first 18 pre-seminar questionnaires as the control for 
last seminar in this study.)  In this way, background changes in treatment principles 
could be evaluated by comparing the pre-seminar data of the earlier participants with 
the pre-seminar data of later participants. 
 
However, it should be noted that the clear change in many of these results within a two-
week period after the seminar could not be explained as normal background changes in 
psychiatry. 
 
Self-report questionnaires 
The questionnaires used in this study were developed prior to the first seminar in 1997, 
with the intention of doing a study to track changes in knowledge, attitude and 
behaviour.  The questionnaires were developed by the Lundbeck Institute and may not 
necessarily represent the optimal style of question-setting technique to measure such 
change. 
 
The self-reporting nature of the seminar questionnaires also present limitations in that 
the data may not be a true reflection of the psychiatrists’ actual treatment of 
schizophrenia patients, but rather a recollection of the discussions held at the seminar, 
or rather a reflection on treatment intentions. 
 
This limitation is partly offset by the two case reports which participants were requested 
to complete, based on data from their patient files.  This could be considered as a more 
reliable indication of their actual treatment habits.  Here again the inclusion of a control 
group would have resulted in a more objective evaluation of change.  Also, a file-review 
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(case audit) of a sample of the attending psychiatrists, using a similar sample of 
psychiatrists who did not attend as a control, could have provided an objective measure 
of the effectiveness of the seminar in achieving its goals.  Another method may be to use 
hospital pharmacy data, which is available in certain countries, or verify treatment by 
receiving the actual prescriptions of the patients treated by the participants. 
 
Lack of an audit of clinical files  
This study should ideally have included a sample audit of patient files of the 
psychiatrists.  This could have countered the self-reporting nature of the questionnaires.  
Patient files could have been used to compare the prescribing habits (actual behaviour) 
to the questionnaire responses (intended behaviour).  It could have been useful to audit 
the patient files of a control group compared to the patient files of psychiatrists who 
attended the seminars. 
 
The international nature of this study contributed to the complexity of using a control 
group.  The participants were from many different countries and thus recorded their 
patient notes in many different languages.  Acquiring access to patient records and 
actually retrieving data, (in foreign languages, in many different locations in each 
country that sent psychiatrists to the seminars) would present a daunting challenge.  
Moreover, had the psychiatrists concerned been randomly selected, one may have been 
required to travel vast distances to a particular hospital to retrieve data on one 
psychiatrist and the control.  This was considered impractical.  In an attempt to minimise 
this limitation, two case studies were included in the pre-seminar and 6-month post-
seminar questionnaires, where doctors were asked to read the cases and find similar 
cases in their patient records and then answer the questions relating to the areas of 
treatment we were researching.  In this way, data were collected, albeit in a self-
reporting format and in relatively small numbers, relating to the actual treatment of 
patients.  The treatment data could then be compared to the data of the psychiatrists’ 
knowledge and their treatment intentions.  This allowed for a comparison of knowledge 
and practise behaviour. 
 
Inconsistent guidelines 
There are major inconsistencies and large variations in the treatment recommendations 
put forward by various authorities in the field of psychiatry.  For example, the 
recommended optimal dose of haloperidol in treatment guidelines varies from 5-14 
mg/day (Baldessarini et al., 1988), 11-19 mg/day (Davis et al., 1989), and 5-20 mg/day 
(Marder, 1996; APA 1997; APA 2004), with newer evidence for ultra-low doses of 1-2 
mg/day (Oosthuizen et al., 2001; McEvoy et al., 1991; McEvoy, personal 
 127 
communication, 2006) while others have until recently studied doses as high as 60 
mg/day (Rifkin et al., 1991) and even 200 mg/day (Chang et al., 1994).  Challenges to 
the validity of the concept of minimum effective dose for haloperidol exist, resulting in 
similarly varying results for haloperidol doses in relapse prevention. 
 
Similar inconsistencies in study results and treatment guidelines are found with regard to 
schizophrenia treatment duration recommendations, the management of agitated 
patients, and guidelines for suicide management. 
 
These inconsistencies contribute significantly, understandably, to scepticism of 
psychiatrists towards evidence-based treatment guidelines, and clearly contribute to a 
lack of consensus. 
 
The pharmaceutical industry association 
The educational seminars studied are hosted and presented by The Lundbeck Institute.  
Also, the content of these seminars have been written and reviewed by international 
experts, and have also been evaluated for objectivity by educational and accreditation 
authorities, and found to be of high standard and lack any bias.  However, it is possible 
that there may be individuals whose answers may be influenced by the association with 
the pharmaceutical company Lundbeck.  Were this to influence the participant’s answers 
in the questionnaire, one should foresee that this may influence the measurement of 
change. 
 
The use of the English language 
The use of the English language throughout this seminar is clearly a limitation to this 
study.  English is spoken as a home language in only of the 29 countries represented in 
this study.  All presentations, literature, discussion and questionnaires used in this study 
were in English.   
 
Differing diagnostic classification systems 
Most, but not all psychiatrists who attend the seminars follow the American Psychiatric 
Association (APA) DSM diagnostic classification system for psychiatry, with many 
countries predominantly following the ICD system of the WHO.  Due to some subtle, but 
often important differences between these two systems, it is clear that these diagnostic 
differences are a confounder in the study, and should be mentioned as a limitation. 
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8.2   Problems identified and recommendations for future studies 
From my reading of the literature, this study is the first of its kind, using trained 
psychiatrists and attempting to measure the effect of continued medical education.  By 
reviewing the limitations and problems identified from this study, recommendations for 
future studies emerge. 
 
Selection process 
The selection of participants in this study is far from optimal.  Although any similar 
international study would be expensive, it is suggested that participant selection is well 
thought through prior to study initiation.  Selection of participants should attempt to 
define a universal process for the selection of countries participating and also of the 
individual psychiatrists.  This may be rather difficult to achieve, but may be addressed 
through own-language education, education taking place in the home country and by 
doing a randomised selection process of participants.  The selection of a randomised and 
representative sample of participants, and a control group, in future studies would 
significantly enhance the value of the results. 
 
Language 
Teaching in a native language is preferable.  Although most international psychiatric 
journals are printed in English, and international congresses and symposia are conducted 
in English, it would be naïve to assume that all psychiatrists are willing, or even able, to 
follow training in English.  After the seminars at the Institute, we ask the participants to 
evaluate the seminars.  Data have been collected asking the participants to what 
degrees they experienced language problems during the seminar.  Although these data 
have not been analysed, experience shows that most participants do not find language 
to have been a problem during the seminar, but there have been a few who have 
reported some or much difficulty.  Future studies should take the matter of home-
language teaching into account where possible. 
 
Retention of knowledge 
There is a clear trend of limited long-term retention of new information over time.  
Although ideal education has not been fully defined, it is clear that didactic lecturing is of 
little benefit.  There should be an emphasis in education in measuring prior knowledge 
and then presenting the new knowledge in the context of existing knowledge of the 
participants. Integrating presentations with workgroups seems to enhance knowledge 
retention.  Promoting discussion of the new knowledge, as well as strengthening the 
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process by encouraging sharing of the new knowledge with others in the field, can 
further enhance knowledge retention. 
 
The Lundbeck Institute’s model of education encourages psychiatrists to return to their 
home countries and hospitals and use the training they received to train other 
psychiatrists, registrars, students and mental health workers.  It may be possible that 
the repetition this training creates may increase long-term knowledge retention.  This 
could be studied in future studies, by comparing knowledge-retention of participants who 
teach their new knowledge, obtained through CME, to others, versus participants who do 
not teach the new knowledge. 
 
Audit problems 
Completing an audit of patient files in this study was considered but was deemed 
excessively expensive and possible completely impractical, taking patient consent and 
language issues in the different countries into account.  In the future, obtaining hospital 
pharmacy data, or checking prescriptions could address the lack of an audit to verify 
participant treatment practises. 
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8.3   Conclusion 
The successful integration of international treatment recommendations into daily 
psychiatric practise could enhance the quality of life of schizophrenia patients.  The value 
of consensus-seeking, evidence-based medical education in the treatment of 
schizophrenia needs to be further encouraged.  However, evidence-based medical 
principles alone do not achieve optimal treatment outcomes. 
 
Clinical experience is a cornerstone for all forms of medicine.  The practice of evidence-
based medicine demands the synergy of experience and science (Sartorius, personal 
communication, April 2006). 
 
There is, to my mind, no conflict between the science of medicine and the art of treating 
the individual patient.  Good medicine is a fine art that aims to find the symbiosis of 
science in medical research, and the art of individualising treatment for each particular 
patient. 
 
The true skill of psychiatry is an art that integrates the complexity of the brain and the 
human personality, with the ambiguity of diagnosis and the understanding our patient's 
non-verbal communication and the reality of stigma and suicide, and the subtlety of 
giving honest answers, yet always treating our patients with compassion and respect 
while tirelessly instilling hope. 
 
Little wonder that ancient Egyptian medical scrolls were referenced as “Art” rather than 
“Science” in the old library at Alexandria. 
 
 
 
To be doctors we should be  
“scientists with our brains  
and artists with our hearts” 
         (Ancient Chinese proverb) 
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Appendix 1:                         
Lundbeck Institute 
 
Pre-seminar Questionnaire Schizophrenia 
 
Participant Name: ___________________   Week: __________ 
Country:  _______________________         Date: D_____M_____Y_____ 
 
1. Educational background 
 
Psychiatrist  
GP  Choose One Only 
Psychologist  
Other    ________________________ 
  
 
2. Where do you practise? (Please tick only the primary place) 
 
University Hospital  
District or General Hospital  
Private Practice  Choose One Only 
Specialised Psychiatric Hospital  
Other  
 
 
3. How many years of experience (including training) do you have in 
treating psychiatric patients? _____________ 
 
 
4. Number of different patients you see on average per month: _____ 
 
 
5. Please indicate the type of patients you see regularly 
 
 (Please tick one or more boxes as appropriate) 
Acute  Forensic  
Chronic  Rehabilitated  Choose One or More 
Adolescents  Mixed  
Elderly  Other  
 
 
6. Primary responsibility? (Please tick one or more boxes as appropriate) 
 
Out patients only  
In patients only  
Mixed group  Choose One or More 
Rehabilitation  
Other  
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7.  Based on your current patient caseload, please indicate the approximate 
percentage of patients you treat for the following disorders ? 
 
Schizophrenia ______ % 
Organic disorders ______ % 
Depression ______ % 
Mania ______ % 
Bipolar ______ % 
Personality disorders ______ % 
Other ______ % 
 
 
8. Approximate number of first-episode schizophrenia patients you see per 
year? __________ 
 
 
 
 
 
 
 
Diagnosis 
 
9. When diagnosing patients with schizophrenia do you use 
  
 Always Mostly Sometimes Never 
DSM IV     
ICD 10     
 
 
10. How useful do you find diagnostic tools when diagnosing patients with 
schizophrenia? 
 
Very useful  
Useful  
Not very useful  
Not useful at all  
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Treatment of acute episodes 
 
The following questions are designed to learn more about your treatment habits. 
Although the treatment of each patient will naturally be adapted to his/her individual 
situation, every doctor has some standards, which he/she modifies according to the 
individual patients’ needs. These questions, based on hypothetical cases, are not 
designed to test your textbook knowledge, but rather to learn more about your 
treatment habits of an average patient. 
 
Case 1: 
A 24 year old unmarried male student with a first-episode paranoid 
schizophrenia (ICD 9: 295.3; ICD 10: F20.0) is not tense, posing no danger to 
himself or others and has no insomnia. 
  
A. If oral monotherapy with oral haloperidol appears to you to be indicated, 
what average daily dose of haloperidol do you think should be 
administered at the end of the first week of treatment if the patients 
exhibit no serious side effects? 
 
 _______ mg haloperidol daily  Don’t know  
 
B. If oral monotherapy with olanzapine, sertindole or risperidone appears 
to you to be indicated, what average daily dose do you think should be 
administered after titrating the dose up? 
 
 Olanzapine _____ mg/month  Don’t know  
 Sertindole _____ mg/month  Don’t know  
 Risperidone _____ mg/month  Don’t know  
 
C. When would you change this patient’s antipsychotic medication if the 
predominantly positive psychotic symptoms prove resistant to the first 
treatment with haloperidol? 
 
 After ______ weeks of full treatment   Don’t know  
 
D.   If you could choose the first antipsychotic for this patient, which drug 
would you use? 
 
Clozapine    _______ mg/day 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
 
Other    _______mg/day _____mg/month 
 
   Don’t know 
 
Please note that all doses should be given in mg/month for depot antipsychotics 
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E.  What would you give this patient as a second antipsychotic? 
 
Clozapine    _______ mg/day 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
 
Other    _______ mg/day_____mg/month 
 
   Don’t know 
 
Please note that all doses should be given in mg/month for depot antipsychotics 
 
 
F. When would you consider using clozapine in the patient described in case 
1? 
 
First line treatment   
Second antipsychotic  
Third antipsychotic   
I never use clozapine  
Don’t know   
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Relapse prevention 
 
Minimum duration of antipsychotic relapse prevention for first-episode patients 
 
Case 2: 
A 24 year old unmarried male student suffered a first schizophrenia episode 
with paranoid and hallucinatory symptoms (ICD 9: 295.3; ICD 10: F20.0) two 
months ago. The patient was treated with an oral antipsychotic drug and his 
symptoms have now remitted. 
 
A. If you had no further knowledge about the patient, what would you 
recommend for further treatment? 
 
 Discontinuation of antipsychotics within 3 months 
 
 Antipsychotic relapse prevention for _____ months with: 
 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Perphenazine    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
 
Other    _______ mg/day_____mg/month 
 
   Don’t know 
 
Please note that all doses should be given in mg/month for depot antipsychotics 
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Minimum duration of antipsychotic relapse prevention for multi-episode 
patients 
 
Case 3: 
A 30 year old female married attorney suffered a first paranoid-hallucinatory 
schizophrenia episode a year ago, full remission was achieved with 
antipsychotic treatment (drug not specified), then discontinuation of the 
antipsychotic. Two months after the discontinuation the patient suffered a 
second schizophrenia episode (ICD 9: 295.3; ICD 10: F20.0) which has just 
remitted fully under antipsychotic treatment. 
 
B. If you had no further knowledge about the patient, what would you 
recommend for further treatment? 
 
 Discontinuation of antipsychotic within 3 months 
 
 Antipsychotic relapse prevention for _____ months with: 
 
Clozapine    _______ mg/day 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Perphenazine    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
Other    _______ mg/day_____mg/month 
   Don’t know 
Please note that all doses should be given in mg/month for depot antipsychotics 
 
C. If you treated this patient for at least one year, down to which minimum 
dose could you reduce the prophylactic antipsychotic, according to the 
literature, without significantly increasing the relapse risk? Please 
answer according to your best knowledge of the literature for all the 
drugs below. 
 
• Oral antipsychotics 
 Haloperidol _____ mg/day  Don’t know  
 Risperidone _____ mg/day  Don’t know 
 Olanzapine _____ mg/day  Don’t know 
 Sertindole _____ mg/day  Don’t know 
 Flupentixol _____ mg/day  Don’t know 
 Zuclopentixol _____ mg/day  Don’t know  
 
• Depot antipsychotics 
 Haloperidol decanoate _____ mg/month  Don’t know  
 Fluphenazine decanoate  _____ mg/month  Don’t know  
 Flupentixol decanoate _____ mg/month  Don‘t know  
 Zuclopentixol decanoate _____ mg/month  Don’t know  
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The following questions are intended to determine on which data your 
treatment habits are based (own experience and/or results in the scientific 
literature). 
 
11. How high do you estimate the relapse rate of the patient described in 
case 1 if no antipsychotic relapse prevention is administered? Please 
answer both the following questions: 
 
According to my experience the relapse rate within the first year is approximately 
_________%   Don’t know 
 
According to my knowledge of the scientific literature the relapse rate within the 
first year is approximately _______%  Don’t know  
 
12. How high do you estimate the relapse rate after a first schizophrenia 
episode if continuous antipsychotic relapse prevention is 
administered? Please answer both the following questions: 
 
According to my experience the relapse rate within the first year is approximately 
_________%   Don’t know 
 
According to my knowledge of the scientific literature the relapse rate within the 
first year is approximately _______%  Don’t know  
 
13. If antipsychotic medication is discontinued in a long term remitted 
(relapse free for 1 - 5 years on antipsychotic treatment) multiple-
episode schizophrenia patient, how high would you estimate the 
average relapse rate to be? 
 
According to my experience the relapse rate within the first year is approximately 
_________%   Don’t know 
 
According to my knowledge of the scientific literature the relapse rate within the 
first year is approximately _______%  Don’t know  
 
 
14. If average schizophrenia patients (20-40 years old, no structural 
brain pathology) are administered an antipsychotic relapse 
prevention therapy with conventional drugs for 5 years in a medium 
dosage range, what percentage can be expected to suffer  from: 
 
Mild, reversible tardive dyskinesia, approximately _______%  Don’t know 
Severe, irreversible tardive dyskinesia, approx.   _______%  Don’t know 
 
 141 
Alternative treatment 
7 A. From current literature, for which of the following diagnosis is ECT 
primarily indicated? 
 
Depression        
Treatment-resistant depression     
Schizophrenia        
Severely psychotic, aggressive, acute schizophrenia  
Treatment-resistant schizophrenia     
Mania        
Don’t know        
 
7 B. Does your hospital use any written guidelines for ECT treatment? 
 
  no 
  yes 
  I don’t know 
 
 
7 C. Do you use ECT? 
 
  no 
  yes 
 
If yes, what percentage of your patients with schizophrenia get ECT?  ______% 
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Quality Management 
 
8. Do you use quality management routinely in your hospital? 
 yes (If yes, please bring the material with you to the seminar) 
 no 
 
If you answered yes to question 8, please answer questions A-C 
A. Do you feed the results of quality management back to your team 
of health care providers in your hospital? 
 yes  no 
 
B.  Do you compare your results with other hospitals? 
 yes  no 
 
C. Do you have regular quality meetings? 
 yes  no 
 
9. Do you use written treatment guidelines which apply to the whole 
hospital? 
 yes   (If yes, please bring the material with you to the seminar) 
 no 
 
If yes, how often are they updated? 
 On a regular basis   
 They are updated whenever it is judged to be needed  
 They have not been updated   
 Don’t know 
 
10.  Quality management is an unnecessary burden on everyday work? 
 Agree strongly 
 Agree slightly 
 Neither agree nor disagree 
 Disagree slightly 
 Disagree strongly 
 
11.  Quality management is a management responsibility? 
 Agree strongly  
 Agree slightly 
 Neither agree nor disagree 
 Disagree slightly 
 Disagree strongly 
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Psychoeducation 
 
12. Have psychoeducational interventions (interventions combining 
information imparting and therapeutic strategies) for patients with 
schizophrenia or their relatives taken place in your hospital in the past 6 
months? 
 
 yes  For patients only 
  For patient relatives only 
  Bifocal groups (patients and relatives)  
  Single family interventions 
  Multiple family interventions 
  Other 
 
 no  No suitable patients  
  No suitable group moderators  
  No time  
  Structural problems  
  No interest  
  Not yet but interventions are planned 
  Other 
 
 
If you answered yes to question 1, please answer questions A-C: 
 
A.  What percentage of your patients with schizophrenia and/or their 
relatives is offered psychoeducation? 
Patients: __________% 
Relatives: _________% 
 
B. According to which strategy are these interventions performed? 
 
•Focus on:- 
 Psychotherapeutic strategies (behavioural) 
 Psychoeducational strategies (supportive) 
 
•Indication 
 Schizophrenics only 
 Mixed diagnoses 
 
•Duration 
 < 3 months 
 3 to 6 months 
 > 6 months 
 
•Setting (Tick more than one, if necessary) 
 in patient only 
 out patient only 
 day hospital 
 mixed 
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C. In your opinion, how do patients/relatives/professionals in your 
opinion generally accept psychoeducation? 
 Highest    Highest 
 resistance     acceptance 
Patients      
Relatives      
Professionals      
 
 
 
 
 
 
Local Workshops 
 
13. To what extent have you arranged local workshops where you practise? 
 
   Formal agreement about a local workshop has been made 
 
 How many local workshops have you agreed to do? _______ 
 
 Is a date set for the local workshop yes no 
 
 
  Informal agreement about a local workshop has been made 
 
  I intent to arrange local workshops, but I don’t know when  
  Please indicate the number of local workshops you plan to do _____ 
 
  I have no current plans of arranging local workshops 
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Patient case studies 
 
One of the objectives of the seminars at the Lundbeck Institute is to reach consensus on 
the treatment of schizophrenia. To encourage this we would like to present some data 
from the real life treatment of patients with schizophrenia. Thus we would like you to fill 
in a patient diary sheet for two patients as described below. If you don’t have a patient 
in your ward that fits the description, please leave the form blank. 
 
All patients should be between 18-60 years of age, with a diagnosis of paranoid 
schizophrenia, multiple episode with no other serious illness and not dangerous to 
themselves or others. 
 
 
Patient 1 
Acute patient: 
The patient should have been admitted approximately 4 to 6 weeks ago. 
 
 
Patient 2 
Chronic patient: 
The patient should have stayed in the hospital for 4 to 6 months. 
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Patient 1 
 
Diagnosis (full text or coded) _____________________ 
Other important diagnosis  _____________________ 
 
Did you use a diagnostic tool?1   ICD10  2  DSM IV  3  Other  4  No 
 
Number of previous episodes     _________ 
Number of previous admissions _________ 
Date of this admission: day _____    month  _____     Year   _____            
Today’s date: day _____    month  _____     Year   _____            
 
Psychopathological Findings 
 
(Tick only one box in each line, please) 
         None/not                               Extremely 
             at all ill  Borderline Mild   Moderate  Marked    Severe       Severe 
Positive symptoms 0  1  2  3  4  5  6  
Negative symptoms 0  1  2  3  4  5  6  
Depression 0  1  2  3  4  5  6  
Other findings 0  1  2  3  4  5  6  
Current CGI  0  1  2  3  4  5  6  
  
 
CGI relative to admission 
0  Very much improved 
1  Much improved 
2  Minimally improved 
3  No change 
4  Minimally worse 
5  Much worse 
6  Very much worse 
 
Side Effects (SEs) 
 
(Tick only one box in each line, please) 
               Mild and not    Interfering             Interfering 
   interfering    moderately           markedly 
   with patient’s        with patient’s        with patient’s 
     None performance    performance          performance 
Tardive dyskinesia 0   1  2  3  
Other EPS 0   1  2  3  
Psychic side effects* 0   1  2  3  
Other important SEs 0   1  2  3  
Global side effect score 0   1  2  3  
 
* delirium, tiredness, insomnia, restlessness, depression or quantitative 
disturbance of consciousness 
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Current therapeutic consequences  
 
0  No action 
1  More frequent assessment 
2  Reduction in dose of drug(s) 
3  Discontinuation of drug(s) 
 
 
Psychotropic Medication 
 
All current antipsychotics 
 
a) generic name ____________if oral ___ mg/day / if depot ___ mg/month 
b) generic name ____________if oral ___ mg/day / if depot ___ mg/month 
c) generic name ____________if oral ___ mg/day / if depot ___ mg/month 
d) generic name ____________if oral ___ mg/day / if depot ___ mg/month 
 
Co-medication: 
 
Anti-parkinsonian 1  No  
 2  Yes - If yes, given as prophylactic Rx? 1   No 
    2   Yes 
 
Benzodiazepines 1  No  
 2  Yes - If yes, given as prophylactic Rx ? 1   No 
    2   Yes 
 
Antidepressants 1  No  
 2  Yes - If yes, given as prophylactic Rx? 1   No 
    2   Yes 
 
Other important medication: _____________________ 
 
How many different neuroleptics has the patient received since admission?____ 
 
 
Psychoeducation (PE) 
 
Does the patient take part in PE?1  No 
   2  Yes - If yes 1  Group sessions 
    2  Others: ________ 
 
 
Do relatives take part in PE?  1  No   
 2  Yes - If yes 1  Group sessions 
    2  Others: ________ 
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Patient 2 
 
Diagnosis (full text or coded) _____________________ 
Other important diagnosis  _____________________ 
 
Did you use a diagnostic tool?1  ICD10 2  DSM IV 3  Other 4  No 
 
Number of previous episodes     _________ 
Number of previous admissions _________ 
Date of this admission: day _____    month  _____     Year   _____            
Today’s date: day _____    month  _____     Year   _____            
 
Psychopathological Findings 
 
(Tick only one box in each line, please) 
         None/not                               Extremely 
             at all ill  Borderline Mild   Moderate  Marked    Severe       Severe 
Positive symptoms 0  1  2  3  4  5  6  
Negative symptoms 0  1  2  3  4  5  6  
Depression 0  1  2  3  4  5  6  
Other findings 0  1  2  3  4  5  6  
Current CGI  0  1  2  3  4  5  6  
  
 
CGI relative to admission 
0  Very much improved 
1  Much improved 
2  Minimally improved 
3  No change 
4  Minimally worse 
5  Much worse 
6  Very much worse 
 
Side Effects (SEs) 
 
(Tick only one box in each line, please) 
               Mild and not    Interfering             Interfering 
   interfering    moderately           markedly 
   with patient’s        with patient’s        with patient’s 
     None performance    performance          performance 
Tardive dyskinesia 0   1  2  3  
Other EPS 0   1  2  3  
Psychic side effects* 0   1  2  3  
Other important SEs 0   1  2  3  
Global side effect score 0   1  2  3  
 
* delirium, tiredness, insomnia, restlessness, depression or quantitative 
disturbance of consciousness 
 149 
Current therapeutic consequences  
 
0  No action 
1  More frequent assessment 
2  Reduction in dose of drug(s) 
3  Discontinuation of drug(s) 
 
 
Psychotropic Medication 
 
All current antipsychotics 
 
a) generic name ___________if oral ___ mg/day / if depot  ____ mg/month 
b) generic name ___________if oral ___ mg/day / if depot  ____ mg/month 
c) generic name ___________if oral ___ mg/day / if depot  ____ mg/month 
d) generic name ___________if oral ___ mg/day / if depot  ____ mg/month 
 
Co-medication: 
 
Anti-parkinsonian 1  No  
 2  Yes - If yes, given as prophylactic Rx? 1   No 
    2   Yes 
 
Benzodiazepines 1  No  
 2  Yes - If yes, given as prophylactic Rx ? 1   No 
    2   Yes 
 
Antidepressants 1  No  
 2  Yes - If yes, given as prophylactic Rx ? 1   No 
    2   Yes 
 
Other important medication: _____________________ 
 
How many different neuroleptics has the patient received since admission? ____ 
 
 
Psychoeducation (PE) 
 
Does the patient take part in PE?1  No 
   2  Yes - If yes 1  Group sessions 
    2  Others: ________ 
 
 
Do relatives take part in PE?  1  No   
 2  Yes - If yes 1  Group sessions 
    2  Others: ________ 
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Appendix 2:                                                                  
Lundbeck Institute  
 
2 Week follow-up Questionnaire of Schizophrenia seminar 
 
Participant Name: ___________________   Week: __________ 
Country:  _______________________         Date: D_____M_____Y_____ 
 
Diagnosis 
 
1. How useful do you find diagnostic tools for patients with schizophrenia? 
  
Very useful   
Useful   
Not very useful  
Not useful at all  
 
 
2. Do you think that diagnosing patients with schizophrenia using ICD 10 
and DSM IV are: 
 
Identical   
Almost identical  
Similar   
Totally different  
Don’t know          
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Treatment of acute episodes 
 
The following questions are designed to learn more about your treatment habits. 
Although the treatment of each patient will naturally be adapted to his/her individual 
situation, every doctor has some standards, which he/she modifies according to the 
individual patients’ needs. These questions, based on hypothetical cases, are not 
designed to test your textbook knowledge, but rather to learn more about your 
treatment habits of an average patient. 
 
Case 1: 
A 24 year old unmarried male student with a first-episode paranoid 
schizophrenia (ICD 9: 295.3; ICD 10: F20.0) is not tense, posing no danger to 
himself or others and has no insomnia. 
 
A. If oral monotherapy with oral haloperidol appears to you to be indicated, 
what average daily dose of haloperidol do you think should be 
administered at the end of the first week of treatment if the patients 
exhibit no serious side effects? 
 
 _______ mg haloperidol daily  Don’t know  
 
B. If oral monotherapy with olanzapine, sertindole or risperidone appears 
to you to be indicated, what average daily dose do you think should be 
administered after titrating the dose up? 
 
 Olanzapine _____ mg/month  Don’t know  
 Sertindole _____ mg/month  Don’t know  
 Risperidone _____ mg/month  Don’t know  
 
C. When would you change this patient’s antipsychotic medication if the 
predominantly positive psychotic symptoms prove resistant to the first 
treatment with haloperidol? 
 
 After ______ weeks of full treatment   Don’t know  
 
D.   If you could choose the first antipsychotic for this patient, which drug 
would you use? 
 
Clozapine    _______ mg/day 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
 
Other    _______mg/day _____mg/month 
   Don’t know 
 
Please note that all doses should be given in mg/month for depot antipsychotics 
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E.  What would you give this patient as a second antipsychotic? 
 
Clozapine    _______ mg/day 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
 
Other    _______ mg/day_____mg/month 
   Don’t know 
 
Please note that all doses should be given in mg/month for depot antipsychotics 
 
 
F. When would you consider using clozapine in the patient described in case 
1? 
 
First line treatment  
Second antipsychotic  
Third antipsychotic   
I never use clozapine  
Don’t know   
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Relapse prevention 
 
Minimum duration of antipsychotic relapse prevention for first-episode patients 
 
Case 2: 
A 24 year old unmarried male student suffered a first schizophrenia episode 
with paranoid and hallucinatory symptoms (ICD 9: 295.3; ICD 10: F20.0) two 
months ago. The patient was treated with an oral antipsychotic drug and his 
symptoms have now remitted. 
 
D. If you had no further knowledge about the patient, what would you 
recommend for further treatment? 
 
 Discontinuation of antipsychotics within 3 months 
 
 Antipsychotic relapse prevention for _____ months with: 
 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Perphenazine    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
 
Other    _______ mg/day_____mg/month 
   Don’t know 
 
Please note that all doses should be given in mg/month for depot antipsychotics 
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Minimum duration of antipsychotic relapse prevention for multi-episode 
patients 
 
Case 3: 
A 30 year old female married attorney suffered a first paranoid-hallucinatory 
schizophrenia episode a year ago, full remission was achieved with 
antipsychotic treatment (drug not specified), then discontinuation of the 
antipsychotic. Two months after the discontinuation the patient suffered a 
second schizophrenia episode (ICD 9: 295.3; ICD 10: F20.0) which has just 
remitted fully under antipsychotic treatment. 
 
E. If you had no further knowledge about the patient, what would you 
recommend for further treatment? 
 
 Discontinuation of antipsychotic within 3 months 
 
 Antipsychotic relapse prevention for _____ months with: 
 
Clozapine    _______ mg/day 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Perphenazine    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
Other    _______ mg/day_____mg/month 
   Don’t know 
 
Please note that all doses should be given in mg/month for depot antipsychotics 
 
F. If you treated this patient for at least one year, down to which minimum 
dose could you reduce the prophylactic antipsychotic, according to the 
literature, without significantly increasing the relapse risk? Please 
answer according to your best knowledge of the literature for all the 
drugs below. 
 
• Oral antipsychotics 
 Haloperidol _____ mg/day  Don’t know  
 Risperidone _____ mg/day  Don’t know 
 Olanzapine _____ mg/day  Don’t know 
 Sertindole _____ mg/day  Don’t know 
 Flupentixol _____ mg/day  Don’t know 
 Zuclopentixol _____ mg/day  Don’t know  
 
• Depot antipsychotics 
 Haloperidol decanoate _____ mg/month  Don’t know  
 Fluphenazine decanoate  _____ mg/month  Don’t know  
 Flupentixol decanoate _____ mg/month  Don‘t know  
 Zuclopentixol decanoate _____ mg/month  Don’t know  
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The following questions are intended to determine on which data your 
treatment habits are based (own experience and/or results in the scientific 
literature). 
 
4. How high do you estimate the relapse rate of the patient described in 
case 1 if no antipsychotic relapse prevention is administered? Please 
answer both the following questions: 
 
According to my experience the relapse rate within the first year is approximately 
_________%   Don’t know 
 
According to my knowledge of the scientific literature the relapse rate within the 
first year is approximately _______%  Don’t know  
 
5. How high do you estimate the relapse rate after a first schizophrenia 
episode if continuous antipsychotic relapse prevention is 
administered? Please answer both the following questions: 
 
According to my experience the relapse rate within the first year is approximately 
_________%   Don’t know 
 
According to my knowledge of the scientific literature the relapse rate within the 
first year is approximately _______%  Don’t know  
 
6.  If antipsychotic medication is discontinued in a long term remitted 
(relapse free for 1 - 5 years on antipsychotic treatment) multiple-
episode schizophrenia patient, how high would you estimate the 
average relapse rate to be? 
 
According to my experience the relapse rate within the first year is approximately 
_________%   Don’t know 
 
According to my knowledge of the scientific literature the relapse rate within the 
first year is approximately _______%  Don’t know  
 
 
7. If average schizophrenia patients (20-40 years old, no structural 
brain pathology) are administered an antipsychotic relapse 
prevention therapy with conventional drugs for 5 years in a medium 
dosage range, what percentage can be expected to suffer from: 
 
Mild, reversible tardive dyskinesia, approximately ______%  Don’t know 
Severe, irreversible tardive dyskinesia, approx.  ______%  Don’t know 
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Alternative treatment 
 
8. From current literature, for which of the following diagnosis is ECT 
primarily indicated? 
 
Depression        
Treatment-resistant depression     
Schizophrenia        
Severely psychotic, aggressive, acute schizophrenia  
Treatment-resistant schizophrenia     
Mania        
Don’t know        
 
 
 
 
Quality Management 
 
9.  Quality management is an unnecessary burden on everyday work? 
 Agree strongly 
 Agree slightly 
 Neither agree nor disagree 
 Disagree slightly 
 Disagree strongly 
 
10.  Quality management is a management responsibility? 
 Agree strongly  
 Agree slightly 
 Neither agree nor disagree 
 Disagree slightly 
 Disagree strongly 
 
 
 
Psychoeducation 
 
11. In your opinion, how do patients/relatives/professionals in your opinion 
generally accept psychoeducation? 
 Highest    Highest 
 resistance     acceptance 
Patients      
Relatives      
Professionals      
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Appendix 3:                                                                 
Lundbeck Institute  
 
6 Month follow-up Questionnaire of Schizophrenia seminar 
 
Participant Name: ___________________   Week: __________ 
Country:  _______________________         Date: D_____M_____Y_____ 
 
 
Diagnosis 
 
1. How useful do you find diagnostic tools for patients with schizophrenia? 
  
Very useful   
Useful   
Not very useful  
Not useful at all  
 
 
2. Do you think that diagnosing patients with schizophrenia using ICD 10 
and DSM IV are: 
 
Identical   
Almost identical  
Similar   
Totally different  
Don’t know          
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Treatment of acute episodes 
 
Case 1: 
A 24 year old unmarried male student with a first-episode paranoid 
schizophrenia (ICD 9: 295.3; ICD 10: F20.0) is not tense, posing no danger to 
himself or others and has no insomnia. 
 
A. If oral monotherapy with oral haloperidol appears to you to be indicated, 
what average daily dose of haloperidol do you think should be 
administered at the end of the first week of treatment if the patients 
exhibit no serious side effects? 
 
 _______ mg haloperidol daily  Don’t know  
 
B. If oral monotherapy with olanzapine, sertindole or risperidone appears 
to you to be indicated, what average daily dose do you think should be 
administered after titrating the dose up? 
 
 Olanzapine _____ mg/month  Don’t know  
 Sertindole _____ mg/month  Don’t know  
 Risperidone _____ mg/month  Don’t know  
 
When would you change this patient’s antipsychotic medication if the 
predominantly positive psychotic symptoms prove resistant to the first 
treatment with haloperidol? 
 
 After ______ weeks of full treatment   Don’t know  
D.   If you could choose the first antipsychotic for this patient, which drug 
would you use? 
 
Clozapine    _______ mg/day 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
 
Other    _______mg/day _____mg/month 
 
   Don’t know 
Please note that doses should be given in mg/month for depot antipsychotics 
 
E.  What would you give this patient as a second antipsychotic? 
 
Clozapine    _______ mg/day 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
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Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
 
Other    _______ mg/day_____mg/month 
   Don’t know 
Please note that all doses should be given in mg/month for depot antipsychotics 
 
 
F. When would you consider using clozapine in the patient described in case 
1? 
 
First line treatment  
Second antipsychotic  
Third antipsychotic   
I never use clozapine  
Don’t know   
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Relapse prevention 
 
Minimum duration of antipsychotic relapse prevention for first-episode patients 
 
Case 2: 
A 24 year old unmarried male student suffered a first schizophrenia episode 
with paranoid and hallucinatory symptoms (ICD 9: 295.3; ICD 10: F20.0) two 
months ago. The patient was treated with an oral antipsychotic drug and his 
symptoms have now remitted. 
 
G. If you had no further knowledge about the patient, what would you 
recommend for further treatment? 
 
 Discontinuation of antipsychotics within 3 months 
 
 Antipsychotic relapse prevention for _____ months with: 
 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Perphenazine    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
 
Other    _______ mg/day_____mg/month 
   Don’t know 
Please note that all doses should be given in mg/month for depot antipsychotics 
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Minimum duration of antipsychotic relapse prevention for multi-episode 
patients 
 
Case 3: 
A 30 year old female married attorney suffered a first paranoid-hallucinatory 
schizophrenia episode a year ago, full remission was achieved with 
antipsychotic treatment (drug not specified), then discontinuation of the 
antipsychotic. Two months after the discontinuation the patient suffered a 
second schizophrenia episode (ICD 9: 295.3; ICD 10: F20.0) which has just 
remitted fully under antipsychotic treatment. 
 
H. If you had no further knowledge about the patient, what would you 
recommend for further treatment? 
 
 Discontinuation of antipsychotic within 3 months 
 
 Antipsychotic relapse prevention for _____ months with: 
 
Clozapine    _______ mg/day 
Flupentixol    _______ mg/day 
Haloperidol    _______ mg/day 
Perphenazine    _______ mg/day 
Risperidone    _______ mg/day 
Olanzapine    _______ mg/day 
Sertindole    _______ mg/day 
Zuclopentixol    _______ mg/day 
 
Fluphenazine decanoate  _______ mg/month 
Flupentixol decanoate  _______ mg/month 
Haloperidol decanoate  _______ mg/month 
Perphenazine decanoate  _______ mg/month 
Zuclopentixol decanoate  _______ mg/month 
Other    _______ mg/day_____mg/month 
   Don’t know 
Please note that all doses should be given in mg/month for depot antipsychotics 
 
I. If you treated this patient for at least one year, down to which minimum 
dose could you reduce the prophylactic antipsychotic, according to the 
literature, without significantly increasing the relapse risk? Please 
answer according to your best knowledge of the literature for all the 
drugs below. 
 
• Oral antipsychotics 
 Haloperidol _____ mg/day  Don’t know  
 Risperidone _____ mg/day  Don’t know 
 Olanzapine _____ mg/day  Don’t know 
 Sertindole _____ mg/day  Don’t know 
 Flupentixol _____ mg/day  Don’t know 
 Zuclopentixol _____ mg/day  Don’t know  
 
• Depot antipsychotics 
 Haloperidol decanoate _____ mg/month  Don’t know  
 Fluphenazine decanoate  _____ mg/month  Don’t know  
 Flupentixol decanoate _____ mg/month  Don‘t know  
 Zuclopentixol decanoate _____ mg/month  Don’t know  
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The following questions are intended to determine on which data your 
treatment habits are based (own experience and/or results in the scientific 
literature). 
 
3. How high do you estimate the relapse rate of the patient described in 
case 1 if no antipsychotic relapse prevention is administered? Please 
answer both the following questions: 
 
According to my experience the relapse rate within the first year is approximately 
_________%   Don’t know 
 
According to my knowledge of the scientific literature the relapse rate within the 
first year is approximately _______%  Don’t know  
 
4. How high do you estimate the relapse rate after a first schizophrenia 
episode if continuous antipsychotic relapse prevention is 
administered? Please answer both the following questions: 
 
According to my experience the relapse rate within the first year is approximately 
_________%   Don’t know 
 
According to my knowledge of the scientific literature the relapse rate within the 
first year is approximately _______%  Don’t know  
 
5.  If antipsychotic medication is discontinued in a long term remitted 
(relapse free for 1 - 5 years on antipsychotic treatment) multiple-
episode schizophrenia patient, how high would you estimate the 
average relapse rate to be? 
 
According to my experience the relapse rate within the first year is approximately 
_________%   Don’t know 
 
According to my knowledge of the scientific literature the relapse rate within the 
first year is approximately _______%  Don’t know  
 
 
6. If average schizophrenia patients (20-40 years old, no structural 
brain pathology) are administered an antipsychotic relapse 
prevention therapy with conventional drugs for 5 years in a medium 
dosage range, what percentage can be expected to suffer  from: 
 
Mild, reversible tardive dyskinesia, approximately    ______%  Don’t know 
Severe, irreversible tardive dyskinesia, approx.     ______%  Don’t know 
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Alternative treatment 
7. From current literature, for which of the following diagnosis is ECT 
primarily indicated? 
 
Depression        
Treatment-resistant depression     
Schizophrenia        
Severely psychotic, aggressive, acute schizophrenia  
Treatment-resistant schizophrenia     
Mania        
Don’t know        
 
 
Quality Management 
 
8. Quality management is an unnecessary burden on everyday work? 
 
  Agree strongly 
 Agree slightly 
  Neither  agree nor disagree 
  Disagree slightly 
  Disagree strongly 
 
9.          Quality management is a management responsibility? 
 
 Agree strongly 
  Agree slightly 
  Neither  agree nor disagree 
  Disagree slightly 
  Disagree strongly 
 
 
Local Workshops 
 
10. To what extent have you arranged local workshops where you practise? 
 
   Formal agreement about a local workshop has been made 
 
 How many local workshops have you agreed to do? _______ 
 
 Is a date set for the local workshop yes no 
 
 
  Informal agreement about a local workshop has been made 
 
  I intent to arrange local workshops, but I don’t know when  
  Please indicate the number of local workshops you plan to do _____ 
 
  I have no current plans of arranging local workshops 
 
 
 164 
Patient case studies 
 
One of the objectives of the seminars at the Lundbeck Institute is to reach consensus on 
the treatment of schizophrenia. To encourage this we would like to present some data 
from the real life treatment of patients with schizophrenia. Thus we would like you to fill 
in a patient diary sheet for two patients as described below. If you don’t have a patient 
in your ward that fits the description, please leave the form blank. 
 
All patients should be between 18-60 years of age, with a diagnosis of paranoid 
schizophrenia, multiple episode with no other serious illness and not dangerous to 
themselves or others. 
 
 
Patient 1 
Acute patient: 
The patient should have been admitted approximately 4 to 6 weeks ago. 
 
 
Patient 2 
Chronic patient: 
The patient should have stayed in the hospital for 4 to 6 months. 
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Patient 1 
 
Diagnosis (full text or coded) _____________________ 
Other important diagnosis  _____________________ 
 
Did you use a diagnostic tool?1   ICD10  2  DSM IV  3  Other  4  No 
 
Number of previous episodes     _________ 
Number of previous admissions _________ 
Date of this admission: day _____    month  _____     Year   _____            
Today’s date: day _____    month  _____     Year   _____            
 
Psychopathological Findings 
 
(Tick only one box in each line, please) 
         None/not                               Extremely 
             at all ill  Borderline Mild   Moderate  Marked    Severe       Severe 
Positive symptoms 0  1  2  3  4  5  6  
Negative symptoms 0  1  2  3  4  5  6  
Depression 0  1  2  3  4  5  6  
Other findings 0  1  2  3  4  5  6  
Current CGI  0  1  2  3  4  5  6  
  
 
CGI relative to admission 
0  Very much improved 
1  Much improved 
2  Minimally improved 
3  No change 
4  Minimally worse 
5  Much worse 
6  Very much worse 
 
Side Effects (SEs) 
 
(Tick only one box in each line, please) 
               Mild and not    Interfering             Interfering 
   interfering    moderately           markedly 
   with patient’s        with patient’s        with patient’s 
     None performance    performance          performance 
Tardive dyskinesia 0   1  2  3  
Other EPS 0   1  2  3  
Psychic side effects* 0   1  2  3  
Other important SEs 0   1  2  3  
Global side effect score 0   1  2  3  
 
* delirium, tiredness, insomnia, restlessness, depression or quantitative 
disturbance of consciousness 
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Current therapeutic consequences  
 
0  No action 
1  More frequent assessment 
2  Reduction in dose of drug(s) 
3  Discontinuation of drug(s) 
 
 
Psychotropic Medication 
 
All current antipsychotics 
 
a) generic name ____________if oral ___ mg/day / if depot ___ mg/month 
b) generic name ____________if oral ___ mg/day / if depot ___ mg/month 
c) generic name ____________if oral ___ mg/day / if depot ___ mg/month 
d) generic name ____________if oral ___ mg/day / if depot ___ mg/month 
 
Co-medication: 
 
Anti-parkinsonian 1  No  
 2  Yes - If yes, given as prophylactic Rx? 1   No 
    2   Yes 
 
Benzodiazepines 1  No  
 2  Yes - If yes, given as prophylactic Rx ? 1   No 
    2   Yes 
 
Antidepressants 1  No  
 2  Yes - If yes, given as prophylactic Rx? 1   No 
    2   Yes 
 
Other important medication: _____________________ 
 
How many different neuroleptics has the patient received since admission?___ 
 
 
Psychoeducation (PE) 
 
Does the patient take part in PE?1  No 
   2  Yes - If yes 1  Group sessions 
    2  Others: ________ 
 
 
Do relatives take part in PE?  1  No   
 2  Yes - If yes 1  Group sessions 
    2  Others: ________ 
 
 167 
 
Patient 2 
 
Diagnosis (full text or coded) _____________________ 
Other important diagnosis  _____________________ 
 
Did you use a diagnostic tool?1  ICD10 2  DSM IV 3  Other 4  No 
 
Number of previous episodes     _________ 
Number of previous admissions _________ 
Date of this admission: day _____    month  _____     Year   _____            
Today’s date: day _____    month  _____     Year   _____            
 
Psychopathological Findings 
 
(Tick only one box in each line, please) 
         None/not                               Extremely 
             at all ill  Borderline Mild   Moderate  Marked    Severe       Severe 
Positive symptoms 0  1  2  3  4  5  6  
Negative symptoms 0  1  2  3  4  5  6  
Depression 0  1  2  3  4  5  6  
Other findings 0  1  2  3  4  5  6  
Current CGI  0  1  2  3  4  5  6  
  
 
CGI relative to admission 
0  Very much improved 
1  Much improved 
2  Minimally improved 
3  No change 
4  Minimally worse 
5  Much worse 
6  Very much worse 
 
Side Effects (SEs) 
 
(Tick only one box in each line, please) 
               Mild and not    Interfering             Interfering 
   interfering    moderately           markedly 
   with patient’s        with patient’s        with patient’s 
     None performance    performance          performance 
Tardive dyskinesia 0   1  2  3  
Other EPS 0   1  2  3  
Psychic side effects* 0   1  2  3  
Other important SEs 0   1  2  3  
Global side effect score 0   1  2  3  
 
* delirium, tiredness, insomnia, restlessness, depression or quantitative 
disturbance of consciousness 
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Current therapeutic consequences  
 
0  No action 
1  More frequent assessment 
2  Reduction in dose of drug(s) 
3  Discontinuation of drug(s) 
 
 
Psychotropic Medication 
 
All current antipsychotics 
 
a) generic name ___________if oral ___ mg/day / if depot  ____ mg/month 
b) generic name ___________if oral ___ mg/day / if depot  ____ mg/month 
c) generic name ___________if oral ___ mg/day / if depot  ____ mg/month 
d) generic name ___________if oral ___ mg/day / if depot  ____ mg/month 
 
Co-medication: 
 
Anti-parkinsonian 1  No  
 2  Yes - If yes, given as prophylactic Rx? 1   No 
    2   Yes 
 
Benzodiazepines 1  No  
 2  Yes - If yes, given as prophylactic Rx ? 1   No 
    2   Yes 
 
Antidepressants 1  No  
 2  Yes - If yes, given as prophylactic Rx ? 1   No 
    2   Yes 
 
Other important medication: _____________________ 
 
How many different neuroleptics has the patient received since admission? ___ 
 
 
Psychoeducation (PE) 
 
Does the patient take part in PE?1  No 
   2  Yes - If yes 1  Group sessions 
    2  Others: ________ 
 
 
Do relatives take part in PE?  1  No   
 2  Yes - If yes 1  Group sessions 
    2  Others: ________ 
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Appendix 4: 
Extended Abstract 
This study reports on the effect of education.  It analyses changes in knowledge, attitude 
and behaviour among psychiatrists who attended evidence-based schizophrenia 
seminars presented by the Lundbeck Institute in Denmark. 
 
The objectives of the study were two-fold.  Firstly, it set out to determine whether 
changes occurred in knowledge, attitude and treatment habits (behaviour) two weeks 
and six months after the seminar; specifically, changes in choice of optimal haloperidol 
dose, duration of maintenance treatment and drug-class (conventional versus new 
generation antipsychotic) used and whether these changes could be ascribed to the 
schizophrenia seminars.  Secondly, it attempted to identify factors that could predict the 
likelihood of participants learning new knowledge or changing their behaviour. 
 
The haloperidol dose prescribed was analysed in two situations: acute treatment 
setting where the most effective dose is used, and in maintenance treatment of 
schizophrenia where the minimum effective dose is used to prevent a relapse.  In the 
acute episode situation, respondents were asked what they thought the most effective 
haloperidol dose would be.  In the case of relapse prevention in multi-episode patients, 
the respondents were asked what the minimum effective haloperidol dose would be for a 
30-year-old female, without increasing the relapse risk.  Changes in doses of haloperidol 
selected were measured using two case studies in the questionnaires (Cases 1 and 2 – 
see appendices 1 and 3). 
 
The analysis of change in selected minimum effective haloperidol dose showed that the 
average recommended dose dropped significantly after the seminar, in comparison with 
the dose before the seminar.  However, evidence of change was less apparent with 
regard to the most effective haloperidol dose. 
 
Changes in the selected optimal duration of treatment were measured for both first-
episode and multi-episode schizophrenia patients.  The analyses showed that significant 
changes occurred in the selected duration of treatment of multi-episode schizophrenia 
patients when the duration of treatment before the seminar and 6-months after were 
compared.  The change in the duration of treatment of first-episode schizophrenia 
patients was not significant.  However, the comparison of mean scores took account of 
the fact that not all participants were expected to change their behaviour; some 
participants knew the correct optimal duration of treatment before the seminar.  The 
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chapter analysing the changes in prescribing pattern showed that participants who were 
prescribing less than the recommended minimum duration of treatment increased the 
duration of their treatment after the seminar, compared to those who were prescribing a 
longer duration than the recommended duration of treatment.  A significant change 
occurred in the behaviour of those participants who, according to accepted guidelines, 
should change their behaviour. 
 
Changes in the antipsychotic drug-class selected were analysed for both first-episode 
and multi-episode schizophrenia patients.  Furthermore, a differentiation was made 
between the intended behaviour and the actual behaviour.  Explain how! 
 
Concerning the intended behaviour, there was a significant shift towards new generation 
drugs from before the seminar to 6-months after the seminar.  However - and quite 
interestingly - the actual drug-class used did not change significantly from what it was 
before the seminar to 6-months after the seminar, despite a significant change in the 
?intended drug-class in question.  This suggests that if the significant change in the 
intended drug-class selected was due to the seminar, the seminar had a greater effect 
on the intended behaviour than on the actual behaviour. 
 
Overall, despite significant changes from before the seminar to 6-months after the 
seminar in all areas, these changes may not necessarily  be attributable to the seminar.  
Knowledge develops over time, so a general increase in background knowledge i.e. ?????  
or e.g. could account for the changes.  To take this factor into account, the development 
in knowledge was analysed by comparing certain key characteristics of the respondents 
in the pre-dataset and the 6-months-dataset. 
 
The analysis of delegates’ knowledge showed that the knowledge of the minimum 
effective haloperidol dose and optimal duration of treatment was stable  over time.  
There was no significant difference between the knowledge of the participants who 
joined the seminar in the first two years they were held versus those who attended the 
seminar in the last two years with regard to the minimum effective haloperidol dose and 
optimal duration of treatment. 
 
By contrast, the most effective haloperidol dose selected and the antipsychotic drug-
class selected changed over time depending on when participants attended the seminar.  
There was a significant difference between the earlier participants at the seminars and 
later participants.  In respect of the most effective haloperidol dose, more of the earlier 
participants were above the target dose of 5 mg/day than the later participants.  Thus, 
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at best, changes in the effective haloperidol dose seem to be only partially attributable to 
the effects of seminar learning. 
  
More of the later participants tended to use new generation drugs before the seminar 
than the earlier participants.  Furthermore, the changes in drug-class selected two weeks 
after the seminar were insignificant among those who attended the later seminars.  The 
latter indicates that the seminar primarily affected earlier participants only.  Based on 
this, the study concluded that the change in drug-class selected from before the seminar 
to 6-months after the seminar was probably due to changes in background knowledge 
about new generation antipsychotic drugs. 
 
Despite the knowledge of duration of treatment and haloperidol dose being stable across 
time, the respondents of the pre-questionnaire and the respondents of the 6-months-
questionnaire might be different.  It could have been that particularly good learners filled 
in the 6-months questionnaire, resulting in an overestimation of the effects of the 
seminar.  In order to take this into account, a comparison was made between the pre-
dataset and the 6-months-dataset on four key-characteristics; country of origin; years of 
practice; number of patients; and workplace.  The comparisons showed no significant 
difference between the datasets. 
  
In light of this, it seems the seminars have a significant effect on the duration of 
treatment and the minimum effective dose of haloperidol used, but a less than 
significant effect on the most effective haloperidol dose and selection of drug-class.  The 
study therefore concentrated on explaining variation in changes in optimal duration of 
treatment and minimum effective haloperidol dose. 
 
Chapter 6 explores why some psychiatrists changed their behaviour and others did not. 
Put differently: why did the seminar have an effect on some participants and not others? 
Which factors influenced a psychiatrist’s ability to learn and practise new behaviour?  
Comprehension of variation in changes is understood with regard to duration of 
treatment and minimum effective haloperidol dose. 
 
The study investigated four hypotheses concerning changes in behaviour.  Changes in 
behaviour after the seminar could be linked to certain nationalities, number of patients 
seen in clinical practice, number of years of psychiatric experience and workplace. 
 
In respect of changes in the selected optimal duration of treatment, the study found that 
the duration of treatment before the seminar explained between 20 and 25% of all the 
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changes in behaviour depending on whether the patients were first-episode or multi-
episode schizophrenia patients.  Therefore a participant, whose selected optimal duration 
of treatment before the seminar was below that recommended in the seminar,  
increased the duration of their treatment after the seminar.  None of the other factors 
affected the changes in duration of treatment of either first-episode or multi-episode 
schizophrenia patients.  In this sense the seminar had the intended effect; those 
participants who most needed to change behaviour did so independently of other 
characteristics such as number of patients seen in clinical practice and nationality. 
 
The seminars did not seem to have any direct effect on participants who chose a dose 
above the target haloperidol dose before the seminar.  In other words, changes in the 
dose after a seminar could not be ascribed solely to the dose used before a seminar.  It 
seems that the seminars had an indirect effect on the participants whose 
recommendation was above the target haloperidol dose before the seminar.  Changes in 
haloperidol dose seemed to occur among participants who prescribed more than the 
target before a seminar and either saw many schizophrenia patients or had a high 
percentage of schizophrenia patients in their caseloads.  These psychiatrists reduced 
their selected optimal haloperidol dose more compared with psychiatrists who were 
above the target, but either saw fewer first-episode schizophrenia patients or had a 
lower percentage of schizophrenia patients.  Therefore, the number of schizophrenia 
patients and the percentages of schizophrenia patients in relation to the overall 
caseload, in combination with the recommended optimal haloperidol dose before the 
seminar, all had a role in explaining the decreases in the haloperidol dose selected. 
 
Of the psychiatrists who prescribed more than the target dose before the seminar, those 
who increased the haloperidol dose saw a high percentage of schizophrenia patients 
and had many patients in general in their clinical practices, compared to those with a 
high percentage of schizophrenia patients, but a lower overall caseload.  Therefore, the 
number of patients had a negative effect in general, but had a positive learning effect if 
the patients were mainly schizophrenia patients. 
 
The country of origin also exercised an influence on the changes in the minimum 
effective dose of haloperidol.  In order to ascertain this, psychiatrists were divided into 
three groups of countries.  Country Group 2 respondents, who were above the target 
dose before the seminar, increased their selected optimal haloperidol dose, compared 
with Group 3 respondents, who also prescribed above the target before the seminar.  To 
a lesser extent, the same was probably true for Group 1 participants. 
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In view of this, it was concluded that the seminars had no direct effect on psychiatrists 
who were prescribing more than the target effective haloperidol dose before the 
seminar.  Participants’ preferred effective haloperidol dose or optimal treatment duration 
pre seminar could not alone account for the changes in prescribed dose post seminar.  It 
seems that the effect of the seminars depended firstly on the number and type of 
patients the psychiatrist saw, and secondly on the country of origin of the psychiatrist, in 
combination with the recommended dose before the seminar.  The other variables 
(workplace, years of experience) did not influence the changes in optimal haloperidol 
dose selected. 
 
In summary, the changes in behaviour concerning duration of treatment and haloperidol 
dose could validly be ascribed to the seminar.  The change in the drug-class used was 
probably due to changes in background knowledge.  There were differences between the 
participants with regard to changes in duration of treatment and changes in optimal 
haloperidol dose.  The changes in the haloperidol dose were also dependent upon the 
dose being prescribed before the seminar.  However, other factors such as caseload size 
and participant nationality must be taken into account in conjunction with the prescribed 
dose before the seminar.   Changes in duration of treatment can be explained by the 
answers of respondents before attending the seminar. 
 
